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Peripheral nerve injuries affect a large proportion of the population and are often 
associated with prolonged disability. Current surgical interventions, including 
autografts and nerve guidance conduits (NGCs), are associated with a number of 
limitations. Decellularised nerve grafts offer considerable potential for peripheral 
nerve repair, by providing a non-immunogenic extracellular matrix (ECM) scaffold 
with biological, biochemical and biomechanical characteristics similar to native 
nerve.  
The aim of this study was to develop a decellularised peripheral nerve allograft with 
a native ECM histioarchitecture and biochemical composition, able to support viable 
cell populations. A previously established protocol for the decellularisation of 
porcine peripheral nerves, utilising a combination of hypotonic buffers, low 
concentration sodium dodecyl sulphate (SDS) and nuclease enzymes, was further 
developed to maintain the efficacy of decellularisation whilst minimising structural 
changes to the ECM. The improved protocol was shown to achieve sufficient cell 
and DNA removal, and decellularised porcine peripheral nerves were shown to be 
biocompatible and retain a native ECM histioarchitecture and composition. The 
protocol was then translated for the decellularisation of human femoral nerves. 
Following further development, the protocol was shown to achieve sufficient cell 
and DNA removal, and decellularised human femoral nerves were also found to be 
biocompatible and retain a native ECM histioarchitecture and composition. Human 
femoral nerves were then cultured in vitro with primary rat dorsal root ganglion 
(DRG) explants to assess long term biocompatibility and neurite outgrowth. The 
results presented suggest that decellularised human femoral nerve is a suitable 
substrate to support cellular infiltration and axon regeneration. Decellularised 
human femoral nerve was shown to support the long-term cell viability, migration, 
and neurite outgrowth of DRG explants, for up to 28 days in vitro. 
In this study, a novel decellularised human femoral nerve graft was developed with 
clinical potential for use in peripheral nerve repair. Although the results presented in 
this study are promising, further studies are required prior to clinical translation. A 
sterilisation process must be developed and evaluated for the decellularised nerve 
graft, and the biomechanical properties of decellularised and sterilised human 
femoral nerves must be investigated. The in vivo biocompatibility and efficacy of a 
decellularised and sterilised human femoral nerve graft for peripheral nerve repair 
must also be evaluated. 
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1 Chapter 1: Introduction 
1.1 General Introduction 
Peripheral nerve injuries are common and debilitating injuries, with approximately 
300,000 cases reported annually in Europe (Bell and Haycock, 2011). The majority 
of injuries are caused by acute trauma, and are often associated with functional 
defects, neuropathic pain or paralysis of the affected limb (Kingham et al., 2007). 
Axons of peripheral nerves are capable of spontaneous regeneration following 
injury, however axon regeneration is slow (approximately one mm per day), and the 
ability of axons and Schwann cells to sustain axon regeneration progressively fails 
over distance and time (Burnett and Zager, 2004; Ruijs et al., 2005).  
Severe peripheral nerve injuries, characterised by a gap defect with complete 
extracellular matrix (ECM) transection, are frequently repaired using autografts or 
nerve guidance conduits (NGCs) to bridge the gap. However, such techniques have 
a limited efficacy and axon regeneration is frequently unsuccessful (Grinsell and 
Keating, 2014). Autografts, the gold standard intervention, require the sacrifice of a 
functional, minor nerve to repair critical defects and often provide insufficient 
material for major reconstruction (Colen et al., 2009; Grinsell and Keating, 2014). A 
number of NGCs have been developed to physically guide regenerating axons, 
fabricated from both natural and synthetic materials, however relatively few are 
clinically available and results of clinical trials have only shown a comparable 
efficacy between autografts and NGCs for small defects, up to 20 mm in length 
(Kehoe et al., 2012; Naryan et al., 2018).  
The limited efficacy of NGCs is thought to be due to the lack of a native ECM 
architecture and composition (Whitlock et al., 2009; Spivey et al., 2012). The 
basement membrane is essential for promoting cell-matrix interactions supporting 
Schwann cell adhesion and axon elongation, and the specific architecture of the 
endoneurium, the innermost layer of the ECM, provides physical guidance to 
regenerating axons (Spivey et al., 2012; Szynkaruk et al., 2012). Decellularisation 
of allogeneic or xenogeneic tissue has the potential to produce a non-immunogenic 
ECM scaffold with biological, biochemical and biomechanical characteristics similar 
to native tissue (Crapo et al., 2011; Kawecki et al., 2018). Decellularised peripheral 
nerve grafts offer considerable potential for peripheral nerve repair by providing a 
native microenvironment to facilitate axon regeneration with ECM properties that 
cannot yet be replicated synthetically (Schmidt and Leach, 2003; Whitlock et al., 
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2009; Szynkaruk et al., 2012). This review will describe the structure and function of 
peripheral nerves and the pathophysiology of peripheral nerve injury, and will 
investigate the current interventions for peripheral nerve repair and the clinical need 
for alternative interventions. This review will then explore experimental therapies for 
peripheral nerve repair. 
1.2 Peripheral nervous system 
The nervous system of vertebrates is divided into two parts: the central nervous 
system (CNS) and peripheral nervous system (PNS). The CNS, consisting of the 
brain and spinal cord, interprets sensory information from the PNS and coordinates 
the activity of the body by providing stimuli to the PNS (Kiernan and Rajakumar, 
2013). The PNS, consisting of cranial and spinal nerves, is subdivided further into 
the somatic nervous system (voluntary control of skeletal muscle) and autonomic 
nervous system (involuntary control of bodily functions, including respiration, 
digestion, and cardiac regulation). The PNS connects the CNS with the rest of the 
body, by relaying sensory information from the internal and external environment to 
the CNS and conducting stimuli from the CNS to muscles and glands (Mai and 
Paxinos, 2011; Kiernan and Rajakumar, 2013).   
There are 31 pairs of spinal nerves, named according to the level of the spinal cord 
they emerge from (Figure 1.1). Spinal nerves are mixed nerves, comprising motor 
and sensory neurons that separate into two nerve roots: the ventral root and the 
dorsal root. Motor neurons, both somatic and autonomic, emerge from the spinal 
cord as the ventral nerve root, and the cell bodies of motor neurons are located in 
the ventral horn of the spinal cord (Mai and Paxinos, 2011). Sensory neurons enter 
the spinal cord as the dorsal nerve root, and on each dorsal root is the DRG, which 
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Figure 1.1. Spinal nerves of the human peripheral nervous system. The 
human peripheral nervous system contains 31 pairs of spinal nerves, each pair 
numbered according to the level of the spinal cord from which it arises (C = Cervical, 
T = Thoracic, L = Lumbar S = Sacral and CO = Coccygeal). Each spinal nerve is 
attached to the spinal cord by two roots: the dorsal and the ventral root. Motor 
neurons emerge from the spinal cord as the ventral nerve root, with cell bodies of 
motor neurons located in the ventral horn. Sensory neurons enter the spinal cord as 
the dorsal nerve root, and each dorsal nerve root contains a swelling of grey matter 
known as the dorsal root ganglion (DRG), which contains cell bodies of sensory 
neurons. Adapted from encyclopedia.lubopitko-bg.com  
1.3 Peripheral nerve 
1.3.1 Structure and function of peripheral nerve 
Peripheral nerves are composed of an ECM, a vascular network (vasa nevorum), 
and both neural and non-neural cells (Kiernan and Rajakumar, 2013). The neural 
cell types in peripheral nerves are neurons, Schwann cells and perineurial cells, 
and the non-neural cell types are primarily fibroblasts and adipocytes. In addition, 
endothelial cells and various cells of the immune system, including macrophages, 
are also located within the nerve (Kerns, 2008; Grinsell and Keating, 2014). The 
ECM of peripheral nerves consists of three layers: endoneurium, perineurium and 
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Figure 1.2 Macroscopic structures of peripheral nerve extracellular 
matrix (ECM). Peripheral nerve ECM consists of three major structures: the 
epineurium, perineurium and endoneurium. Individual axons are located in 
endoneurial tubes, which are bundled into fascicles surrounded by the perineurium. 
Fascicles are separated by inter-fascicular epineurium, which also contains 
longitudinally aligned blood vessels. The external epineurium forms a sheath 
surrounding the whole nerve. Figure adapted from Grinsell et al. (2014). 
The endoneurium is the innermost ECM layer, forming a network of fine tubules 
surrounding individual myelinated axons (or multiple non-myelinated axons), 
associated Schwann cells and fibroblasts (Figure 1.2). Individual endoneurial tubes 
consist primarily of fine collagen type I and type II fibrils, and provide topographic 
guidance to regenerating axons (Topp and Boyd, 2012). Endoneurial tubes also 
contain a basement membrane, comprised of collagen type IV, laminin and 
fibronectin, which is essential for promoting cell-matrix interactions and supporting 
Schwann cell adhesion and axon elongation (Gabella, 2012). The larger blood 
vessels of the peripheral nerve vascular network (vasa nevorum) do not directly 
access the endoneurium, and a fine capillary network connects individual axons 
with the vasculature (Kerns, 2008).  
Multiple axons, individually surrounded by endoneurial tubes, are bundled into 
nerve fascicles and surrounded by the perineurium (Figure 1.2).  The perineurium is 
a concentric layered lamellar structure, consisting of collagen type I and type II, and 
each perineurial layer also contains a basement membrane similar to that of the 
endoneurium (Kerns, 2008; Topp and Boyd, 2012). Squamous perineurial cells, 
joined by gap junctions, function as a blood-nerve barrier and enable regulation of 
the intrafascicular microenvironment, including the regulation of pressure and 
concentration of soluble molecules and ions. Intercellular tight junctions, comprising 
proteins including occludins and claudins, regulate the transport of molecules to 
axons in individual endoneurial tubes (Peltonen et al., 2013). The perineurium 
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nerve, and also provides local protection to axons and Schwann cells within 
individual endoneurial tubes from external mechanical forces, such as compression 
and tension (Topp and Boyd, 2012; Peltonen et al., 2013).  
The epineurium is the outermost layer of the ECM and consists of two regions: the 
inter-fascicular epineurium and the external epineurium. The inter-fascicular 
epineurium fills the space between fascicles with an irregular matrix, consisting of 
collagen types I and III and adipose tissue, and contains the major vessels of the 
vasa nevorum (Sunderland, 1990; Ishibe et al., 2011). The external epineurium 
forms a dense, sheath-like structure of collagen type I and type III around the nerve, 
providing insulation from the external environment (Mason and Phillips, 2011). The 
external epineurium interfaces with other ECM regions along the nerve path and is 
tethered at some points, facilitating nerve mobility. In addition to the perineurium, 
the epineurium also contributes to the overall mechanical strength of the nerve, 
primarily due a high collagen type I content (Kerns, 2008; Topp and Boyd, 2012). 
1.3.2 Extracellular matrix (ECM) components in peripheral nerve 
1.3.2.1 Collagens 
Collagen is a major component of peripheral nerve ECM, maintaining overall ECM 
histioarchitecture (tissue architecture) and biomechanical properties (Mason and 
Phillips, 2011; Gao et al., 2013). Fibrillar collagens (including collagens type I, II, III 
and V) are structural molecules with a tri-helical conformation, providing mechanical 
strength to the nerve (Koopmans et al., 2009). Collagen type I, the main collagen in 
peripheral nerve ECM, is found in all ECM layers. Collagen type I is longitudinally 
arranged in the endoneurium and perineurium, often in association with collagen 
type II, and forms an irregular network in the epineurium (Wenger et al., 2007).  
Collagen type III is located in the epineurium in association with collagen type I, 
where it forms in an undulated orientation along the nerve to provide tensile 
strength to protect the inner ECM layers (Wenger et al., 2007; Gao et al., 2013). 
Collagen type IV is a highly glycosylated network-forming collagen molecule located 
mainly in the basement membrane of the endoneurium and perineurium (Masand et 
al., 2012). Collagen type IV provides structure to the basement membrane and 
provides binding sites for key moieties, including laminins, enabling the cellular 
processes of Schwann cells and axons (Yurchenco et al., 2002; Yurchenco, 2011; 
Gao et al., 2013). 
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1.3.2.2 Laminin 
Laminin, along with collagen type IV, fibronectin and various proteoglycans, is a 
ubiquitous component of the basement membrane, located in both the 
endoneurium and perineurium (Yurchenco, 2011). Laminin is a heterotrimeric 
glycoprotein with several cell adhesion motifs (Figure 1.3) (Dalton and Mey, 2009; 
Nieuwenhuis et al., 2018). Adhesion motifs enable the binding of cellular integrins, 
enabling cell adhesion and signal transduction from contact with different ligands 
(Grinsell and Keating, 2014).The RGD sequence has been identified as an 
adhesion motif for a variety of cell types, including neurons and Schwann cells 
(Table 1.1), and many studies have investigated the use of RGD functionalised 
polymers to promote cell adhesion (Hersel et al., 2003). Laminin also contains 
several other neuron adhesion motifs, including YIGSR, IKVAV, RNIAEIIKDI and 
RYVVLPR, however YIGSR and IKVAV have both been shown to significantly 
increase neuronal adhesion and are considered key neuron adhesion motifs (Rao 
and Winter, 2009). Laminin has extensive functions in regulating Schwann cell 
adhesion and proliferation, and promoting axonal regeneration (Geuna et al., 2009). 
Several studies have investigated the axon-growth promoting activity of laminin, 
providing the adhesive stimulus for successful axon regeneration following injury 
(Chen et al., 2000; Sun et al., 2009; Suri and Schmidt, 2010). 
Figure 1.3 Structure of laminin and key cell adhesion motifs. Laminin is a 
cross-shaped glycoprotein with three polypeptide chains: the α-chain, β1-chain and 
β2-chain. Laminin contains key cell adhesion motifs that bind with integrin receptors. 
The YIGSR sequence is located on the β1-chain, and the IKVAV and RGD sequences 
are on the long and short arm of the α-chain respectively. Figure adapted from Dalton 
et al. (2009). 
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1.3.2.3 Fibronectin 
Fibronectin is a glycoprotein component of the basement membrane synthesised by 
Schwann cells in vivo (Ahmed et al., 2003; Gao et al., 2013). Fibronectin has three 
types of sequence homology organized into structural domains with interaction sites 
for binding other ECM molecules, including collagen and fibrin (Gratchev et al., 
2001). Fibronectin contains cell adhesion motifs which enable the binding of cellular 
integrins expressed by Schwann cells (Table 1.1), and has been shown to stimulate 
Schwann cell proliferation and migration (Ahmed et al., 2003). In addition, 
fibronectin contains domains for binding neuronal integrins (Table 1.1), including 
the RGD sequence, and fibronectin has been implicated in axon regeneration and 
myelination (Gardiner et al., 2007; Han et al., 2010; Gardiner, 2011; Nieuwenhuis et 
al., 2018). 
1.3.2.4 Proteoglycans 
Proteoglycans are formed of glycosaminoglycans (GAGs) covalently bound to core 
proteins. GAGs can be sulphated, such as heparan sulphate and chondroitin 
sulphate, or non-sulphated (Gandhi and Mancera, 2008). The main GAGs found in 
peripheral nerve are heparan sulphate and chondroitin sulphate (Gao et al., 2013).  
Proteoglycans are located in peripheral nerve ECM, typically associated with the 
basement membrane in the endoneurium and perineurium, and within blood 
vessels (Braunewell et al., 1995). Chondroitin sulphate proteoglycans (CPSGs) are 
proteoglycans comprising a protein core and a chondroitin sulphate side chain. 
They are the main proteoglycans involved in the regulation of axonal growth, 
specifically inhibiting the axon growth promoting activity of laminin (Zuo et al., 
2002). CPSGs are thought to be inhibitory to axonal regeneration, and several 
studies have shown that CPSGs bind to and inhibit the axon growth promoting 
activity of endoneurial laminin and are rapidly upregulated following nerve injury, 
providing a non-permissive substrate for axonal growth (Krekoski et al., 2001; Zuo 
et al., 2002; Neubauer et al., 2007). However, as CPSGs are degraded as part of 
the regeneration process of axons, it has also been suggested that the degradation 
of CPSGs may represent a mechanism by which the growth-promoting properties of 
laminin may be restored, thus promoting axonal regeneration (Krekoski et al., 2001; 
Wang et al., 2012). 
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1.3.3 Cell types in peripheral nerve 
1.3.3.1 Neurons 
Neurons are the primary functional cell type of peripheral nerves, responsible for 
transmitting sensory and motor signals in the form of electrical impulses (Topp and 
Boyd, 2012). Neurons are a diverse cell type, varying considerably in morphology 
and electrochemical properties, however a typical neuron consists of a soma (cell 
body), dendrites, and an axon projecting into the peripheral nervous system (Figure 
1.4) (Geuna et al., 2009). The soma is usually compact, and the filamentous 
dendrites and axon extrude from the soma. The soma can produce multiple 
dendrites which branch extensively from the soma and become thinner in diameter 
with increasing distance, but only one axon, either myelinated or unmyelinated, 
which can extend for great distances (over one metre in an adult human) 
maintaining a constant diameter (Topp and Boyd, 2012). Although axons of 
peripheral nerves can be myelinated or non-myelinated, in general axons with a 
larger diameter become myelinated to facilitate fast conduction of action potentials 
via saltatory conduction (Sheng and Cai, 2012; Kiernan and Rajakumar, 2013). 
Saltatory conduction is the propagation of action potentials along myelinated axons 
between Nodes of Ranvier (breaks in the myelin sheath), which increases the 
conduction velocity of action potentials (Figure 1.4) (Koenig, 2012; Yuan et al., 
2012; Sheng and Cai, 2012). 
Figure 1.4 Structure of a neuron. A typical neuron consists of a soma (cell body) 
containing the nucleus, dendrites and an axon. Synaptic signals from other neurons 
are received by the soma and dendrites, and signals to other neurons are transmitted 
by the axon, with the axon terminal containing the synapses to communicate with 
other neurons. Schwann cells form a myelin sheath around myelinated axons with 
breaks (Nodes of Ranvier) enabling fast conduction of action potentials by 
propagation from one Node of Ranvier to another. Image adapted from Wikimedia 
commons. 
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1.3.3.2 Schwann cells  
Schwann cells, a type of glial cell, are an essential component of neural tissue and 
are required for the survival of both myelinated and non-myelinated axons 
(Chernousov et al., 2008; Salzer, 2012). The primary function of Schwann cells is to 
myelinate certain axons to facilitate the fast conduction of impulses (saltatory 
conduction) by wrapping around them, adopting a flattened morphology to create a 
membranous, insulating barrier, with each individual Schwann cell covering 
approximately 100 micrometres of an axon (Pereira et al., 2012; Salzer, 2015). 
Schwann cells also have important functions in neural development and 
regeneration (Jessen et al., 2015). In response to injury, Schwann cells rapidly 
switch phenotype to a “repair Schwann cell” phenotype and assemble into 
longitudinal bands (termed Bands of Bungner), and the ECM basement membrane 
essentially serves as a conduit for regeneration (Kim et al., 2013; Jessen and 
Mirsky, 2016). Schwann cells also produce several growth factors, such as nerve 
growth factor (NGF) and brain derived neurotrophic factor (BDNF) (Table 1.1) 
(Gaudet et al., 2011; Jessen and Mirsky, 2016). During homeostasis and post-
injury, Schwann cells also adopt immunological functions by serving as phagocytic 
cells following axon damage, phagocytosing axon and myelin debris, presenting 
antigens to CD4+ T-lymphocytes, and producing pro-inflammatory cytokines IL-6, 
TNFα, IL-1α and IL-1β (Burnett and Zager, 2004; Gaudet et al., 2011; Grinsell and 
Keating, 2014). 
1.3.3.3 Perineurial cells 
Perineurial cells bundle individual axons, whether myelinated or non-myelinated, 
into fascicles and are arranged in three zones, in one to 15 concentric layers 
(Peltonen et al., 2013). The innermost zone consists of a single layer of flat, 
squamous perineurial cells joined by tight junctions to form a blood-nerve barrier, 
and the intermediate zone consists of three to 15 layers of perineurial cells (Hirose 
et al., 2003; Topp and Boyd, 2012). The external zone also consists of layers of 
perineurial cells, bound with collagen type I and II, and elastin fibres in 
circumferential arrangements (Kerns, 2008; Bilbao and Schmidt, 2015). The 
perineurial cells contribute to the biomechanical properties of peripheral nerve, and 
the number of cell layers increases where nerves cross the articulating joints and at 
bifurcation points, where nerve strain is increased (Topp and Boyd, 2012). 
Furthermore, larger nerve fascicles tend to have more perineurial cell layers to 
modulate tensile and compressive forces, whereas nerves composed of many 
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fascicles tend to have fewer perineurial cell layers to accommodate shear forces as 
the fascicles glide during body movement (Topp and Boyd, 2012; Koch et al., 
2012). 
1.3.3.4 Fibroblasts 
Fibroblasts are mainly located in the endoneurium and epineurium, although in the 
endoneurium fibroblasts are found in close proximity to the basement membrane, in 
association with collagen type I and II fibres, and in the epineurium fibroblasts are 
found in a looser arrangement with collagen type I and III fibres and adipose tissue 
(Gingras et al., 2003; Kim et al., 2013). The primary functions of fibroblasts, both in 
the endoneurium and epineurium, are to synthesise and maintain the complex 
ECM, support neurons by cell-cell contacts, and release various growth factors and 
signalling molecules, including BDNF and vascular endothelial growth factor 
(VEGF) to promote axon growth (Table 1.1) (Grothe and Nikkhah, 2001; Haastert et 
al., 2006). Fibroblasts have further roles in axon regeneration, by producing NGF 
along with Schwann cells, producing inflammatory cytokines including IL-6, and 
promoting the proliferation and migration of Schwann cells by providing physical 
guidance and cell-cell contacts (Grothe and Nikkhah, 2001; Gaudet et al., 2011; 
Wong et al., 2017). 
1.3.3.5 Adipocytes 
Adipocytes are mainly located in the epineurium, both in the inter-fascicular 
epineurium and the external epineurium, although their exact functions in peripheral 
nerves are not well understood (Chernousov et al., 2008; Grinsell and Keating, 
2014). Adipocytes are thought to contribute to the biomechanical properties of the 
epineurium, allowing gliding between nerve fascicles in the inter-fascicular 
epineurium to reduce shear forces, and supporting the blood vessels passing form 
the extraneural regions (Kerns, 2008; Topp and Boyd, 2012). Adipocytes are also 
implicated in fatty acid metabolism by supplying a source of fatty acids, as several 
metabolic studies have reported that fatty acids have a high turnover rate in the 
endoneurium (Verheijen et al., 2003). However, several studies, using adult mouse 
peripheral nerve, have reported high expression of adipokines in the epineurium, 
including Acrp30 and resistin, and suggest that in addition to supplying fat 
metabolites the epineurium may regulate the lipid metabolism of Schwann cells and 
axons using the vascular network (Garbay et al., 2000; Verheijen et al., 2003; 
Pereira et al., 2012). 
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Table 1.1 Growth factors and integrins expressed by neurons, Schwann 
cells and fibroblasts in peripheral nerve. Growth factors produced by Schwann 
cells and fibroblasts. NGF = Nerve growth factor, BDNF = Brain derived neurotrophic 
factor, FGF = Fibroblast growth factor, IGF = Insulin like growth factor, CTNF = Ciliary 
derived neurotrophic factor, GDNF = Glial cell line derived neurotrophic factor, VEGF 
= Vascular endothelial growth factor, NT-3 = Neurotrophin-3, NT-4/5 = Neurotrophin 
4/5. Neurons, Schwann cells and fibroblasts express various integrins including 
laminin, fibronectin and collagen associated integrins. Data adapted from Jessen et al 
(2016), Gardiner et al. (2011) and Nieuwenhuis et al. (2018). 
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1.3.4 Peripheral nerve biomechanics 
Unlike the nerves of the CNS, peripheral nerves have no physical protection from 
bone (i.e. from the skull or spine) or biological protection (i.e. from the blood-brain 
barrier), and are exposed to an array of mechanical forces associated with body 
movement, including tensile, compressive and shear forces, particularly in the 
upper extremities (Burnett and Zager, 2004; Topp and Boyd, 2012). Peripheral 
nerves are able to withstand mechanical forces, particularly across articulating 
joints, because of the viscoelastic properties of the ECM (Tassler et al., 1994). 
Viscoelasticity enables the nerve to elongate in response to longitudinal tensile 
stress during body movements, such as wrist and elbow extension. A study by 
Topp and Boyd (2006) used cadaveric human limbs to measure increases in nerve 
strain induced by nerve elongation during certain body movements in the upper 
extremities. For example, during wrist extension (0 – 60°) with 90° shoulder 
abduction and 10° elbow flexion, median nerve strain increased by 7.4 % at the 
elbow and 9.6 % at the wrist and ulnar nerve strain increased by 5.2 % at the elbow 
and 20.7 % at the wrist.  
Peripheral nerves are also able to accommodate longitudinal tensile stress during 
body movements by excursion. Excursion is the displacement or gliding of the 
nerve relative to the surrounding nerve bed and may be longitudinal or transverse 
relative to the nerve tract, however the direction (proximal or distal) and magnitude 
of excursion varies depending on the joint movement (Verheijen et al., 2003; 
Grinsell and Keating, 2014). Although it is essential that nerves can glide relative to 
surrounding tissue during body movement, the gliding of nerves against interfacing 
non-neural connective tissue can also impose significant shear forces. Nerve 
excursion follows a consistent pattern - when nerve paths are elongated during 
body movement, the nerve must slide towards the point of extension and the 
magnitude of excursion is greatest closest to the moving joint. For example, the 
median and ulnar nerve paths are elongated during wrist extension, and both the 
median and ulnar nerves slide towards the point of extension, i.e. the wrist, to 
accommodate this movement (Figure 1.5 B) (Topp and Boyd, 2012).  
It is also essential that peripheral nerves can withstand significant compression 
from surrounding tissue, as excessive compression disrupts vascular perfusion and 
can either prevent or cause dysfunctional electrical impulses (Burnett and Zager, 
2004; Madura, 2012). Various body movements can impose compressive forces, 
such as the increase in carpal tunnel pressure resulting from wrist movement (i.e. 
extension or flexion) and forearm supination (Burnett and Zager, 2004; Grinsell and 
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Keating, 2014). If the magnitude of any shear, compressive or tensile forces 
exceeds the capacity of the nerve, either acutely (typically trauma) or cumulatively 
(typically repeatedly exceeding the upper threshold for vascular perfusion causing a 
reduction in intra-neural blood flow), injury is likely to occur (Burnett and Zager, 
2004; Topp and Boyd, 2012; Madura, 2012). 
 
Figure 1.5 Excursion of the median and ulnar nerves during elbow 
extension and wrist extension. Excursion of the median nerve (solid line) and 
the ulnar nerve (dotted line) during elbow extension from 90° - 0° (A), followed by 
wrist extension from 0° -  60° (B). All measurements are reported in millimetres of 
excursion in the proximal (P) or distal (D) direction. During elbow extension, the 
median nerve bed lengthens and the median nerve glides towards the elbow (distal), 
whereas the ulnar nerve shortens and glides away from the elbow (proximal). During 
wrist extension, both nerve beds lengthen and both nerves glide towards the wrist. 
Adapted from Topp & Boyd (2006). 
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1.4 Peripheral nerve injury and regeneration 
1.4.1 Peripheral nerve injury 
1.4.1.1 Injury mechanisms 
Peripheral nerve injuries affect 1 in 1000 of the population in Europe, with the 
majority of injuries resulting from acute trauma including laceration, traction 
(excessive stretch induced by longitudinal tensile stress) and compression. 
Peripheral nerve injuries disproportionately affect young and healthy individuals 
most at risk of traumatic injury (Kingham et al., 2007; Bell and Haycock, 2011). 
Severe peripheral nerve injuries, characterised by extensive ECM damage, account 
for approximately 20% of all peripheral nerve injuries and are often painful, 
debilitating conditions associated with functional defects, intractable neuropathic 
pain or complete paralysis of the affected limb (Kingham et al., 2007). Traction 
injuries are the most common, and although a loss of continuity in the affected 
nerve can occur, such as in brachial plexus avulsion, continuity is usually retained, 
for example with traction injuries to the nerve associated with extremity bone 
fractures (Burnett and Zager, 2004). Lacerations account for up to 30% of 
peripheral nerve injuries, and although these can result in a complete nerve 
transection, some degree of continuity is often retained (Jacques and Kline, 2000). 
Compression injuries do not involve a severance or loss of continuity of the affected 
nerve and include entrapment neuropathies as well as direct compression, such as 
radial nerve compression. Although the pathophysiology associated with 
compression injuries is unclear, it is thought that compression nerve injuries are 
caused by ischaemia induced by excessive compression, dependent on the 
magnitude and exposure time (Burnett and Zager, 2004; Madura, 2012). 
1.4.1.2 Injury classification 
Clinical injury grading systems have been developed that allow correlation of the 
extent of ECM damage, patient symptomology and likelihood of functional recovery 
(Figure 1.6). The most widely recognized systems were devised by Seddon (1943) 
and Sunderland (1951). Seddon assigned nerve injuries to three broad categories: 
neuropraxia, axonotmesis and neurotmesis (Seddon, 1943). Several years later, 
Sunderland subsequently subdivided these categories further: type I (neuropraxia), 
type II (axonotmesis), and type III, IV and V (neurotmesis) to represent the variation 
in clinical findings and functional recovery in neurotmesis injuries (Sunderland, 
1951). Frequently, peripheral nerve injuries comprise multiple types and a type VI 
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injury, a mixed pattern injury, has been added to the original classification 
(Mackinnon, 1988). 
Neuropraxia, the most common and least severe type of nerve injury, does not 
affect axon continuity but causes a transient function loss, in which a segment of 
nerve loses its ability to conduct impulses. This is thought to be due to a local ion-
induced conduction block and the segmental demyelination of axons, both of which 
can be restored as structural continuity is maintained. Mild compression injuries, 
such as sleeping with pressure on the nerves, are typical examples of neuropraxia 
and recover within 8 - 12 weeks, without intervention (Seddon, 1943; Burnett and 
Zager, 2004; Madura, 2012).  
Axonotmesis injuries, whereby the axon is severed, result in a complete loss of 
continuity of the nerve axon and associated myelin, but the surrounding ECM, 
particularly the perineurium and epineurium, remain intact (Seddon, 1943; 
Sunderland, 1951; Sunderland, 1990). Distal to the injury site, the axon and 
surrounding myelin degenerate causing total denervation of the nerve path, 
although functional recovery is usually achieved without surgical intervention as the 
remaining ECM provides guidance for subsequent axons to re-innervate the nerve 
path following the degenerative process (Madura, 2012).  
Damage to the ECM of the nerve, in addition to the axon itself, is termed 
neurotmesis (Sunderland, 1951). As with axonotmesis, degeneration and some 
subsequent axonal regrowth occurs, except functional recovery is rarely achieved 
without surgical intervention because of intraneural scarring and the ECM damage, 
as the loss of the blood-nerve barrier and the necessary structures to direct axon 
regrowth significantly hampers the regenerative process (Gaudet et al., 2011). The 
prospect of functional recovery, even with surgical intervention, is difficult to predict 
as the likelihood is dependent on the location of the injury, time elapsed before 
intervention and the extent of the ECM damage (corresponding to type III, IV and V 
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Figure 1.6 Seddon and Sunderland peripheral nerve injury classification 
systems. (A) Peripheral nerve injury classification systems described by Seddon 
(1943) and Sunderland (1951) define injury severity by the extent of ECM damage, 
and correlates the extent of ECM damage with the likelihood of functional recovery. 
(B) Corresponding injury categories described by the Seddon and Sunderland 
systems. Neuropraxia (Sunderland type I) is defined by transient loss of axon 
function, Axonotmesis (Sunderland type II) is defined by axon severance, and 
neurotmesis (Sunderland types III, IV and IV) is defined by complete transection of 
axons and ECM structures. Adapted from Burnett et al. (2004) 
1.4.2 Peripheral nerve regeneration 
For neurotmesis injuries, with extensive ECM damage and a nerve gap, a series of 
complex and finely regulated degenerative processes must occur prior to 
regeneration, which often delay or impair the regenerative process (Gaudet et al., 
2011). Axon degeneration follows a specific sequence of events, starting within the 
zone of trauma and extending both proximally and distally to the axotomy (Madura, 
2012). The proximal axon segment seals the injured axon to prevent cytoplasm 
leakage, retracts to the next node of Ranvier and degenerates via chromatolysis, a 
focal degeneration pathway similar to the degeneration that occurs in other tissues, 
e.g. muscle, following trauma. The distal axon segment disintegrates via a process 
known as Wallerian degeneration (Gaudet et al., 2011). Wallerian degeneration 
occurs in the distal axon segment, beginning with an intracellular calcium influx 
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activates axoplasmic proteinases, which break down microtubules and 
neurofilaments causing axoplasmic granulation, which impedes axonal transport 
and accelerates degeneration. Responding to a loss of axon contact from the 
transected axon, Schwann cells switch from a supportive to a reactive phenotype, 
secreting inflammatory mediators including interleukins IL-1-β and IL-6 instead of 
secreting myelin and, along with fibroblasts, undergo rapid proliferation (Jessen and 
Mirsky, 2016). Inflammatory mediators secreted by Schwann cells recruit cells of 
the immune system, particularly macrophages and T-cells. Macrophages infiltrate 
the distal axon segment tip and complete the elimination of axons by phagocytosing 
axon and myelin debris (Jessen et al., 2015; Jessen and Mirsky, 2016).  
Before Wallerian degeneration has subsided the proximal axon segment starts to 
produce regenerative sprouts, as many as 50-100, which mature into a growth cone 
and elongate responding to neurotrophic signals secreted by Schwann cells (He 
and Jin, 2016). A fibrin cable forms across the gap between the proximal and distal 
axon segments, and Schwann cells assemble into bands of Bungner in empty 
endoneurial tubes (longitudinally aligned columns of laminin-1 and Schwann cells) 
to physically guide regenerating axons and secrete neurotrophic factors, including 
NGF, Neurotrophin 3, 4, 5 and 6 as well as BDNF (Madura, 2012; Jessen and 
Mirsky, 2016). ECM components including laminin and fibronectin also support 
axon elongation by providing cell-matrix adhesion points (Chernousov et al., 2008). 
Importantly, this environment can only occur when some of the ECM remains intact, 
explaining why although neuropraxia and axonotmesis injuries typically successfully 
regenerate without intervention, neurotmesis injuries do not (Grinsell and Keating, 
2014). Axon regeneration is slow (approximately one mm per day), and the ability of 
neurons and Schwann cells to sustain axon regeneration progressively fails over 
distance and time (Burnett and Zager, 2004). When regenerating axons reach the 
injury site they encounter disorganized Schwann cells, fibroblasts, cells of the 
immune system, collagen fibres and cytoskeletal elements as a result of the 
degenerative process. Many axons fail to elongate beyond the injury site and form 
whorls within the tissue, turn back along the proximal segment, innervate 
inappropriate endoneurial tubes (e.g. sensory as opposed to motor) or take an 
extra-neural course, significantly hampering regeneration (De Ruiter et al., 2014). 
Furthermore, if an endoneurial tube is not reached, the regenerative growth cone 
can develop into a neuroma, manifesting clinically as a painful lump, and empty 
endoneurial tubes undergo progressive fibrosis with intraneural scarring prohibiting 
regeneration (Rajput et al., 2012). 
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1.4.3 Treatment options for peripheral nerve repair 
Numerous interventions have been developed to improve functional recovery 
following severe peripheral nerve injuries (Grinsell and Keating, 2014). The 
intervention used is typically determined by the severity of the injury (i.e. injury 
grade), the location of the injury (i.e. proximal or distal) and the importance of the 
injured nerve, (i.e. a critical motor nerve or a sensory nerve) (Figure 1.7). 
 
Figure 1.7 Current interventions for peripheral nerve injury. Current interventions 
for peripheral nerve injury are determined by several factors, including infection and delay in 
repair, but primarily injury severity. For transection injuries with no gap, where direct 
coaptation can be achieved, nerve ends are directly repaired, either by end-end or end-side 
repair, or transfer of an end of an undamaged nerve. For transection injuries with a gap 
defect, injuries less than 30 mm are repaired using an autograft, decellularised nerve 
allograft or a nerve guidance conduit (NGC), however gap defects longer than 30 mm are 
currently repaired using an autograft, or an allograft for severe injuries requiring major 
reconstruction. Adapted from Grinsell and Keating (2014) 
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1.4.4 Surgical reconstruction 
Small defects, usually up to three mm, are directly sutured together to reunite the 
proximal and distal segments, providing a tension free coaptation in a well 
vascularized bed can be achieved (Grinsell and Keating, 2014). Microsutures can 
be used for gross fascicular matching, using the surface blood vessel patterns as a 
guide, and although as there is an increased risk of intraneural scarring and 
devascularisation, epineurial sutures are typically used (Kerns, 2008). Direct repair 
under excessive tension usually causes devascularisation of the nerve, leading to 
further atrophy along the nerve path and prohibiting regeneration. As such, nerve 
defects greater than the few millimeters permissive for suturing either require a graft 
to bridge the defect, which is most often the case, or an alternative reconstructive 
option depending on the location of the injury (Szynkaruk et al., 2012). 
1.4.5 Autografts  
Reversed interposition autologous nerve grafts (autografts) are considered the gold 
standard for severe nerve gap defects (De Luca et al., 2014). The grafts can be 
single, cable (multiple small nerve grafts aligned in parallel), trunk (mixed motor and 
sensory nerve grafts) or vascularized (nerve graft with arterial and venous blood 
supply intact), depending on the diameter and location of the injured nerve (Colen 
et al., 2009; Houschyar et al., 2016). Single grafts can be used to bridge the gap of 
an injured nerve with a smaller diameter, but cable grafts are required to 
approximate the diameter of larger nerves. Donor graft segments are harvested 
from more expendable (usually sensory) nerves, typically the sural or medial 
antebrachial nerve, to repair more critical (usually motor) nerve defects (Grinsell 
and Keating, 2014).  
Following transplantation, the donor autograft undergoes Wallerian degeneration, 
thus providing physical guidance for regenerating axons in a similar manner to 
spontaneous regeneration (Bell and Haycock, 2011; Grinsell and Keating, 2014). 
However, in addition to physical guidance, autografts provide a stimulating, 
permissive scaffold for regeneration, comprising appropriate ECM composition and 
architecture, and a basement membrane with adhesion motifs (Gaudet et al., 2011; 
Madura, 2012). Although autografts are considered the gold standard, 
approximately only 50 % of patients achieve functional sensory recovery and even 
less, approximately 40 – 50%, achieve functional motor recovery following nerve 
autografting (Lee and Wolfe, 2000; Ruijs et al., 2005; Grinsell and Keating, 2014). 
In addition, autografts are associated with significant limitations, including 
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sacrificing a functional nerve, donor site morbidity and unavoidable size and 
fascicle mismatch (Siemionow and Brzezicki, 2009). 
1.4.6 Nerve Guidance Conduits (NGCs) 
The various limitations of autografts and direct suturing, the most widely used 
interventions for peripheral nerve repair, has led to the development of NGCs as an 
alternative (de Ruiter et al., 2009; De Luca et al., 2014). NGCs can be 
manufactured to any specification, are readily available and easily prepared, and do 
not require a second site of surgery or sacrifice of a functional nerve (Silva et al., 
2017). NGCs are primarily tubular constructs designed to enclose the opposing 
stumps of the severed axon and provide physical guidance to regenerating axons 
(Faroni et al., 2015). Following suturing of the severed axon into the NGC, protein 
rich axoplasmic fluid containing fibrinogen, various growth factors and neurotrophic 
factors is released into the NGC. A fibrin clot then forms, enabling cellular infiltration 









Figure 1.8 Peripheral nerve regeneration through a nerve guidance 
conduit (NGC). NGCs are used to repair nerve gap defects by suturing at the 
proximal and distal ends of a severed axon. Protein-rich axoplasmic fluid is released 
from the nerve stumps, and a fibrin clot then forms. The fibrin clot provides physical 
guidance to migrating Schwann cells and fibroblasts, enabling ECM remodelling and 
subsequent elongation of regenerating axons. Adapted from Steed et al. (2011) 
 
NGCs can be manufactured from synthetic and natural materials, and there are a 
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for NGCs include biocompatibility, to not induce an adverse host immune response, 
and biodegradability, enabling tissue remodelling whilst maintaining a mechanically 
stable environment during the regenerative process (Kehoe et al., 2012; Mobini et 
al., 2017). In addition, NGCs must have flexibility to enable nerve excursion and 
movement across articulating joints, and permeability to enable diffusion of 
nutrients and small molecules (Kehoe et al., 2012). 
1.4.6.1 Synthetic materials 
A number of different synthetic materials have been used for NGC fabrication, and 
their physical and chemical properties, including porosity and mechanical strength, 
can be modified (Wang and Cai, 2010; Bell and Haycock, 2011). Non-degradable 
polymers have previously been used, including silicone and polytetrafluoroethylene 
(PTFE). However, non-degradable polymers, such as silicone, have been reported 
to cause long-term inflammation and chronic nerve compression in clinical studies. 
For example, a study by Dahlin et al. (2001) investigated the use of silicone NGCs 
for the repair of median and ulnar repair defects, and reported that although 
promising functional recovery was observed up to 12 months post repair, localised 
inflammation and discomfort forced the removal of 7 out of 11 implanted conduits 
(Dahlin et al., 2001). Therefore, as non-degradable NGCs require a second surgery 
for removal, biodegradable synthetic polymers are preferred, providing that their 
degradation products are non-cytotoxic (Belkas et al., 2004; Siemionow et al., 2010; 
Kehoe et al., 2012).  
Synthetic biodegradable polymers frequently used for NGCs include polylactic acid 
(PLA), polyglycolic acid (PGA), and polycaprolactone (PCL) (Wang and Cai, 2010; 
Daly et al., 2012; Kehoe et al., 2012). However, these polymers are frequently 
synthesised as co-polymers, such as polylactic-co-glycolic acid (PLGA) or modified, 
including functionalisation with bioactive molecules, to optimise bioactivity, 
degradation rate, porosity, rigidity and biocompatibility (De Luca et al., 2014; 
Dalamagkas et al., 2016). A small number of NGCs manufactured from synthetic 
materials are commercially available, including resorbable NGCs Neurolac® and 
Neurotube® (Table 1.2). 
Neurotube® is a biodegradable, porous mesh NGC manufactured from PGA with a 
highly woven tubular structure (Battiston et al., 2007; Kehoe et al., 2012). Clinical 
studies of Neurotube® have reported comparable efficacy to autografts in defects 
up to 20 mm in length, however the NGC was found to degrade rapidly in vivo 
(within one – two months) (Mackinnon and Dellon, 1990; Donoghoe et al., 2007; 
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Bushnell et al., 2008). Furthermore, the high rates of degradation resulted in acidic 
degradation products (glycolate and pyruvate) (Kehoe et al., 2012). 
Neurolac® is a hollow tubular NGC manufactured from the co-polymer poly (D, L-
lactide-co-ɛ-caprolactone) (PCL). Neurolac® has been shown to degrade at a 
steady rate, without the production of toxic degradation products, and is 
transparent, enabling easy clinical insertion (Stang et al., 2009; Kehoe et al., 2012). 
Clinical studies of Neurolac® have demonstrated comparable efficacy to autografts 
in defects up to 30 mm in length (Bertleff et al., 2005; Meek et al., 2006). However, 
Neurolac® has also been shown to have high rigidity, and has been shown to 
induce swelling and fragmentation due to incomplete degradation (Kehoe et al., 
2012). 
1.4.6.2 Natural materials 
Naturally derived polymers, including ECM molecules (e.g. collagens, laminin, fibrin 
and hyaluronan), other polysaccharides (e.g. chitosan, alginate, agarose) and 
proteins (silk fibroin, keratin), have been used extensively for manufacturing NGCs 
and many of the currently commercially available NGCs are manufactured from 
natural polymers, particularly ECM derived polymers such as collagen (Table 1.2) 
(Bell and Haycock, 2011; Kehoe et al., 2012; Dalamagkas et al., 2016). The surface 
chemistry of natural polymers contains adhesion motifs which bind to cellular 
integrins, enabling cellular adhesion (Hersel et al., 2003; Dalamagkas et al., 2016). 
For example, collagen type I contains various adhesion motifs, including the RGD 
amino acid sequence, which bind collagen-associated integrins α1β1 and α2β1 
expressed by neurons and Schwann cells, as shown in Table 1.1 (Heino, 2007; 
Nieuwenhuis et al., 2018). 
Although the degradation rate of natural polymers can be modified, for example by 
chemical cross-linking, natural polymers are associated with poor mechanical 
properties (Xie et al., 2008; Wang and Cai, 2010; Khaing and Schmidt, 2012). As 
such, natural polymers are usually used in combination, as co-polymers, with either 
another biodegradable natural polymer (e.g. collagen-chitosan scaffolds) or with a 
biodegradable synthetic polymer (e.g. collagen-PGA) (Bell and Haycock, 2011; De 
Luca et al., 2014). 
NeuraGen®, NeuroFlex™ and NeuroMatrix™ are NGCs manufactured from bovine 
collagen type I, a major component of peripheral nerve ECM (Kehoe et al., 2012). 
Collagen type I is a commonly used biomaterial due to high biocompatibility, easy 
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isolation and modification, although there is high batch variation in collagen type I 
production and therefore reproducibility represents the main limitation of collagen 
type I NGCs (Stang et al., 2004; Kehoe et al., 2012).  
NeuraGen® is a semi permeable, hollow bovine collagen type I construct, and the 
fibrillar collagen structure is maintained in the fabrication process (Du et al., 2018). 
Clinical studies of NeuraGen® have shown comparable clinical efficacy to 
autografts in defects up to 20 mm in length (Farole and Jamal, 2008; Lohmeyer et 
al., 2009). Furthermore, pre-clinical studies of NeuraGen® have also demonstrated 
efficacy in defects up to 40 mm in length (Archibald et al., 1991).  
NeuroFlex™ and NeuroMatrix™ are crimped, semi-permeable, hollow bovine 
collagen type I constructs, however NeuroFlex™ is also flexible and kink-resistant 
up to 140° of flexion. Interestingly, there are currently no published studies on the 
clinical efficacy of NeuroFlex™ or NeuroMatrix™, however both conduits are not 
recommended for the repair of defects exceeding 25 mm (Kehoe et al., 2012; 
Lackington et al., 2017). However, whereas the degradation time of NeuroFlex™ 
and NeuroMatrix™ is 4 – 8 months, NeuraGen® has a degradation time of 
approximately 4 years, which may lead to long-term chronic nerve compression and 
require further surgery for the removal of the conduit. Clinical studies of NeuraGen® 
have only included follow up of a maximum of two years, so the long-term 





Table 1.2 Current FDA approved absorbable nerve guidance conduits (NGCs). Current FDA approved absorbable NGCs for use in peripheral 
nerve repair. Non-resorbable conduits, cuffs and wraps are not included in the table. Adapted from Kehoe et al. (2012) and Lackington et al. (2017).            
 
 Company Biomaterial Composition Diameter Length Degradation Clinical studies  







Polyglycolic acid (PGA) 
 
Hollow tubular construct 2.3–8 mm 2–4 cm 3 months 4 repairs, median nerve <30 
mm, unspecified follow up – 
(Donoghoe et al., 2007) 
Good recovery of motor and 
sensory function 
 
136 repairs, digital nerve, < 
4 mm gap, follow up 8 – 10 
months (Bushnell et al., 
2000) 
Good recovery, however no 
statistical significance between 
conduit and control group 
 
NeuraGen® Integra Life 
Sciences 
Corp. 
Bovine collagen type I 
 
Hollow tubular construct 1.5–7 mm 
 
2–3 cm 36-48 months 12 repairs digital nerve < 20 
mm, 12-22 months follow up 
(Farole et al., 2008) 
4/9 excellent 4/9 good 
1/9 fair 
 
15 repairs digital nerve, < 20 
mm gap, 12 months follow 
up – Lohmeyer et al., 2009) 
4/12 excellent sensibility 
5/12 good 
1/12 poor 







Hollow tubular construct 1.5–
10 mm 
 
3 cm 16 months 34 repairs, digital nerve, < 
20 mm, follow up 12 months 
(Bertleff et al., 2005) 
Good recovery, however no 
statistical significance between 
conduit and control group 
 




Bovine collagen type I 
and glycosaminoglycan 
(chondroitin-6-sulfate) 
Tubular collagen conduit 
with porous inner hydrogel 
matrix of collagen and 
chondroitin-6-sulfate 




Unknown Clinical data not yet available in the published literature  
NeuroMatrix™ Collagen 
Matrix Inc. 
Bovine collagen type I Hollow tubular construct 2–6 mm 2.5 cm 
 
4-8 months Clinical data not yet available in the published literature  
NeuroFlex™ Collagen 
Matrix Inc. 
Bovine collagen type I Hollow tubular construct 2–6 mm 2.5 cm 
 
4-8 months Clinical data not yet available in the published literature  
NerBridge® Toyobo Co., 
Ltd 
Polyglycolic acid (PGA) 
with porcine collagen 
type I and III 
Tubular construct with 
outer and inner surfaces 
coated with collagen 
0.5 – 4 
mm 
3 – 5 cm Unknown Clinical data not yet available in the published literature  
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1.4.6.3 Recent advances in NGC fabrication 
Recent developments in NGC fabrication have included architectural modifications 
at the macro, micro and nanoscale level, designed to provide different 
topographical cues to promote axon regeneration (Lackington et al., 2017). 
Macroscale modifications include the development of single lumen, multi-lumen, 
rolled and hydrogel based luminal fillers (Ansselin et al., 1997; Stang et al., 2005; 
Chang et al., 2007; Jenkins et al., 2015). Microscale modifications include the 
development of highly axially aligned channels, microgrooves, microfilaments and 
fibres, and microporous scaffolds to provide intraluminal surface topography to 
support cellular attachment and alignment (Cai et al., 2005; Lin et al., 2008; Lee et 
al., 2012; Gnavi et al., 2018). Various techniques are used for these modifications, 
including direct moulding to shape multi-lumen NGCs and controlled crosslinking, 
freeze drying and electrospinning to generate pores and fibres (Sill and von Recum, 
2008; Haugh et al., 2010; Gnavi et al., 2018). 
Another advance in NGC fabrication is surface modification of constructs with ECM 
proteins, including basement membrane proteins to enhance cell attachment and 
axon regeneration (Gao et al., 2013; Lackington et al., 2017). ECM molecules, 
including laminin and fibronectin, have been added to the surface of NGCs and 
incorporated into luminal fillers to stimulate cell adhesion, migration and axon 
regeneration (Gao et al., 2013; De Luca et al., 2014). The incorporation of laminin 
has been shown to promote Schwann cell proliferation and stimulate neurite 
extension in vitro and in vivo (Matsumoto et al., 2000; Suri and Schmidt, 2010; Cao 
et al., 2011). Fibronectin has been shown to act synergistically with laminin, and 
requires controlled deposition as excess debris prevents completion of regeneration 
(Chen et al., 2000; Ahmed et al., 2003; Mosahebi et al., 2003; Han et al., 2010). In 
addition to ECM molecules themselves, research has focused on incorporating 
selective cell-binding motifs derived from ECM proteins, as these motifs can be 
incorporated at a higher density and can convey specific cell-material interactions 
(Gao et al., 2013). Several motifs, including the RGD, IKVAV and YIGSR amino 
acid sequences have been shown to promote Schwann cell and neuron adhesion 
(Hersel et al., 2003; Wei et al., 2007). However, there are few studies investigating 
functionalized NGCs in vivo, aside from NGCs functionalised with the RGD motif 
which has been shown to successfully promote axon regeneration in a 10 mm rat 
sciatic defect model up to three months post-injury (Ahmed and Jayakumar, 2003). 
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1.4.6.4 Limitations of NGCs 
Relatively few NGCs are commercially available, confined to those manufactured 
from a limited number of biodegradable materials such as collagen I, PGA and PCL 
(Table 1.2) (Kehoe et al., 2012). Clinical studies of the currently available NGCs 
have reported a comparable efficacy between autografts and NGCs for small 
defects, typically up to 20 mm in length, however clinical studies have yet to 
demonstrate superior efficacy to autografts (Kehoe et al., 2012; Gerth et al., 2015). 
In addition, outcomes from clinical studies are highly variable, and variations in 
nerve type, cause of injury, and outcome measures limit comparisons between 
NGCs (Gerth et al., 2015).  
The majority of NGCs currently available are hollow tubular conduits, and 
NeuraGen® is the only NGC containing a collagen-glycosaminoglycan hydrogel 
luminal filler (Faroni et al., 2015). It is thought that the limited efficacy of NGCs, 
particularly for the repair of longer defects, is due to the lack of a native ECM 
architecture and biochemical composition necessary to provide physical guidance 
to regenerating axons, and support the attachment and proliferation of Schwann 
cells (Whitlock et al., 2009; Faroni et al., 2015). Although, as discussed previously, 
recent advances in NGC development have focused on architectural modifications 
and the addition of ECM components to NGCs, the majority of this research is still 
experimental and is yet unable to replicate the complex properties of the natural 
ECM (Mobini et al., 2017; Lackington et al., 2017). 
1.4.7 Allografts 
Human cadaveric allografts are rarely used, except in a limited number of cases 
when there is insufficient autograft material available for major nerve reconstruction 
following extensive injury (Grinsell and Keating, 2014). In contrast to autografts, 
there are no donor supply or donor site morbidity limitations associated with the use 
of allografts, although there are several other complications (Schmidt and Leach, 
2003; Siemionow and Brzezicki, 2009).  
Allografts contain donor cells, displaying major histocompatibility complex (MHC) 
molecules (Ayala-García et al., 2012). The role of MHC molecules is to present 
foreign antigens, such as epitopes from cytoplasmic or internalised pathogens, 
inducing a specific cell-mediated immune response. However, as MHC molecules 
are specific to each individual, MHC molecules displayed on allogeneic cells are 
recognised as foreign by the host immune system, and induce a T-cell mediated 
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immune response, ultimately causing rejection of the graft. Initial acute rejection of 
transplants can be caused by direct or indirect recognition of allogeneic MHC class 
II proteins presented by antigen presenting cells, or by indirect recognition of MHC 
molecules shed by allogeneic cells (Ayala-García et al., 2012; Lakkis and Lechler, 
2013). Consequently, nerve allograft recipient patients require systemic 
immunosuppression (typically for up to two years) until the graft has been 
repopulated with recipient cells, and are exposed to associated risks of infection 
and malignancy (Grinsell and Keating, 2014). As a result, it is widely stated that 
allografts should be reserved for patients with injuries irreparable by autograft 
which, without an allograft, would result in limb paralysis (Moore et al., 2009; 
Grinsell and Keating, 2014). 
1.4.8 Decellularised tissue grafts 
Decellularisation of allogeneic or xenogeneic tissue has the potential to produce a 
non-immunogenic ECM scaffold with biological, biochemical and biomechanical 
characteristics similar to native tissue (Badylak et al., 2009; Crapo et al., 2011; 
Kawecki et al., 2018). Decellularisation processes have been designed to remove 
cells and nucleic acids from tissue, thus minimising the potential for an adverse 
immunological response by removing the major immunogenic components (Gilbert 
et al., 2006; Nagata et al., 2010). Xenogeneic ECM proteins, such as collagens, 
can also elicit an adverse immune response (Wong and Griffiths, 2014; Aamodt and 
Grainger, 2016). However, ECM proteins are highly conserved within higher 
mammals, including humans and pigs, and therefore porcine ECM proteins are also 
non-immunogenic (Badylak, 2004; Bayrak et al., 2010). 
The decellularised tissue retains overall ECM histioarchitecture and biochemical 
composition, and contains appropriate regenerative cues, including topographical 
and biological cues necessary for forming cell-cell and cell-matrix contacts, 
providing a three-dimensional, native scaffold for regeneration (Gilbert et al., 2006; 
Badylak, 2014). As such, decellularised tissues have great potential as scaffolds for 
uses in tissue engineering applications, and a number of allogeneic and xenogeneic 
decellularised tissue products are commercially available (Table 1.3) (Crapo et al., 
2011; Chen and Liu, 2016; Parmaksiz et al., 2016; Boccafoschi et al., 2019).  
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Table 1.3 Commercially available decellularised tissue products.  
Examples of commercially available allogeneic and xenogeneic decellularised tissue 
products for the repair of various tissues. NHSBT TES = NHS Blood and Transplant 
Tissue and Eye Services, BDM = Demineralised Bone Matrix, AV = Arteriovenous. 
Adapted from Chen and Liu (2016), Parmaksiz et al. (2016) and Boccafoschi et al. 
(2019). 
Product Manufacturer ECM source Application 
AlloDerm® LifeCell Corp., USA Human dermis Skin and soft tissue repair 
AlloMatrix® Wright Medical Inc., USA Human bone (DBM 
with calcium sulphate) 
Bone repair (cavitary bone 
deficiency, augmentation of 
segmental bone loss) 
AlloPatch® Musculoskeletal transplant 
foundation, USA 
Human fascia lata Rotator cuff augmentation 
AlloPatch HD™ Musculoskeletal transplant 
foundation, USA 
Human dermis Tendon reconstruction 
Artegraft® Artegraft Inc., USA Bovine carotid artery AV access 
CorMatrix ECM™ CorMatrix Cardiovascular 
Inc., USA 
Porcine small intestine Cardiovascular repair 





NHSBT TES, UK Human dermis Skin and soft tissue repair 
dCELL® DBM NHSBT TES, UK Human bone (DBM 
combined with glycerol) 
Bone void filler 
DermaMatrix™ Depuy Synthes Inc., UK Human dermis Soft tissue repair 
Epic™ SJM Biocor®, St. Jude 
Medical Inc., USA 
Porcine heart valve Cardiovascular repair 
Grafton® Osteotech Inc., USA Bone (BDM combined 
with glycerol) 
Bone repair (cavitary bone 
deficiency) 
GraftJacket® Wright Medical Inc., USA Human dermis Augmentation of rotator 
cuff, tendon repairs 
Hancock® II, Mosaic®, 
and Freestyle® 
Medtronic Inc., USA Porcine heart valve Valve replacement 
NeoForm™ Mentor Worldwide LLC, 
USA 
Human dermis Breast augmentation 
Optefil®, Opteform® 
and Optecure® 
Exactech Inc., USA Human bone (DBM 
ready to be hydrated in 
gelatin carrier 
Bone repair (cavitary bone 
deficiency, augmentation of 
segmental bone loss) 
Perimount® Edwards Lifesciences LLC, 
USA 
Bovine pericardium Valve replacement 
Prima™ Plus Edwards Lifesciences LLC, 
USA 
Porcine heart valve Valve replacement 
Restore™ DuPuy, West Chester, PA, 
USA 
Porcine small intestine Soft tissue repair 
Surgisis®, Durasis® 
and Stratasis® 
Cook Biotech, USA Porcine small intestine Soft tissue repair 
Strattice™ LifeCell Corp., USA Porcine dermis Skin and soft tissue repair 
Viagraf® Smith & Nephew Inc., USA Human bone (DBM 
combined with glycerol) 
Bone void filler 
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1.4.8.1 Decellularisation criteria 
Decellularisation processes should remove sufficient immunogenic material from 
the tissue to minimise the potential for an adverse immunological response (Gilbert 
et al., 2006; Nagata et al., 2010; Crapo et al., 2011). Whilst there are no existing 
national or international standards for defining tissue decellularisation, the widely 
used criteria for the successful removal of immunogenic material are based upon 
data presented by Crapo et al. (2011). The criteria proposed include a total of less 
than 50 ng of double stranded DNA (dsDNA) per mg of tissue (dry weight), no 
fragments of DNA greater than 200 base pairs in length, and no nucleic acids 
visible when decellularised tissue sections are stained with haematoxylin and eosin 
(H & E) (Crapo et al., 2011). These criteria proposed by Crapo et al. (2011) are 
considered as guidelines, and are based on evidence suggesting that the amount of 
double stranded DNA in a decellularised tissue scaffold is proportional to the host 
immune response upon implantation (Gilbert et al., 2009; Crapo et al., 2011; 
Kawecki et al., 2018). Residual fragments of double stranded DNA are recognised 
by intracellular sensor proteins of cells of the innate immune system, such as 
macrophages and dendritic cells (Paludan and Bowie, 2013). Binding of double 
stranded DNA activates signalling pathways which initiate an inflammatory 
response, characterised by the induction of the M1 phenotype in activated 
macrophages, and enhanced secretion of pro-inflammatory cytokines including IL-
1β and IL-6 (Erdag and Morgan, 2004; Paludan and Bowie, 2013; Jønsson et al., 
2017). 
However, several studies have reported no adverse immune responses from 
decellularised tissues containing trace amounts of DNA, and many clinically 
available decellularised tissue products have been found to contain residual 
quantities of DNA, including the Oasis™ and Restore™ products, processed from 
porcine small intestinal submucosa (Gilbert et al., 2009; Gilpin and Yang, 2017; 
Kawecki et al., 2018). Gilbert et al. (2009) reported quantifiable DNA levels in eight 
commercially available decellularised tissues, however each scaffold demonstrated 
clinical efficacy and no adverse immune response (Gilbert et al., 2009). 
Furthermore, it has been suggested that residual DNA in isolation may only induce 
localised calcification (Booth et al., 2002; Kawecki et al., 2018).  
It has also been suggested that the host immune response to decellularised tissue 
scaffolds may primarily be due to cellular remnants, including membrane 
phospholipids and associated proteins (Wong and Griffiths, 2014; Badylak, 2014; 
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Morris et al., 2017; Gilpin and Yang, 2017). A study by Londono et al., (2017) 
supplemented PuracolTM Plus collagen scaffolds with differing concentrations of 
xenogeneic cellular remnants that may be present in decellularised ECM scaffolds, 
including calf thymus DNA, mitochrondia isolated from L929 fibroblasts, and cell 
membranes isolated from porcine red blood cells. The supplemented scaffolds were 
then cultured in vitro with primary murine macrophages for 18 hours, or implanted in 
vivo in a rat abdominal wall defect model for 14 days. The study reported that 
murine macrophages showed an increase in pro-inflammatory marker inducible 
nitric oxide synthase (iNOS), and no expression of pro-remodelling marker Fizz1, 
regardless of concentration of cellular remnants when cultured in vitro with collagen 
scaffolds supplemented with cellular remnants. However, immunolabelling of rat 
macrophages following implantation of collagen scaffolds supplemented with 
cellular remnants in vivo showed a dose dependent pro-inflammatory response to 
differing concentrations of cellular remnants (Londono et al., 2017). Although the 
quantities of cellular remnants required to elicit an adverse host immune response 
upon implantation have yet to be established, these results reinforce the importance 
of the removal of cellular remnants from decellularised tissues. Therefore, it has 
recently been proposed that in addition to the criteria proposed by Crapo et al. 
(2011), decellularisation criteria should include the removal of cell membrane 
debris, including intracellular membrane compartments such as mitochondrial 
membranes (Kawecki et al., 2018). 
1.4.8.2 Immune response to xenografts 
Although both allogeneic and xenogeneic cells are recognised as foreign and can 
elicit immune rejection, as discussed previously, there are further risks associated 
with the presence of xenoantigens (Badylak, 2004). Xenogeneic cells of 
mammalian origin, with the exception of humans, apes and old world monkeys, 
possess a cell surface sugar, galactose α1-3 galactose (α-gal) (Galili et al., 1987). 
Humans have an abundance of anti-α-gal antibodies due to constant antigenic 
stimulation from bacteria in the gut, which rapidly bind to the α-gal epitope upon 
transplantation of xenogeneic cells, initiating hyper-acute rejection of xenografts 
(Erdag and Morgan, 2004). However, decellularisation of xenogeneic tissues 
removes immunogenic material, including whole cells, membranes and cytoplasmic 
proteins, and although small quantities of α-gal have been shown to be present in 
some decellularised scaffolds, such as porcine small intestinal submucosa (SIS), 
several studies have shown that this does not induce graft rejection (McPherson et 
al., 2000). A study in which α1,3 galactosyltransferase knockout mice were 
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implanted with decellularised porcine SIS containing high levels of α-gal found that 
the presence of α-gal increased the duration of inflammation and delayed tissue 
remodelling, but that the graft ultimately remodelled (Raeder et al., 2002). Another 
study by Daly et al. (2009) investigated decellularised porcine SIS containing α-gal 
in a primate model, and reported that the presence of α-gal elicited a serum 
antibody response, but had no adverse effect upon tissue remodelling (Daly et al., 
2009). Furthermore, several studies have shown that non-cell associated α-gal can, 
in fact, enhance wound healing, by the rapid recruitment and activation of 
macrophages to the injury site (Wigglesworth et al., 2011; Hurwitz et al., 2012). 
1.4.8.3 Methods of decellularisation 
Numerous methods have been developed for tissue decellularisation. Methods 
used in decellularisation processes can be broadly classified as physical, chemical, 
or enzymatic methods, and are often used in combination in decellularisation 
protocols to achieve sufficient removal of immunogenic material (Gilbert et al., 
2006; Crapo et al., 2011; Gilpin and Yang, 2017). However, although effective in 
removing immunogenic material, many decellularisation methods disrupt the 
structure and composition of the ECM, potentially compromising the biological and 
mechanical integrity of the resulting decellularised biological scaffold (White et al., 
2017). Consequently, decellularisation protocols are developed using a number of 
different methods to optimise the removal of immunogenic material whilst 
minimising alterations to ECM properties, preserving the integrity and regenerative 
capacity of the ECM scaffold (Gilbert et al., 2006; Kawecki et al., 2018). 
1.4.8.3.1 Chemical methods 
1.4.8.3.1.1 Detergents 
Detergents are surfactants, with a hydrophilic head region and a hydrophobic tail. 
Detergents are amphipathic molecules, and are able to solubilise hydrophobic 
molecules, such as membrane proteins in water (Seddon et al., 2004; White et al., 
2017). Detergents disrupt the cell membrane by integrating into the phospholipid 
bilayer, interacting with the hydrophobic portion of the bilayer and replacing the 
lipids. At concentrations above the critical micelle concentration, the detergent 
molecules form micelles containing lipids from the phospholipid bilayer and 
encapsulating solubilised membrane proteins, ultimately causing cell membrane 
disintegration into mixed micelles with detergent molecules which can then be 
washed from the tissue (Seddon et al., 2004; Gilbert et al., 2006). 
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1.4.8.3.1.2 Ionic detergents 
Ionic detergents have a hydrophilic head group with either a negative or a positive 
net charge. Ionic detergents are highly effective for the solubilisation of both nuclear 
and cytoplasmic membranes, acting by disrupting non-covalent protein-protein, 
protein-lipid and lipid-lipid interactions (Seddon et al., 2004). However, ionic 
detergents can cause significant ECM protein denaturation (White et al., 2017). 
Ionic detergents, such as sodium dodecyl sulphate (SDS) and sodium deoxycholate 
(SDC) are widely used and have been shown to be much more effective than non-
ionic or zwitterionic detergents for decellularisation (Seddon et al., 2004). SDS, an 
anionic detergent, is highly effective in disrupting cell membranes and facilitating 
the removal of both phospholipid and protein components, but has also been shown 
to disrupt matrix components, with decellularised tissues showing collagen damage 
and a reduction in GAG content when SDS is used at high concentrations for 
prolonged periods of time (Bhuyan, 2010; Faulk et al., 2014a). Using low SDS 
concentrations (0.1 % w/v; 0.5 % w/v) has been shown to minimise the disruption of 
ECM proteins, with improved retention of collagen structure and GAGs reported in 
decellularised tissues (Paniagua Gutierrez et al., 2014). Incorporating protease 
inhibitors, such as aprotinin, has also been shown to further minimise ECM 
disruption, by inhibiting the activity of matrix metalloproteinases released during cell 
membrane disintegration and cell lysis and preventing enzymatic ECM degradation 
(Wilshaw et al., 2012). 
1.4.8.3.1.3 Non-ionic detergents 
Non-ionic detergents have an uncharged hydrophilic head region and do not disrupt 
protein-protein interactions, and therefore have minimal effects on ECM proteins. 
Triton X-100 is one of the most widely used non-ionic detergents for 
decellularisation (Seddon et al., 2004; White et al., 2017). Decellularisation using 
Triton X-100 has shown mixed results, in terms of efficacy and the effects on the 
ECM, dependent on tissue type, concentration and exposure time (Gilbert et al., 
2006; Crapo et al., 2011). A study by Dahl et al. (2003) comparing decellularisation 
of porcine carotid arteries with Triton X-100 and SDS reported that decellularisation 
with Triton X-100, even at high concentrations (5 % v/v or 10 % v/v), had a lower 
efficacy in terms of cell nuclei and DNA removal compared to decellularisation with 
1.8 mM SDS (Dahl et al., 2003) 
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1.4.8.3.1.4 Zwitterionic detergents 
Zwitterionic detergents have a net neutral charge, possessing both a positive and a 
negative charge at different regions of the molecule, and as such exhibit properties 
of both ionic and non-ionic detergents and disrupt protein-protein interactions more 
effectively than non-ionic detergents. One of most commonly used zwitterionic 
detergents is 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
(CHAPS) (Seddon et al., 2004; Crapo et al., 2011). CHAPS has been used to 
successfully decellularise human and porcine lung tissue, and the use of 8 mM 
CHAPS was shown to preserve tissue architecture and biomechanical properties 
better than 1.8 mM SDS (O'Neill et al., 2013). However, other studies have reported 
incomplete decellularisation using CHAPS. Booth et al. (2002) reported incomplete 
decellularisation of porcine aortic heart valve tissue with CHAPS (0.5 % w/v), 
although no deleterious effects on ECM architecture or biochemical composition 
were observed (Booth et al., 2002). Ferng et al. (2017) reported incomplete 
decellularisation of whole porcine hearts with CHAPS, and showed that whole cell 
nuclei were still present in the tissue (Ferng et al., 2017). 
1.4.8.3.1.5 Hypotonic and hypertonic buffers 
Hypotonic buffers induce cell swelling and cell lysis by osmosis, and hypertonic 
buffers dissociate DNA-protein complexes within cells (Crapo et al., 2011). These 
solutions are also used to aid the removal of cellular debris from tissue, however it 
is often necessary to use these solutions in combination with other chemical or 
enzymatic treatments, e.g. detergents, to increase efficacy and fully remove DNA 
and cellular material (Gilbert et al., 2006). 
1.4.8.3.1.6 Other chemical agents 
Acids and bases hydrolyse biomolecules, enabling solubilisation and removal of cell 
membrane components and intracellular nucleic acids (Crapo et al., 2011). 
Peracetic acid is an effective decellularisation agent and also a sterilant, with a high 
level of oxidative activity inducing the denaturation of intracellular and membrane-
associated microbial proteins (Dai et al., 2016). Low concentrations of peracetic 
acid (0.1 % v/v in 4 % v/v ethanol) have been used to successfully decellularise 
several thin tissues, such as intestinal submucosa and bladder, with minimal effects 
on ECM structure (Rosario et al., 2008; Syed et al., 2014).  However, such 
treatments have also been shown to disrupt ECM collagen. Analysis of murine lung 
tissue treated with peracetic acid showed denaturation of collagens type I, IV and VI 
and laminin, most likely caused by oxidative damage (Bonenfant et al., 2013). 
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Porcine small intestinal submucosa decellularised using a 12 hour incubation in 0.1 
% (v/v) peracetic acid showed significant increases in Young’s modulus and yield 
stress, and a significant reduction in failure strain (Syed et al., 2014). Peracetic acid 
has also been used in combination with other reagents to facilitate decellularisation. 
Porcine bladder has been successfully decellularised using a combination of 0.1 % 
(v/v) SDS and 0.1 % (v/v) peracetic acid, with minimal effects on ECM structure or 
biomechanical properties (Rosario et al., 2008).  
Chelating agents such as ethylene diamine tetra-acetic acid (EDTA) are often 
incorporated into decellularisation processes to facilitate the removal of cells from 
the ECM (Crapo et al., 2011). Chelating agents disrupt the interactions between cell 
adhesion molecules and the ECM by chelating metal ions (e.g. Mg2+, Ca2+) that are 
necessary for adhesions through attachment molecules such as integrins (Yamniuk 
and Vogel, 2005; Faulk et al., 2014a). Furthermore, the chelation of metal ions 
inhibits the activity of matrix metalloproteinases released during cell lysis (Gilbert et 
al., 2006). Booth et al. (2002) used SDS (0.1 % w/v) for the decellularisation of 
porcine aortic valves, and included EDTA (0.1 %; w/v) in combination with aprotinin 
(10 KIU.mL−1), a serine proteinase inhibitor, in the decellularisation process to 
inhibit all proteinases that may be present within the tissue (Booth et al., 2002). 
1.4.8.3.2 Enzymatic methods 
Enzymes, such as nucleases, proteinases and lipases are often used as part of 
decellularisation processes to mediate highly specific removal of certain 
components (Gilbert et al., 2006).  
Proteinases, such as trypsin, have been considered for use in isolation for 
decellularisation (Crapo et al., 2011). However, the relatively high enzyme 
concentration and long exposure times required to complete decellularisation have 
been shown to cause significant damage to various ECM components, including 
collagen fibres and elastin (Kasimir et al., 2003; Zou and Zhang, 2012). Lower 
concentrations of trypsin have been successfully used as an initial decellularisation 
step, to mediate the detachment of cells and enhance the diffusion of reagents in 
tissues with a relatively dense ECM (Rana et al., 2017). The use of trypsin in 
combination with other reagents, such as EDTA, SDS or Triton X-100 has been 
shown to increase the efficacy of decellularisation of various tissues, including 
human articular cartilage, porcine articular cartilage, and porcine trachea (Rahman 
et al., 2018).  
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Nucleases are used to cleave nucleic acids, and are essential for the removal of 
DNA and nucleic acids which remain in the tissue following cell lysis induced by 
physical or chemical treatments (Gilpin and Yang, 2017; Philips et al., 2018; 
Kawecki et al., 2018). Nucleases have been shown to reduce the DNA content of 
several tissues, including heart valves, tendon, and osteochondral tissues following 
detergent treatment (Crapo et al., 2011; Philips et al., 2018; Kawecki et al., 2018). 
Endonucleases, such as Benzonase, are advantageous in that they are able to 
cleave nucleotide sequences from within, as opposed to exonucleases which 
remove nucleotides from the ends of the sequence (Gilpin and Yang, 2017). 
1.4.8.3.3 Physical methods 
A number of physical methods can be used as part of decellularisation procedures, 
with freeze-thaw cycles, sonication and agitation often incorporated (Crapo et al., 
2011). Repetitive freeze-thaw cycles are commonly used, and have been included 
in decellularisation processes for various tissues including cartilage, liver and lung 
(Venkatasubramanian et al., 2006; Poornejad et al., 2015). Freezing produces ice 
crystals, which induce cell lysis but also increase tissue permeability, enhancing 
diffusion of solutions. However, the formation of ice crystals can also damage ECM 
proteins and adversely affect ECM microstructure, therefore it is important to 
optimise the freezing rate and temperature to control ice crystal size and formation 
(Keane et al., 2015). 
Agitation and sonication are commonly employed in decellularisation protocols to 
enhance the permeation of chemical and enzymatic solutions and aid the wash out 
of cellular debris. Sonication is often used to increase the permeability of dense 
tissues and agitation, provided by using orbital shakers, magnetic stirrers or rollers, 
is used to enhance diffusion of reagents and has been shown to increase DNA 
wash out from tissues (Montoya and McFetridge, 2009a; Azhim et al., 2014). 
However, excessive agitation speed or sonication frequency can lead to the 
disruption of ECM structure, so these processes must be optimised for each tissue 
type, size and density (Keane et al., 2015; Gilpin and Yang, 2017).    
1.4.8.4 Decellularised peripheral nerve grafts 
Decellularised peripheral nerve grafts offer considerable potential for peripheral 
nerve repair, overcoming the limitations associated with the immunogenicity of 
allografts and providing a native microenvironment to facilitate axon regeneration 
with ECM properties that cannot yet be recapitulated using current NGC fabrication 
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techniques (Schmidt and Leach, 2003; Whitlock et al., 2009; Szynkaruk et al., 
2012). It has been hypothesised that a decellularised nerve graft will promote axon 
elongation and facilitate regeneration through the provision of a native 
microenvironment, particularly intact endoneurial tubes and a basement membrane 
(Whitlock et al., 2009; Karabekmez et al., 2009; Moore et al., 2011). A number of 
methods have been documented for the decellularisation of allogeneic and 
xenogeneic peripheral nerve, including physical, chemical or enzymatic methods 
(Hiles, 1972; Sondell et al., 1998; Hudson et al., 2004a; Wang et al., 2016; Zilic et 
al., 2016). 
1.4.8.4.1 Avance® nerve graft 
The Avance® nerve graft is currently the only commercially available decellularised 
peripheral nerve graft, a decellularised human allograft with lengths ranging 
between 15 and 70 mm marketed for clinical use in the USA since 2007 (AxoGen 
Inc. Alachua, FL). A chemical decellularisation process developed by Hudson et al. 
(2004), using Triton X-200 (0.14 % v/v) in combination with zwitterionic detergents 
sulfobetaine-10 (125 mM) and sulfobetaine-16 (0.6 mM) to decellularise rat sciatic 
nerve, has been licenced by Axogen® Inc. to produce the Avance® graft (Hudson 
et al., 2004a). The decellularisation process used to produce the Avance®  graft 
has been further developed for human nerves, with the addition of enzymatic 
digestion of CSPG, a known inhibitor of axon regeneration (Zuo et al., 2002). The 
Avance® nerve graft has been shown to achieve positive results in several clinical 
case studies, demonstrating performance superior to NGCs for small defects (up to 
approximately 30 mm), and often equivalent performance to autografts 
(Karabekmez et al., 2009; Moore et al., 2011; Johnson et al., 2011). Early clinical 
studies have shown that the Avance®  graft is safe and effective in sensory nerve 
defects up to 30 mm in length. The Mayo clinic reported on ten nerve injuries within 
the hand and fingers, and found that all ten subjects recovered two-point 
discrimination of 6 mm or better (Karabekmez et al., 2009). 
A comprehensive, multi-centre clinical study between 2007 and 2012 investigated 
the efficacy of Avance® grafts in sensory, mixed and motor nerve injuries with a 
mean graft length of 22 ± 11 (5 – 50) mm (Brooks et al., 2012). The study involved 
132 individual nerve injuries, with the majority of injuries in the digital nerves in the 
hand (60 %), followed by upper extremity nerves (32 %), head/neck regions (5 %) 
and lower extremities (3 %). Sufficient data for efficacy analyses was reported for 
76 injuries (49 sensory, 18 mixed, and 9 motor nerves). The graft was found to be 
safe, as no graft related adverse events were reported, and a 5 % revision rate was 
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reported. Meaningful recovery was observed in 87 % of the repairs, and subgroup 
analysis to determine the effects of factors known to influence outcome, including 
but not limited to nerve type, patient age, gap length, and mechanism of injury, 
found no significant differences with regard to recovery outcomes between the 
groups, demonstrating consistency. However, although not significant, several of 
the factors identified in the subgroup analysis did affect recovery, including nerve 
type (88.6 %, 85.7 % and 77 % meaningful recovery for sensory, motor and mixed 
nerves respectively), and defect length (100 %, 90.0% and 76.2 % for defects 5-14 
mm, 30-50 mm and 15-29 mm respectively). Overall, the Avance®  graft was found 
to be safe and effective in sensory, mixed and motor nerve defects between 5 and 
50 mm. In comparison to similar studies, the results compared favourably to 
autografts, and were superior to those reported for NGCs (Brooks et al., 2012). 
However, the study by Brooks et al. (2012) has various limitations, such as an 
increased risk of heterogeneity in the datasets, variability between subjects, injuries 
and data sources, and that observational studies could not be performed in a 
prospective, randomised manner. Furthermore, there are no obvious conclusions 
with respect to the relationship between outcome and influencing factors including 
gap length, patient age, and nerve type, in contrast to other literature reporting 
statistically significant relationships between these factors and outcomes. These 
findings could be attributed to the variation in the number of subjects in each group, 
the distribution of covariates across the groups, the impact of the graft on 
regeneration or differences in surgical approach (Brooks et al., 2012). 
1.4.8.4.2 Limitations of decellularised nerve grafts 
Although the Avance® graft has demonstrated superior clinical efficacy to NGCs 
when used to treat a range of nerve defect sizes, clinical studies using the Avance® 
graft have not yet demonstrated consistently superior outcomes in comparison to 
autografts, even in small defects (up to 30 mm) (Whitlock et al., 2009; Karabekmez 
et al., 2009; Moore et al., 2011; Szynkaruk et al., 2012). A functional model of a rat 
sciatic nerve defect showed that for defects of 14 and 28 mm, the Avance® graft 
facilitated the growth of a 20 fold greater population of myelinated axons in 
comparison to NeuraGen®, an NGC manufactured from type 1 bovine collagen, 
and contained significantly more nerve fibres at all time points (Whitlock et al., 
2009). However, the study also reported that the Avance® nerve graft contained 
only approximately 30 % of the number of nerve fibres found in autografts. A 
potential explanation for this could be that the decellularised nerve graft had 
diminished regenerative capacity as a consequence of ECM disruption (Whitlock et 
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al., 2009). It has been hypothesised that inadequate preservation of the linear 
architecture of endoneurial tubes and specific basement membrane components, 
including laminin and collagen type IV, impairs axon regeneration and cellular 
infiltration in a decellularised nerve graft (Whitlock et al., 2009; Lovati et al., 2018). 
1.4.9 Experimental strategies for peripheral nerve regeneration 
Autografts remain the gold standard intervention for the repair of longer nerve gap 
defects (over 30 mm)  (Siemionow and Brzezicki, 2009; Faroni et al., 2015; 
Lackington et al., 2017). Currently available NGCs are limited to the repair of 
shorter distances, typically 20 – 30 mm, and clinical studies have only 
demonstrated efficacy equivalent to autografts for the repair of defects up to 20 mm 
(Kehoe et al., 2012; Gerth et al., 2015). Although the Avance® graft has 
demonstrated superior clinical efficacy to NGCs for the repair of defects up to 30 
mm, clinical studies using the Avance® graft have shown limited efficacy over 
longer distances (up to 60 mm) (Moore et al., 2011).  
It is hypothesised that the efficacy of decellularised nerve grafts and NGCs is 
limited to shorter distances due to insufficient host Schwann cell migration to 
sustain axon regeneration (Szynkaruk et al., 2012; Gerth et al., 2015; Busuttil et al., 
2017). As discussed previously, Schwann cells are intrinsic for axonal survival and 
function, and serve a pivotal role in orchestrating peripheral nerve repair (Jessen et 
al., 2015; Jessen and Mirsky, 2016; López-Leal and Diaz, 2018). In addition to 
providing physical guidance to regenerating axons, Schwann cells produce various 
neurotrophic factors and cytokines and express cell adhesion molecules, as shown 
in Table 1.1 (Jessen and Mirsky, 2016). A study by Poppler et al. (2016) used rat 
decellularised nerve grafts for the repair of 30 mm and 60 mm defects in a rat 
sciatic nerve injury model, and although the study reported successful axon 
regeneration across the 30 mm defect, axonal elongation and regeneration was 
arrested across the 60 mm defects (Poppler et al., 2016). The study reported a 
higher stromal cell presence in the 60 mm grafts and found higher levels of 
Schwann cell senescence markers, including p16, concluding that longer nerve 
defects induce Schwann cell senescence and that host Schwann cell migration is 
insufficient to promote axon regeneration across longer defects (Poppler et al., 
2016).  
Recent experimental strategies for enhancing peripheral nerve regeneration have 
focused on the supplementation of NGCs and decellularised nerve grafts with 
exogenous factors to provide trophic support, stimulating axon regeneration and 
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delaying cell senescence (Figure 1.9). There have been two primary experimental 
approaches to supplementing NGCs and decellularised nerve grafts with 
exogenous factors: cellular therapies and pharmacotherapy (Faroni et al., 2015; 
Mobini et al., 2017; Lackington et al., 2017). Cellular therapies have included 
repopulation with Schwann cells and various stem cells including adult 
multipotential stem cells (MSCs), and pharmacotherapies have included delivery of 
the various neurotrophic factors produced by Schwann cells during axon 
regeneration. 
 
Figure 1.9 Supplementation of nerve guidance conduits (NGCs) with 
exogenous factors. Recent experimental advances in NGC fabrication have 
included the incorporation of axially aligned channels, microfibers and pores to 
provide physical guidance to regenerating axons. NGCs have also been 
supplemented with exogenous factors such as ECM proteins, support cells such as 
Schwann cells and various stem cells, and neurotrophic factors. Adapted from 
Bellamkonda et al. (2006)   
 
1.4.10 Cellular therapies 
1.4.10.1 Autologous Schwann cells 
An extensive number of studies have focussed on supplementing NGCs with 
Schwann cells, and have demonstrated improved regenerative outcomes in vivo in 
rat sciatic nerve defect models for varying distances (8 – 20 mm) (Zack-Williams et 
al., 2015; Lackington et al., 2017; Jiang et al., 2017). Several different methods 
have been used to introduce Schwann cells into NGCs, including direct injection, 
suspension within an intraluminal hydrogel, or release from the luminal wall (Faroni 
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et al., 2015; Fathi and Zaminy, 2017). Hydrogels, including alginate/fibronectin, 
gelatin, collagen, and Matrigel™, have been commonly used as substrates to 
incorporate Schwann cells into the lumen of NGCs (Faroni et al., 2015; Houschyar 
et al., 2016; Jiang et al., 2017). Autologous Schwann cells seeded into collagen 
type I NGCs have been shown to increase axon regeneration distance and improve 
functional recovery when used to treat 18 mm and 20 mm defects in a rat sciatic 
nerve injury model (Ansselin et al., 1997; Stang et al., 2005). A study by Georgiou 
et al., (2013) describes the development of an engineered neural tissue (EngNT) as 
a method to introduce Schwann cells. Self-alignment of primary Schwann cells 
within a tethered collagen hydrogel, followed by the removal of interstitial fluid, was 
shown to produce an aligned sheet of cellular collagen hydrogel. The sheets were 
then rolled up and delivered within a NeuraGen® conduit for the repair of a 15 mm 
rat sciatic nerve defect model. The study reported that, at 8 weeks post-
implantation, the constructs had facilitated axon regeneration across the defect 
(Georgiou et al., 2013).  
A number of studies have also focussed on supplementing human and rat 
decellularised nerve grafts with Schwann cells (Pedrini et al., 2018). Studies of in 
vivo rat sciatic nerve defects of 10-12 mm have demonstrated minimal improvement 
in axon regeneration with the inclusion of Schwann cells, however several studies 
of longer nerve gap defects have shown enhanced axon regeneration with the 
inclusion of Schwann cells (Guenard et al., 1992; Frerichs et al., 2002; Jesuraj et 
al., 2011; Szynkaruk et al., 2012). It has been hypothesised that this is due to the 
fact that host Schwann cells are able to traverse shorter distances, and that 
supplementation with Schwann cells may be most beneficial for the repair of longer 
defects in which endogenous Schwann cell infiltration is insufficient to support axon 
regeneration (Szynkaruk et al., 2012; Pedrini et al., 2018). 
Minimally manipulated autologous Schwann cells are currently the only clinically 
viable source of Schwann cells for supplementation of NGCs or decellularised 
nerve grafts, however they are associated with numerous limitations (Lackington et 
al., 2017). Schwann cell isolation requires an invasive nerve biopsy, consequently 
sacrificing a healthy, donor nerve, and several weeks of expensive, labour intensive 
culture expansion is required to obtain a sufficient number of viable cells (typically 
1-2 x 106 cells) (Jiang et al., 2010; Muheremu and Ao, 2015). In addition, culture 
expanded Schwann cells may display an abnormal phenotype following extensive 
manipulation as Schwann cell culture requires a highly specific medium, often with 
the addition of exogenous mitogens to induce proliferation (e.g. heregulin, or 
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forskolin) (Casella et al., 1996; Rodrı́guez et al., 2000; Komiyama et al., 2003; 
Dahlin et al., 2007). Due to these limitations, research has shifted towards stem 
cells and alternative cell sources to provide more accessible sources of Schwann 
cells for clinical application (Dahlin et al., 2007; Gu et al., 2011). 
1.4.10.2 Stem cells 
Embryonic stem cells (ESC), neural stem cells (NSC), and induced pluripotent stem 
cells (iPSC) have been considered for use in peripheral nerve repair (Zack-Williams 
et al., 2015; Jiang et al., 2017; Fathi and Zaminy, 2017). Mouse ESC-derived neural 
progenitor cells have been shown to promote nerve repair in immunocompromised 
rats in a 10 mm sciatic nerve defect model, and histological, molecular and 
electrophysiological studies demonstrated functional axon regeneration (Cui et al., 
2008). Furthermore, Schwann cell-like cells have been generated from human 
ESCs, and have been shown to promote axon regeneration in vitro and express 
myelin protein (Ziegler et al., 2011). Rat NSCs seeded in NGCs manufactured from 
chitosan have demonstrated comparable results to autografts when used to repair a 
10 mm rat sciatic nerve defect (Murakami et al., 2003). In addition, NSCs can be 
induced to overexpress trophic factors involved in axon regeneration, including 
glial-cell derived neurotrophic factor (GDNF) or NT-3 (Lackington et al., 2017; 
Busuttil et al., 2017). Functional neural crest cells have been generated from rat 
iPSCs, and have been shown to support axon regeneration in a 10 mm rat sciatic 
nerve defect model when incorporated into PLA-PCL conduits using FGF-enriched 
gelatin microspheres (Ikeda et al., 2014). However, human ESCs and NSCs are not  
clinically viable cell sources, and due to ethical considerations and the risk of 
teratoma formation or undesired cell differentiation, alternative adult stem cell types, 
mainly multipotential stem cells (MSCs), have received more interest (Jiang et al., 
2017; Busuttil et al., 2017; Lackington et al., 2017).  
Bone marrow-derived MSCs (BMSCs), harvested by aspiration of bone marrow 
from the long bones or iliac crest, have been extensively researched due to their 
accessibility, rapid culture expansion and inherent plasticity (Jiang et al., 2010; 
Zack-Williams et al., 2015; Jiang et al., 2017). Human and rat BMSCs have 
demonstrated promising results both in vitro and in vivo, and have been shown to 
differentiate into a Schwann cell-like phenotype and express glial markers such as 
glial fibrillary acid (GFAP) and S100 (Safford et al., 2004; Franco Lambert et al., 
2009). Chen et al. (2007) used rat BMSCs incorporated in silicone NGCs and 
reported increased numbers of regenerating axons and reduced muscle atrophy 
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when used to repair a rat sciatic nerve defect (Chen et al., 2007). A study by Fan et 
al. (2014) demonstrated improved functional recovery with the incorporation of rat 
BMSCs, differentiated into Schwann cells, into a decellularised nerve allograft used 
to repair a rat sciatic defect model, with similar outcomes reported to autografts 
(Fan et al., 2014). However, BMSCs also present several limitations, including the 
painful surgical procedure required to harvest bone marrow aspirates, and the 
relatively low cellular yield (Faroni et al., 2014; Fathi and Zaminy, 2017; Jiang et al., 
2017). 
Adipose-derived MSCs (ASCs) have been considered as a viable alternative to 
BMSCs as a source of multipotent stem cells (Zack-Williams et al., 2015). ASCs are 
easier to harvest, requiring a less invasive liposuction procedure and subsequent 
isolation of ASCs from the stromal vascular fraction, and have a 500-600 fold 
greater yield and faster culture expansion than BMSCs (Zack-Williams et al., 2015; 
Jiang et al., 2017). Several studies have demonstrated that human and rat ASCs 
can be induced to express glial cell markers, including S100, GFAP and P75 
neurotrophin receptor in vitro (Kingham et al., 2007). Oliveira et al. (2010) used rat 
ASCs incorporated in PCL conduits and demonstrated improved functional 
regeneration and myelination in a rat sciatic nerve defect model in comparison to 
PCL conduits in isolation (Oliveira et al., 2010). Similar to these findings, another 
study by Orbay et al. (2012) demonstrated functional improvement comparable to 
autografts when using a collagen conduit with rat ASCs incorporated into a collagen 
gel luminal filler (Orbay et al., 2012). Rat ASCs have also been used to supplement 
decellularised nerve grafts, and ASCs were shown to improve functional recovery 
and support an increased number of myelinated fibres when used to repair a rat 
sciatic nerve defect model (Sowa et al., 2016).  
Recent research has also focused on the use of skin derived precursor cells, 
(SKPs), and human and rat SKPs have been shown to differentiate into Schwann 
cell-like cells expressing S100, myelin basic protein (MBP), and GFAP (Biernaskie 
et al., 2006; McKenzie et al., 2006). Schwann cell-like cells differentiated from rat 
SKPs have been incorporated into rat decellularised nerve grafts, and were shown 
to improve functional recovery with electrophysiological outcomes similar to those 
observed for autografts (Walsh et al., 2009). Recently, adult human skin fibroblasts 
have been transdifferentiated into mature Schwann cells (Kitada et al., 2019). 
Genome-wide expression analysis suggested the conversion of fibroblasts to a 
Schwann cell lineage, and the Schwann cells were shown to improve axon 
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regeneration in a sciatic nerve defect model using immunosuppressed rats (Kitada 
et al., 2019). 
CTX0E03 is a clinical grade, clonal human neural stem cell line derived originally 
from the foetal cortex. CTX0E03 cells are multipotent, and are able to differentiate 
into neurons, astrocytes, and oligodendrocytes both in vitro and in vivo (Hicks et al., 
2013). CTX0E03 cells have been shown to be a suitable option for allogeneic 
implantation in humans without immunosuppression, and have been recently used 
in a Phase II clinical trial for patients with stroke disability (PISCES trial, 
NCT02117635), and a Phase I clinical trial for patients with lower limb ischaemia 
(NCT01916369). Recently, O’Rourke et al. (2018) used differentiated CTX0E03 
cells combined with collagen to form EngNT (EngNT-CTX). The EngNT-CTX 
constructs were then delivered within a NeuraGen® conduit to repair a 12 mm 
sciatic nerve defect model in athymic nude rats. The study reported no adverse 
events, and that the EngNT-CTX constructs supported neurite outgrowth and 
vascular growth through the injury site and facilitated the reinnervation of the target 
muscle (O’Rourke et al., 2018). However, although these results suggest that 
EngNT-CTX constructs could have clinical potential, differentiated CTX0E03 cells 
represent a source of extensively manipulated stem cells and are associated with a 
number of limitations (O’Rourke et al., 2018).  
Despite promising experimental results and the advantages to using stem cells as 
support cells, particularly the relative ease of harvest and rapid culture expansion in 
comparison to autologous Schwann cells, there remain several obstacles 
preventing their clinical use (Szynkaruk et al., 2012; Jiang et al., 2017; Lackington 
et al., 2017). The molecular mechanisms by which stem cells, including BMSCs and 
ASCs, enhance regeneration are not well understood, and further research is 
required prior to clinical translation (Zack-Williams et al., 2015; Jiang et al., 2017). 
For example, it has been suggested that implanted MSCs may enhance 
regeneration by synthesising ECM components or producing neurotrophic 
molecules, delaying cell death and stimulating regeneration (Chen et al., 2007; 
Wang et al., 2009). Furthermore, recent research has also suggested that the 
immunomodulatory properties of MSCs may also influence regeneration via indirect 
modulation of Schwann cell behaviour and / or establishing a favourable 
microenvironment for regeneration (Wang et al., 2009; Jiang et al., 2017). Further 
concerns regarding the use of stem cells include de-differentiation of Schwann cell-
like cells and the long term behaviour of the implanted cells, as this has not been 
established in detail, and the potential for teratoma formation or other malignancies 
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associated with extensively manipulated stem cells (Szynkaruk et al., 2012; 
Lackington et al., 2017). 
1.4.11 Pharmacotherapy  
Currently, there are no clinically available pharmacological treatments for peripheral 
nerve injury (Faroni et al., 2015; Lackington et al., 2017). However, several 
peptides, hormones, growth factors and other small molecules have been 
suggested as therapeutic agents (Faroni et al., 2015). Several hormones, including 
progesterone or allopreganolone, have been suggested as therapeutic targets as 
neuroactive steroids, modulating Schwann cell myelination (Melcangi et al., 2005; 
Faroni and Magnaghi, 2011). Several neurotransmitters have also been considered, 
including γ-aminobutiric acid (GABA), adenosine triphosphate (ATP), glutamate and 
acetylcholine, involved in neuron-glial interactions and neuron metabolism 
(Magnaghi et al., 2009). However, research has mainly focused on neurotrophic 
factors and other growth factors as potential therapeutic targets (Faroni et al., 2015; 
Mobini et al., 2017).  
Schwann cells provide trophic support to regenerating axons, releasing various 
neurotrophic molecules, cytokines and growth factors including NGF, brain-derived 
BDNF, and IGF (Jessen and Mirsky, 2016). Although the mechanisms by which 
MSCs promote axon regeneration are not well understood, it is thought that it is due 
to the provision of trophic support similar to Schwann cells (Jiang et al., 2017; Fathi 
and Zaminy, 2017). Several studies of rat sciatic nerve defect models have 
observed enhanced axon regeneration rates upon transplantation of 
undifferentiated ASCs seeded in poly-3-hydroxybutyrate and PCL NGCs, and did 
not observe any cell differentiation in situ, therefore concluding axon regeneration 
was likely enhanced by neurotrophin expression (Santiago et al., 2009; Erba et al., 
2010). 
NGF has been shown to support axon regeneration when administered both 
systemically and locally following peripheral nerve injury in rat sciatic nerve defect 
models (Wang et al., 2014; Emin Önger et al., 2016). Similarly, BDNF and ciliary 
derived neurotrophic factor (CTNF) have also been shown to improve axon 
regeneration and re-myelination (Sahenk et al., 1994; Lewin et al., 1997; Fine et al., 
2002). Neurotrophic molecules and other growth factors have been researched 
extensively as part of NGC development, and supplementation of collagen type I 
conduits with NGF has been shown to enhance axon regeneration across a 20 mm 
defect in a rat sciatic nerve injury model (Bellamkonda, 2006; Dodla and 
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Bellamkonda, 2008). Several studies have also demonstrated enhanced axon 
regeneration in decellularised nerve grafts used to repair 10-20 mm rat sciatic nerve 
defect models when supplemented with NGF, hepatocyte growth factor (HGF) and 
VEGF (Rovak et al., 2004; Li et al., 2008; Hu et al., 2009).    
Clinical application of growth factors is associated with significant limitations, 
including the timing and dosage of the growth factor, the method of administration, 
release and interactions with other growth factors and potent side effects 
(Szynkaruk et al., 2012; Faroni et al., 2015; Lackington et al., 2017). For example, 
mistimed or excessive concentrations of BDNF have been shown to inhibit axonal 
growth or induce neuronal death (Boyd and Gordon, 2002). In addition, several 
neurotrophins, including NGF and CTNF have half-lives of approximately 10 
minutes (Poduslo and Curran, 1996). As continuous infusion of growth factors is not 
a clinically viable delivery method, alternative methods for local delivery must be 
explored (Magnaghi et al., 2009; Szynkaruk et al., 2012). Therefore, current 
research has focused on exogenous modulation of endogenous growth factors, 
controlled growth factor release systems, or genetic modification of Schwann cells, 
BMSCs and ASCs to induce expression of desired growth factors (Busuttil et al., 












1.5 Rationale for the study 
Current interventions for peripheral nerve repair are limited and variable in efficacy, 
and are associated with a number of limitations (Siemionow and Brzezicki, 2009; 
Grinsell and Keating, 2014). Direct surgical repair is limited to defects of up to three 
mm, where a tension free coaptation can be achieved, and autografts, the gold 
standard intervention, require the sacrifice of a functional, minor nerve and often 
provide insufficient material for major reconstruction (Lee and Wolfe, 2000; Schmidt 
and Leach, 2003). Cadaveric fresh-frozen allografts can provide a native ECM to 
support axon regeneration in a similar manner to autografts, but the potential 
immunogenicity and risks associated with recipient immunosuppression present a 
significant limitation (Lee and Wolfe, 2000; Gao et al., 2013). 
Despite the development of a diverse array of NGCs relatively few are clinically 
available, confined to a limited number of biodegradable materials (Gu et al., 2014; 
De Luca et al., 2014). Furthermore, clinical studies of currently available NGCs 
have only demonstrated efficacy equivalent to autografts for the repair of defects up 
to 20 mm (Kehoe et al., 2012; Naryan et al., 2018). Clinical studies of the Avance®  
nerve graft, currently the only commercially available decellularised nerve allograft, 
have reported equivalent efficacy to autografts for the repair of defects up to 30 
mm, and have demonstrated superior clinical efficacy to NGCs when used to treat a 
range of nerve defect sizes (Karabekmez et al., 2009; Johnson et al., 2011). 
The limited efficacy of NGCs is thought to be due to the lack of a native ECM 
architecture and composition, at both a macrostructural and microstructural level 
(Whitlock et al., 2009; Faroni et al., 2015). The basement membrane, comprised of 
collagen type IV, laminin and fibronectin is essential for promoting cell-matrix 
interactions and supporting Schwann cell adhesion and axon elongation and 
maturation (Yurchenco et al., 2002; Yurchenco, 2011). Furthermore, the topography 
of endoneurial tubes is critical for guiding regenerating axons and avoiding axon 
deviation to restore function (Gao et al., 2013). However, clinical studies of the 
Avance® graft have not yet demonstrated consistently superior clinical outcomes to 
autografts, even in small defects (Karabekmez et al., 2009; Faroni et al., 2015). A 
potential explanation for this could be that the decellularised nerve graft has 
diminished regenerative capacity as a consequence of ECM disruption caused by 
the decellularisation process. Therefore, it has been hypothesised that a 
decellularised nerve allograft, with intact endoneurial tubes and a basement 
membrane, will promote axon regeneration and support Schwann cell infiltration 
(Whitlock et al., 2009). 
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Currently, autografts remain the gold standard intervention for the repair of longer 
nerve gap defects (over 30 mm) (Siemionow and Brzezicki, 2009; Lackington et al., 
2017). Clinically available NGCs are limited to the repair of shorter distances, 
typically 20 – 30 mm, and clinical studies using the Avance® graft have shown 
limited efficacy over longer distances (up to 60 mm) (Moore et al., 2011; Gerth et 
al., 2015). As discussed previously, Schwann cells have a pivotal role in axon 
regeneration and peripheral nerve repair, and it is hypothesised that the efficacy of 
decellularised nerve grafts and NGCs is limited to shorter distances due to 
insufficient host Schwann cell migration (Szynkaruk et al., 2012; Gerth et al., 2015; 
Busuttil et al., 2017). It is therefore essential for decellularised nerve grafts and 
NGCs to support viable Schwann cell populations and promote cellular adhesion, 
migration and proliferation (Lackington et al., 2017; Mobini et al., 2017). 
Recently, a collaborative partnership between the University of Leeds and the 
University of Sheffield resulted in the development of a decellularisation process for 
porcine peripheral nerve (Zilic et al., 2016). This process was adapted from the 
proprietary University of Leeds decellularisation process, which has been adapted 
for the decellularisation of various tissues, including porcine (Luo et al., 2014) and 
human (Vafaee et al., 2018) heart valves, porcine dermis (Helliwell et al., 2017), 
porcine tendon (Jones et al., 2017) and cartilage (Kheir et al., 2011). The 
decellularisation process utilises low concentration SDS (0.1 %; w/v) plus protease 
inhibitors, in combination with hypotonic and hypertonic buffers and nuclease 
treatment. The process was shown to sufficiently remove cellular and nuclear 
material from porcine peripheral nerves and preserve several key basement 
membrane components including laminin and collagen type IV (Zilic et al., 2016). 
However, the decellularisation process resulted in structural changes to ECM 
histioarchitecture, and changes in the distribution of laminin and fibronectin (Zilic et 
al., 2016). Therefore, the decellularisation process could be developed further to 






It is hypothesised that a biocompatible decellularised peripheral nerve graft, with a 
native ECM histioarchitecture and basement membrane, can be developed for use 
in peripheral nerve repair. 
1.7 Aims and objectives 
1.7.1.1 Aim 
The aim of this project is to develop a decellularised peripheral nerve allograft with 
a native ECM histioarchitecture and biochemical composition, able to support viable 
cell populations, for use in peripheral nerve repair. 
1.7.1.2 Objectives 
I. To further develop the decellularisation process previously developed for 
porcine peripheral nerves, maintaining the efficacy of decellularisation in 
terms of sufficient cell removal and DNA content reduction, whilst ensuring 
the preservation of overall histioarchitecture and major ECM structures.  
II. To characterise the biological and biochemical properties of native and 
decellularised porcine peripheral nerve by histological, 
immunohistochemical and biochemical analyses 
III. To develop a process for the decellularisation of human femoral nerves by 
translating the decellularisation process developed for porcine peripheral 
nerve 
IV. To characterise the biological and biochemical properties of native and 
decellularised human femoral nerve by histological, immunohistochemical 
and biochemical analyses 
V. To assess the in vitro recellularisation capacity of decellularised human 
femoral nerve and investigate the importance of endoneurial structure by 
culture with primary dorsal root ganglion (DRG) explants 
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2 Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Equipment 
The equipment used and equipment suppliers are listed in Appendix A, Table I. 
2.1.2 Consumables 
The consumables and plastic ware used and suppliers are listed in Appendix A, 
Table II. 
2.1.3 Chemicals and reagents 
The chemicals and reagents used and suppliers are listed in Appendix A, Table III. 
2.1.4 Glassware 
Glassware (beakers and bottles [100 mL, 1,000 mL and 2,000 mL]) were cleaned 
by immersion in a 1 % (v/v) detergent solution (Neutracon®, Decon Laboratories 
Ltd) overnight. Glassware were then rinsed in tap water followed by distilled water 
to remove residual detergent. Items were then dried and sterilised as described in 
Section 2.2.1.3. 
2.1.5 Cell lines 
The cell lines used in this study and suppliers are listed in Table 2.1 
Table 2.1 Cell lines used throughout the study 
Cells 
 






Epithelial Hamster Health Protection Agency 
L929  
 





The primary, secondary and isotype control antibodies used and suppliers are listed 
in Table 2.2. 






Isotype Supplier Code 
Primary Laminin Monoclonal 
mouse IgG1 













Sigma Aldrich C8035 







































- Dako X0942 
Secondary Goat anti-mouse 
IgG AlexaFluor 
488 
- Invitrogen A11001 
Secondary Goat anti-rabbit 
IgG AlexaFluor 
488 
- Invitrogen A11070 
 
Secondary Goat anti-mouse 
IgG AlexaFluor 
647 
- Abcam Ab150115 
Secondary Goat anti-mouse 
IgM AlexaFluor 
647 




2.1.7 General chemical stock solutions 
2.1.7.1 Phosphate buffered saline (PBS) 
Ten PBS tablets were dissolved in 1 L distilled water, and the pH adjusted to 7.2 – 
7.4 as described in Section 2.2.1.1. The solution was autoclaved as described in 
Section 2.2.1.2 and stored at room temperature for up to one month. 
2.1.7.2 Sodium hydroxide solution (NaOH), 6M 
NaOH pellets (120 g) were dissolved into 500 mL distilled water. The solution was 
stored at room temperature for up to six months. 
2.1.7.3 Ethanol (70 %; v/v) 
Distilled water (300 mL) was added to 100 % (v/v) ethanol (700 mL) to make up 1 L 
of 70 % (v/v) ethanol. 
2.1.7.4 Virkon solution (1 %; w/v) 
Virkon powder (50 g) was added to 5 L distilled water to make Virkon solution (1 %; 
w/v). 
2.1.8 Decellularisation solutions 
2.1.8.1 Antibiotic solution (0.05 mg.mL-1 vancomycin, 0.5 mg.mL-1 
gentamicin, 0.2 mg.mL-1 polymyxin B) 
Vancomycin hydrochloride (50 mg), gentamicin sulphate (500 mg) and polymyxin B 
(200 mg) were added to PBS (100 mL). The pH was adjusted to 7.2 – 7.4 as 
described in Section 2.2.1.1, and made up to 1L with PBS. The solution was used 
within one hour of production. 
2.1.8.2 EDTA solution (200 mM) 
EDTA (74.4 g) was added to 1 L distilled water. The pH was adjusted to 7.2 – 7.4 
as described in Section 2.2.1.1, and the solution was autoclaved as described in 
Section 2.2.1.3. The solution was stored for up to one month at room temperature. 
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2.1.8.3 Hypotonic buffer (10 mM Tris, 2.7 mM EDTA, 10 KIU. mL-1 
aprotinin) 
Trizma base (1.21 g) and EDTA (1 g) were added to 900 mL distilled water. The pH 
was adjusted to 8.0 – 8.2 as described in Section 2.2.1.1, and the solution was 
autoclaved as described in Section 2.2.1.3. The solution was stored for up to one 
month at room temperature. Immediately before use, 1 mL of aprotinin (10,000 KIU. 
mL-1) was added aseptically using a needle and syringe. 
2.1.8.4 SDS hypotonic buffer (0.1 % (w/v) SDS, 10 mM Tris, 2.7 mM 
EDTA, 10 KIU. mL-1 aprotinin) 
Sodium dodecyl sulphate (SDS) solution (10 mL; 10 %(w/v)) was added to 990 mL 
of autoclaved hypotonic buffer aseptically. Immediately before use, 1 mL of 
aprotinin (10 KIU.mL-1) was added aseptically using a needle and syringe. 
2.1.8.5 PBS EDTA solution (2.7 mM EDTA, 10 KIU. mL-1 aprotinin) 
Ten PBS tablets and EDTA (1 g) were dissolved in 1 L distilled water. The pH was 
adjusted to 7.2 – 7.4 as described in Section 2.2.1.1, and the solution was 
autoclaved as described in Section 2.2.1.3. The solution was stored for up to one 
month at room temperature. Immediately before use, 1 mL aprotinin (10 KIU.mL-1) 
was added aseptically using a needle and syringe. 
2.1.8.6 Nuclease solution (50 mM Tris, 1 mM MgCl2.6H2O, 1 U.mL-1 
Benzonase) 
Trizma base (6.1 g) and magnesium chloride (0.203 g) were added to 100 mL 
distilled water. The pH was adjusted to 7.5 – 7.7 as described in Section 2.2.1.1, 
and the solution was autoclaved as described in Section 2.2.1.3. The solution was 
stored for up to one month at room temperature. Immediately before use, 4 μL of 
Benzonase (250 U.μL-1) was added aseptically. 
2.1.8.7 Hypertonic solution (50 mM Tris, 1.5 M NaCl) 
Sodium chloride (87.66 g) and Trizma base (6.06 g) were added to 900 mL distilled 
water. The pH was adjusted to 7.5 – 7.7 as described in in Section 2.2.1.1, and the 
solution was autoclaved as described in Section 2.2.1.3. The solution was stored 
for up to one month at room temperature. 
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2.2 Methods 
2.2.1 General methods 
2.2.1.1 Measurement of pH 
The pH of solutions was measured using a Jenway 3020 pH meter. Prior to use, the 
pH meter was calibrated using solutions of pH 4, pH 7 and pH 10, with a 
temperature probe. Drop-wise addition of either 6 M hydrochloric acid or 6 M 
sodium hydroxide was used to adjust the pH of solutions. 
2.2.1.2 Microscopy 
Bright field (Köhler), circularly polarised light and fluorescent microscopy were 
performed using an Axio Imager M2 microscope (Zeiss). An AxioCam MCr5 digital 
camera (Zeiss) and Zen Pro software (Zeiss blue edition version 2.3) were used to 
capture digital images. A fluorescent illuminator, in conjunction with appropriate 
filters, was used for fluorescent microscopy. Phase contrast microscopy was 
performed using a BX51 inverted microscope (Olympus), and an XC-50 Camera 
(Olympus) and Cell B software (Olympus version 3.2) were used to capture digital 
images. 
2.2.1.3 Sterilisation 
Solutions and equipment were sterilised using dry heat, moist heat or filtration: 
 Dry heat sterilisation: items for dry heat sterilisation were placed in a hot 
oven for four hours at 180 °C. 
 Moist heat sterilisation: items not suitable for dry heat sterilisation were 
autoclaved for 20 minutes at 121 °C, at a pressure of 103 kPa. 
 Filter sterilisation: solutions not suitable for heat sterilisation were filtered 
using 0.2 μm pore sized filters with a disposable 10 mL syringe in a Class II 
safety cabinet. 
2.2.2 Acquisition of porcine peripheral nerves 
2.2.2.1 Porcine hind leg procurement 
Porcine hind legs (from Large White Yorkshire pigs, between 24 and 26 weeks of 
age) were obtained from a local abattoir (J. Penny, Leeds, United Kingdom). Hind 
legs were received up to three days following slaughter.  
54 
2.2.2.2 Porcine peripheral nerve dissection 
Peripheral nerves were dissected from the posterior and lateral sections of the 
posterior compartment of the hind leg respectively, to isolate the sciatic, peroneal 
and tibial nerves (Figure 2.1). Excess fat was removed by blunt dissection, and 
each nerve was washed for ten minutes three times using sterile PBS to remove 
excess blood and tissue fluid, at 4 °C and agitated at 50 rpm. Tissues were then 
stored at -70 °C on PBS moistened filter paper for future use.  
 
Figure 2.1 Dissection of porcine peripheral nerves from hind legs. (A) 
Porcine peripheral nerves were dissected from the posterior and lateral sections of 
the posterior compartment of each porcine hind leg. (B) The whole peripheral nerve 
plexus was dissected to isolate the sciatic, peroneal, tibial and sural nerves.  
2.2.3 Acquisition of human femoral nerves 
2.2.3.1 Human tissue procurement 
Following ethical approval (North East Health Research Authority and Tyne and 
Wear South NHS Research Ethics Committee ref 15/NE/0082, IRAS project ID 
199203), human femoral bundles were procured from NHS Blood and Transplant 
Tissue and Eye Services (NHSBT TES). Full written consent for the use of femoral 
bundles for research and development purposes was obtained from donors or 
donor families by the NHSBT National Referral Centre. Femoral bundles were 
obtained from cadaveric donors by NHSBT TES Tissue Retrieval personnel, and 
anonymised and assigned a tissue reference number. Femoral bundles were stored 







transported from NHSBT TES to the University of Leeds in 48 hour dry ice storage 
boxes. Upon receipt, femoral bundles were stored at -80 ºC until use.  
2.2.3.2 Human tissue handling 
Human tissue storage, dissection, processing and disposal was carried out in 
accordance with the Human Tissue Act (2004). All tissue samples were assigned 
unique identification codes and tracked using an electronic tracking system 
(Achiever Medical, Version 1712.4, Interactive Software Ltd, Birmingham, UK). 
Storage locations for all samples were recorded using this system.  
2.2.3.3 Human femoral nerve dissection 
Prior to dissection, human femoral bundles were thawed for approximately three 
hours in a 37 °C incubator or until fully thawed. Femoral nerves were dissected 
from each femoral bundle aseptically using a Class II safety cabinet. Femoral 
nerves were located in close proximity to the femoral artery, and excess tissue and 
fascia were cut away to isolate the femoral nerve (Figure 2.2). Excess fat was 
removed by blunt dissection, and each nerve was washed for ten minutes three 
times using sterile PBS to remove excess blood and tissue fluid, at 4 °C and 
agitated at 50 rpm. Each nerve was then processed for decellularisation, 
histological analysis (Section 2.2.4), DNA quantification (Section 2.2.8) or 
biochemical analysis (Section 2.2.9) immediately.  
 
Figure 2.2 Dissection of human femoral nerves from femoral bundles. (A) 
Femoral nerves were dissected from each femoral bundle. Femoral nerves were located in 
close proximity to the femoral artery. (B) The femoral nerve and associated branches were 
isolated from each femoral bundle, and branches were cut away and discarded. 
 












2.2.4 Basic histological techniques 
2.2.4.1 Fixation, processing and paraffin wax embedding 
Tissue samples (10 mm) of native or decellularised peripheral nerve were placed 
into pencil labelled plastic histology cassettes. All tissue samples were fixed and 
processed using a Leica TP1020 automatic tissue processor using a predetermined 
protocol (Table 2.3). Tissue samples were then oriented in metal wax block moulds 
using heated forceps, covered in molten paraffin wax and left to set overnight at 
room temperature. 
Table 2.3 Automatic tissue processing protocol 
 
 
2.2.4.2 Sectioning and slide preparation 
Paraffin wax embedded samples were cooled using ice and sectioned at a 
thickness of 5 μm using a microtome (Leica RM2255). Sections were floated onto 
Superfrost plus slides (Thermo Scientific) using a water bath at 30 °C. All sections 
were allowed to air dry at room temperature overnight. 
Station  Solution  
 
Duration (hours) 
1 10 % (w/v) neutral buffered formalin 1 
2 70 % (v/v) ethanol 1 
3 90 % (v/v) ethanol 1 
4 100 % (v/v) ethanol 0.5 
5 100 % (v/v) ethanol 1 
6 100 % (v/v) ethanol 1 
7 100 % (v/v) ethanol 1 
8 Xylene 1 
9 Xylene 1 
10 Xylene 1 
11 Molten wax 1 
12 Molten wax 1 
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2.2.4.3 Dewaxing and rehydration 
Sections were dewaxed using two successive changes of xylene (100 %; v/v) for 
ten minutes each. Sections were then rehydrated in three successive changes of 
ethanol (100 %; v/v) for three minutes, two minutes and two minutes respectively, 
followed by immersion in ethanol (70 %; v/v) for two minutes. Sections were then 
immersed in running tap water for three minutes to rehydrate. 
2.2.4.4 Dehydration and mounting 
Stained sections were dehydrated by immersion in ethanol (70 %; v/v) for five 
seconds, followed by successive immersion in ethanol (100 %; v/v) for one minute, 
two minutes and three minutes respectively. Sections were then immersed twice in 
xylene, for ten minutes each, before covering with DPX mountant and a glass 
coverslip. Slides were left to air dry in a fume cupboard for a minimum of four hours 
before viewing. 
2.2.5 Histological staining 
2.2.5.1 Haematoxylin and Eosin (H&E) staining 
H&E staining was used to visualise cell nuclei and tissue histioarchitecture. 
Following dewaxing and rehydration (Section 2.2.4.3.), tissue sections were 
immersed in haematoxylin (Mayer’s) for one minute, rinsed in running tap water for 
three minutes and immersed in Scott’s tap water substitute for three minutes. 
Sections were then rinsed again in running tap water for three minutes and 
immersed in eosin for three minutes, followed by dehydration and mounting 
(Section 2.2.4.4.). Stained slides were viewed using normal Köhler illumination 
(Section 2.2.1.2). 
2.2.5.2 DAPI staining 
Reagents: 
 DAPI stock solution (1 mg.mL-1) 10 mg DAPI 
10 mL nuclease free water 
 DAPI working solution (0.1 µg.mL-1) 10 µL DAPI stock solution 
100 mL PBS 
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Method: 
Fluorescent visualisation of whole cell nuclei and nuclear remnants was performed 
using 4’,6-diamidino-2-phenylindole (DAPI), a fluorescent nucleic acid stain. 
Following dewaxing and rehydration (Section 2.2.4.3.), each section was immersed 
in DAPI working solution for ten minutes in the dark. Sections were then immersed 
in three changes of PBS in the dark, for ten minutes each, and mounted using 
fluorescent mounting medium. Slides were viewed under fluorescence illumination 
with a DAPI filter (460 nm) and images captured digitally (Section 2.2.1.2). 
2.2.5.3 Sirius Red / Miller’s staining 
Reagents: 
 Potassium permanganate (5 %; w/v) 15 g potassium permanganate 
100 mL distilled water 
 Oxalic acid (1 %; w/v) 1 g oxalic acid 
100 mL distilled water 
 Weigert’s haematoxylin 1 part solution A 
1 part solution B 
 Sirius red (0.1 %; w/v) 0.1 g Sirius red 
100 mL saturated picric acid 
solution 
50 mL distilled water 
Method: 
Sirius red was used to stain collagen, Miller’s stain was used to stain elastin fibres, 
and Weigert’s haematoxylin was used to stain cell nuclei. Using circularly polarised 
light to view sections stained with Sirius red, collagen fibre diameter can be 
deduced based on the birefringence of the fibres, with thicker fibrils appearing as 
yellow/red, and smaller fibrils appearing as green. Following dewaxing and 
rehydration (Section 2.2.3.3.), sections were immersed in potassium permanganate 
(5 %; w/v) for five minutes, and rinsed using distilled water. Sections were then 
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immersed in oxalic acid solution (1 %; w/v) for two minutes, followed by distilled 
water for one minute then four minutes. Sections were dehydrated in ethanol (70 %; 
v/v) for one minute and ethanol (95 %; v/v) for one minute before immersion in 
Miller’s stain for one hour. Sections were rinsed in ethanol (70 % v/v), immersed in 
ethanol (95 %; v/v) for one minute and rinsed in running tap water for two minutes. 
Sections were then immersed in Weigert’s haematoxylin for ten minutes, rinsed 
using running tap water for one minute, and immersed in distilled water for 30 
seconds. Sections were then immersed in Sirius red (0.1 %; w/v) for one hour 
followed by rinsing with distilled water prior to dehydration and mounting (Section 
2.2.3.4.). Slides were viewed and imaged using both Köhler illumination and 
circularly polarized light, and images captured digitally (Section 2.2.1.2). 
2.2.5.4 Sirius Red, Luxol Fast Blue and Haematoxylin staining 
Reagents: 
 Luxol fast blue (0.1 %; w/v) 0.1 g Luxol fast blue 
0.5 mL glacial acetic acid 
100 mL 95 % (v/v) ethanol 
 Lithium carbonate solution (0.05 %; 
w/v) 
0.05 g Lithium carbonate 
100 mL distilled water 
 Sirius red (0.1 %; w/v) 0.1 g Sirius red 
100 mL saturated picric acid 
solution 
50 mL distilled water 
 Weigert’s haematoxylin 1 part solution A 
1 part solution B 
Method: 
Sirius red was used to stain collagen, Luxol fast blue was used to stain myelin, and 
Weigert’s haematoxylin was used to stain cell nuclei. Following dewaxing and 
rehydration (Section 2.2.3.3.), sections were immersed in Luxol fast blue (0.1 %; 
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w/v) in a coplin jar, and placed in a 56 °C water bath overnight (approximately 14 – 
16 hours). The coplin jar was sealed with Parafilm before placing in the water bath. 
Sections were rinsed with 95 % (v/v) ethanol, and rinsed with distilled water to 
remove excess stain. Sections were then differentiated using lithium carbonate 
solution (0.05 %; w/v) for approximately 20 seconds. Sections were rinsed twice 
with 70 % (v/v) ethanol, and rinsed with distilled water. Sections were then 
immersed in Sirius red (0.1 %; w/v) for 30 minutes. Sections were rinsed twice in 
distilled water, and immersed in Weigert’s haematoxylin for ten minutes. Sections 
were then dewaxed and rehydrated (Section 2.2.3.4.). Slides were viewed and 
imaged using both Köhler illumination and circularly polarized light, and images 
captured digitally (Section 2.2.1.2). 
2.2.5.5 Masson’s Trichrome staining 
Reagents: 
 Ponceau fuschin (Masson) working 
solution 
 30 mL Ponceau fuschin 
(Masson) 10 X concentrate 
270 mL distilled water 
 Weigert’s haematoxylin 1 part solution A 
1 part solution B 
 Acid alcohol (0.5 %; v/v) 2.5 mL hydrochloric acid 37 % 
(v/v) 
497 mL 70 % (v/v) ethanol 
 Acetic acid (1 % v/v) 5 mL glacial acetic acid 
495 mL distilled water 
Method: 
Masson’s trichrome staining was used to visualise collagen (light green), nuclei 
(dark brown) and cytoplasm (red). Following dewaxing and rehydration (Section 
2.2.3.3.), sections were immersed in Bouin’s fixative for 24 hours. Sections were 
then rinsed in running tap water for four minutes, followed by distilled water for one 
minute. Sections were immersed in Weigert’s haematoxylin for 25 minutes and 
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rinsed in running tap water to remove excess stain. Sections were differentiated in 
acid alcohol (0.5 %; v/v), and rinsed in running tap water for one and three minutes 
respectively. Sections were then immersed in Ponceau Fuschin (Masson) working 
solution for five minutes, and rinsed in running tap water to remove excess stain. 
Sections were immersed in distilled water for one minute followed by 
phosphotungstic acid (1 %; w/v) twice for eight minutes each. Sections were 
immersed in light green Masson solution for 15 minutes, and rinsed in running tap 
water. Sections were immersed in distilled water for one minute, immersed in 
phosphotungstic acid (1 %; w/v) for five minutes, immersed in acetic acid (1 %; v/v) 
for five minutes and rinsed in running tap water for three minutes. Sections were  
dehydrated and mounted (Section 2.2.3.4.). Sections were viewed using normal 
Köhler illumination, and images captured digitally (Section 2.2.1.2). 
2.2.6 Immunofluorescent labelling of tissue sections 
2.2.6.1 Antigen retrieval methods 
2.2.6.1.1 Proteinase K 
Sections were covered with Proteinase K solution and incubated for 20 minutes at 
room temperature. Sections were rinsed with TBS for five minutes. 
2.2.6.1.2 Proteinase K and Trypsin / EDTA 
Sections were covered with Proteinase K solution and incubated for 20 minutes. 
Sections were covered with Trypsin/EDTA solution and incubated for 30 seconds at 
room temperature, and rinsed with TBS for five minutes. 
2.2.6.1.3 Citric acid buffer (pH 6) 
2.2.6.1.4 Reagents 
2.2.6.1.4.1 Citric acid buffer (10 mM) 
 
 Citric acid buffer (10 mM, pH 6) 2.1 g citric acid (monohydrous) 
1 L distilled water 
2.2.6.1.5 Method 
Sections were immersed in citric acid buffer (10 mM, pH 6) for one hour at room 
temperature. Sections were rinsed with TBS for five minutes. 
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2.2.6.2 Immunofluorescent labelling of tissue sections with primary 
antibodies and fluorescently tagged secondary antibodies: 
2.2.6.2.1 Reagents 
 Sodium chloride solution (3 M) 175.32 g sodium chloride 
1 L distilled water 
 Tris solution (2 M, pH7.6) 242.26 g Trizma base 
Made up to 1 L with  distilled water 
 Tris buffered saline (TBS) (20 mM 
tris, 150 mM NaCl, pH 7.6)  
25 mL tris solution (2 M)  
50 mL sodium chloride solution (3 M)  
Made up to 1 L with distilled water 
 TBS-Tween (0.05 % (w/v) Tween-
20, pH 7.6) 
500 µL Tween-20 
1 L TBS 
 Goat serum blocking solution 
(TBS, 10 % (w/v) goat serum, 0.1 
% (w/v) Triton X-100) 
1 mL goat serum 
10 µL Triton X-100 
Made up to 10 mL with TBS 
 Bovine serum albumin (BSA) 
solution (5 %; w/v) 
2.5 g BSA 
50 mL PBS 
 Antibody diluent (TBS, 0.1 % 
(w/v) BSA, 0.1 % (w/v) sodium 
azide, pH 6) 
300 µL BSA solution 
6 mL sodium azide solution (1 %; 
w/v) 





Specific primary, isotype and secondary antibodies, antibody dilutions, and antigen 
retrieval methods used for immunofluorescent labelling of tissue sections are 
specified within individual chapters. Cryosections for immunofluorescent labelling of 
specific antigens were thawed for 30 minutes, and rinsed in running tap water for 
three minutes. Wax sections were dewaxed and rehydrated as described in Section 
2.2.4.3. If required, antigen retrieval was carried out as described in Section 2.2.6.1. 
Following antigen retrieval, sections were washed twice with TBS, for five minutes 
each with gentle agitation. Sections were circled using a hydrophobic marker 
(ImmEdge barrier pen). Sections were incubated with goat serum blocking solution 
for one hour at room temperature. Primary antibodies or isotype control antibodies 
(diluted to appropriate concentration in antibody diluent) or antibody diluent were 
added to test, isotype control or negative control sections respectively, and 
incubated in a humidified chamber for 1 hour at room temperature. Sections were 
washed for five minutes twice with TBS-Tween and washed twice for five minutes 
with TBS with gentle agitation. Secondary antibodies (diluted to appropriate 
concentration in antibody diluent) were added to each section, and incubated in a 
humidified chamber in the dark for 30 minutes at room temperature. Sections were 
washed for five minutes twice with TBS-Tween and washed for five minutes twice 
with TBS with gentle agitation. Sections were then immersed in DAPI working 
solution for ten minutes in the dark. Sections were immersed in three changes of 
PBS in the dark, for ten minutes each, and mounted using fluorescent mounting 
medium. Slides were viewed under fluorescence illumination using appropriate 
filters and images captured digitally (Section 2.2.1.2). 
2.2.7 DNA quantification 
2.2.7.1 Lyophilisation 
Tissue samples were macerated and placed in sterile Eppendorf tubes. Samples 
were weighed three times to calculate a mean wet weight. Samples were placed in 
a freeze dryer (Thermo, Savant ModulyoD) at -50 °C, 0.15 – 0.2 mbar, and the 
weight measured every 24 hours until constant (48 - 72 hours). 
2.2.7.2 DNA extraction 
Tissue samples were lyophilised to a constant weight as described in Section 
2.2.7.1. DNA was extracted from tissue samples using the DNeasy Blood and 
Tissue kit (Qiagen) according to the manufacturer’s instructions. Following 
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lyophilisation, 360 μL Buffer ATL and 40 μL Proteinase K were added to each 
sample. Samples were vortexed for 15 seconds, and incubated at for three hours at 
56 °C, with vortexing for 15 seconds every 30 minutes. Samples were vortexed for 
15 seconds, and 400 μL Buffer AL and 400 μL ethanol (100 %; v/v) were added to 
each sample. Each sample (600 μL) was added to a DNeasy spin column and 
centrifuged at 6000 x g for one minute. The flow-through was discarded. This step 
was repeated until all of the original solution had been filtered through the spin 
column. The spin columns were transferred to fresh collection tubes, and 500 μL 
Buffer AW1 was added. The spin columns were centrifuged at 6000 x g for one 
minute and the collection tube was discarded. The spin columns were transferred to 
fresh collection tubes and 500 μL Buffer AW2 was added, before centrifugation at 
16,000 x g for five minutes. The spin columns were transferred to fresh sterile 
Eppendorf tubes, and 200 μL Buffer AE was added to the membrane at the base of 
the columns. The columns were incubated at room temperature for one minute and 
then centrifuged at 6000 x g for one minute. The eluted DNA contained was stored 
at - 20 °C until quantification. 
2.2.7.3 Spectrophotometric DNA quantification 
Reagents: 
 Digestion buffer (5 mM L-cysteine 
hydrochloride, 5 mM Na2EDTA, pH 
6.0) 
0.788 g L-cysteine hydrochloride 
1.8612 g Na2EDTA 
1 L PBS 
 Calf thymus DNA stock solution (1 
mg.mL-1) 
5 mg calf thymus DNA 
5 mL nuclease free water 
Method: 
Calf thymus DNA stock solution was diluted in digestion buffer to produce calf 
thymus DNA standards of known concentration (ranging from 0 to 50 ng.mg -1). Calf 
thymus DNA standards were used to create a standard curve to assess the 
accuracy of the spectrophotometer. The total DNA content of samples and 
standards (2 μL) was quantified by measuring absorbance (at 260 nm) using a 
NanoDrop spectrophotometer. Each sample was blanked against Buffer AE, and 
measured in triplicate. DNA content (ng.mg-1) of tissues was calculated by 
normalising for dilution volume and dry tissue weight.  
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2.2.7.4 Quantification of double stranded DNA 
The double stranded DNA content of DNA samples extracted from tissues was 
determined using the PicoGreen™ detection kit. TE buffer was produced by diluting 
TE buffer stock solution (20 X) in nuclease free water. PicoGreen working solution 
was produced by diluting PicoGreen stock solution (200 X) in TE buffer, and this 
was kept in the dark until use. Lambda DNA (1 mg.mL-1) was diluted in TE buffer to 
produce lambda DNA standards of known concentration (1, 10, 100, 1000, 1500 
and 2000 ng.mL-1). Lambda DNA standards (100 μL) were added to individual wells 
of a 96-well black walled plate, in triplicate. DNA samples were diluted 1:10 by 
adding 30 μL of each DNA sample to 270 μL TE buffer. Diluted DNA samples (100 
μL) were also added to individual wells of the 96-well black walled plate, in 
triplicate. PicoGreen working solution (100 μL) was added to each well, and the 
plate was incubated for five minutes at room temperature in the dark. The 
luminescence of each well (excitation at 480 nm and emission at 520 nm) was then 
determined using a microplate spectrophotometer, measured in arbitrary 
fluorescent units. Lambda DNA values were used to create a standard curve to 
interpolate unknown values of test samples. DNA content (ng.mg-1) was calculated 
by normalising for dilution volume and dry tissue weight. 
2.2.8 Biochemical analyses 
2.2.8.1 Acid hydrolysis 
Tissue samples were lyophilised as described in Section 2.2.7.1. Lyophilised 
samples were then placed in vented glass test tubes and 5 mL of HCl (6 M) was 
added to each tube. Samples were then autoclaved in a bench top autoclave for 
121 °C  for four hours at a pressure of 103 kPa to hydrolyse the tissue samples. 
Samples were then neutralized by the addition of NaOH (6 M). The volume of the 
hydrolysed samples was recorded for final calculations. 
2.2.8.2 Quantification of hydroxyproline content 
The amino acid hydroxyproline is a major constituent of collagen in vertebrates. 
Hydroxyproline occurs at a known frequency in the amino acid sequence of 
collagen, and therefore quantification of hydroxyproline within a tissue sample can 
be used to estimate collagen content. Hydroxyproline content was quantified using 
a colourimetric assay based on the method described by Edwards and O’Brien 
(1980). Pyrroles formed by oxidation of hydroxyproline react with p-
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dimethylaminobenzaldehyde to produce a red chromophore, which can then be 
measured spectrophotometrically.   
Reagents: 
 Hydroxyproline buffer (pH 6.2) 13.3 g citric acid 
32 g sodium acetate 3 hydrate 
9.1 g sodium hydroxide 
3.2 mL glacial acetic acid 
80 mL propan-1-ol 
Made up to 400 mL with distilled 
water 
 Chloramine T solution 1.41 g Chloramine T 
100 mL distilled water 
 Ehrlich’s reagent  7.5 g p-dimethylbenzaldehyde 
13 mL perchloric acid (62 %; v/v) 
30 mL propan-1-ol 
Made up to 50 mL with distilled water 
Method: 
Samples were lyophilized and hydrolysed as described in Sections 2.2.7.1 and 
2.2.8.1 respectively. Trans-4-hydroxy-L-proline was diluted in hydroxyproline buffer 
to produce hydroxyproline standards of known concentration (0, 2, 4, 6, 8, 10, 15, 
20, 25 and 30 µg.mL-1). Test samples were diluted 1:20 in hydroxyproline buffer. 
Test samples and standards (50 μL) were added to a clear flat-bottomed 96-well 
plate, in triplicate. Chloramine T solution was added to each well (100 μL), and the 
plate incubated for five minutes at room temperature with gentle agitation. Ehrlich’s 
reagent (100 μL) was then added to each well, and the plate was incubated at 60 
°C for 45 minutes. The optical density of each well was then measured at 570 nm 
using a microplate spectrophotometer. Hydroxyproline standard values were then 
used to create a standard curve of absorbance vs concentration to interpolate 
67 
unknown test values. Hydroxyproline content of test samples (µg.mg-1) was 
calculated by normalising for dilution volume and dry tissue weight. 
2.2.8.3 Quantification of denatured collagen content 
Reagents: 
 Digestion buffer (pH 7.8) 1.21 g Trizma base 
0.15 g calcium chloride 
100 mL distilled water 
 α-chymotrypsin digestion solution 
(5 mg.mL-1)  
100 mg α-chymotrypsin (≥40 
units.mg-1) 
20 mL digestion buffer 
Method: 
Samples were lyophilized as described in Section 2.2.7.1. α-Chymotrypsin working 
solution (5 mL) was added to each sample, and the samples were incubated in a 
water bath for 24 hours at 30 °C. The digested samples were centrifuged at 600 g 
for ten minutes, and the supernatant (4 mL) was transferred to vented glass test 
tubes. Supernatants were then hydrolysed and neutralized as described in Section 
2.2.8.1. The hydroxyproline content of each hydrolysed sample was then 
determined using a hydroxyproline assay, as described in Section 2.2.8.2. The 
hydrolysed samples were not diluted prior to hydroxyproline assay. 
2.2.8.4 Quantification of GAG content 
The GAG content (sulphated GAGs) of tissues samples was determined using a 
colourimetric assay based on the method described by Farndale et al (1982). The 
cationic dye 1,9-dimethylene blue (DMB) reacts with sulphate groups of GAGs 







 Papain digest buffer (pH 6.0) 0.788 g L-cysteine hydrochloride 
1.8612 g Na2EDTA 
1 L distilled water 
 Papain digestion solution 1250 U papain 
25 mL digestion buffer 
 Sodium di-hydrogen 
orthophosphate solution (0.1 M)  
3.45 g sodium di-hydrogen 
orthophosphate 
250 mL distilled water 
 Di-sodium hydrogen 
orthophosphate solution (0.1 M)  
3.55 g di-sodium hydrogen 
orthophosphate 
250 mL distilled water 
 Assay buffer (pH 6.0)  137 mL sodium di-hydrate 
orthophosphate solution 
63 mL di-sodium hydrogen 
orthophosphate solution 
 DMB dye (pH 3.0) 16 mg DMB 
2 mL formic acid 
5 mL ethanol (100 %; v/v)  sodium 
formate 
2 g sodium formate 
Made up to 1 L with distilled water 
 
Method: 
Tissue samples were lyophilised to a constant weight as described in Section 
2.2.7.1. Papain digestion solution (5 mL) was added to each sample, and the 
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samples were were incubated at 60 °C for 36 hours. Chondroitin sulphate B was 
diluted in assay buffer to produce chondroitin sulphate B standards of known 
concentration (0, 3.125, 6.25, 12.5, 25, 50, 100, 150, 200 μg.mL-1). Test samples 
were assayed without dilution. Test samples and standards (40 μL) were added to a 
clear flat-bottomed 96-well plate, in triplicate. DMB dye (250 μL) was added to each 
well, and the plate was incubated at room temperature for two minutes with gentle 
agitation. The optical density of each well was then measured at 525 nm using a 
micro plate spectrophotometer. Chondroitin sulphate B standard values were used 
to create a standard curve of absorbance vs concentration to interpolate unknown 
test values. GAG content of test samples (µg.mg-1) was calculated by normalising 
for dilution volume and dry tissue weight. 
2.2.8.5 Quantification of fat content 
The fat content of tissue samples was determined using a colourimetric assay 
based on the method developed by Stern and Shapiro (1953). Hydroxamic acids 
are formed by a reaction between hydroxylamine and esters of fatty acids in 
solution. The colourimetric change formed by the reaction between hydroxamic 
acids and iron (III) chloride can then be measured spectrophotometrically.  
Reagents: 
 Sodium hydroxide solution (3.5 
M) 
14 g sodium hydroxide 
100 mL distilled water 
 Hydrochloric acid solution (4 M) 60 mL hydrochloric acid (6 M) 
30 mL distilled water 
 Hydroxylamine hydrochloride 
solution (2 M)  
1.39 g hydroxylamine hydrochloride 
10 mL distilled water 
 Iron (III) chloride solution  500 mg iron (III) chloride 
(hexahydrate)  
3.75 g trichloroacetic acid 




Tissue samples were lyophilised to a constant weight as described in Section 
2.2.7.1 in rubber-sealed Eppendorf tubes. Ethanol (100 %; v/v, 600 μL) was added 
to each sample, and samples were incubated at 42 °C for 4 hours, with gentle 
agitation. Lard was diluted in ethanol (100 %; w/v) to produce fat standards of 
known concentration (0, 39, 78, 156, 312.5, 625, 1250, 2500 μg.mL-1). Fat 
standards (600 μL) were added to rubber-sealed Eppendorf tubes. Hydroxylamine 
hydrochloride solution (100 μL) and sodium hydroxide solution (100 μL) were added 
to each test sample and standard. The test samples and standards were incubated 
for 20 minutes at room temperature, before adding hydrochloric acid solution (100 
μL) and iron (III) chloride solution (100 μL) to each. The samples and standards 
(250 μL) were then added to individual wells of a clear flat-bottomed 96-well plate, 
in triplicate. The optical density of each well was measured at 540 nm using a 
microplate spectrophotometer. Fat standard values were then used to create a 
standard curve of absorbance vs concentration to interpolate unknown test values. 
The fat content of test samples (µg.mg-1) was calculated by normalising for dilution 
volume and dry tissue weight. 
2.2.9 Cell culture 
All cell culture work was performed aseptically in a Class II safety cabinet. Cells 
were cultured in cell culture medium, as described in Section 2.2.9.1. All cells were 
incubated at 37 °C in 5 % CO2 (v/v) in air. Before use, all cell culture medium and 
appropriate additives were equilibrated to 37 °C in a water bath. 
2.2.9.1  BHK and L929 cell culture media 
2.2.9.1.1 Tryptone phosphate broth (TPB) stock solution (29.5 g.L-1) 
Tryptone phosphate broth stock (7.98 g) was added to 250 mL distilled water. The 
solution was filter sterilised as described in Section 2.2.1.3, and stored at -25 °C for 
up to six months. 
2.2.9.1.2 BHK cell culture medium (5 % (v/v) FBS, 10 % (v/v) TPB, 2 mM L-
glutamine, penicillin/ streptomycin 100 U / 100 µg.mL-1) 
To make up BHK cell culture medium, 5 mL foetal bovine serum (FBS), 10 mL TPB 
stock solution, 1 mL L-glutamine (200 mM) and 2 mL penicillin/ streptomycin 
(penicillin 5000 U.mL-1; streptomycin 5 mg.mL-1) was added to 82 mL Glasgow’s 
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minimal essential medium (GMEM). The medium was stored at 4 °C for up to one 
week.  
2.2.9.1.3 L929 cell culture medium (10 % (v/v) FBS, 2 mM L-glutamine, 
penicillin/ streptomycin 100 U / 100 µg.mL-1) 
To make up L929 cell culture medium, 10 mL foetal bovine serum (FBS), 1 mL L-
glutamine (200 mM) and 2 mL penicillin/ streptomycin (penicillin 5000 U.mL-1; 
streptomycin 5 mg.mL-1) was added to 87 mL Dulbecco’s minimal essential medium 
(DMEM). The medium was stored at 4 °C for up to one week.  
2.2.9.2 Resurrection and maintenance of cells 
L929 and BHK cells were stored in appropriate culture medium containing dimethyl 
sulfoxide (DMSO; 20 %; v/v) in the vapour phase of liquid nitrogen. Following 
removal from storage, cell stocks (1 mL) were thawed rapidly at 37 °C in a water 
bath, and appropriate cell culture medium (10 mL) was added dropwise. To remove 
the DMSO, the cell suspension was centrifuged at 150 g for ten minutes. The 
supernatant was aspirated, and cells were re-suspended in 10 mL fresh cell culture 
medium and transferred to a T75 tissue culture flask. Cell culture medium was 
replaced every 48 hours until cells had reached approximately 80  - 90 % 
confluency and could be passaged.  
2.2.9.3 Cell passaging 
Cell culture medium was aspirated and the cell monolayer gently washed twice with 
10 mL PBS (without Ca2+ or Mg2+). Adherent cells were detached from the tissue 
culture plastic by adding trypsin/ EDTA solution (2 mL) and incubating the flask for 
five minutes. Flasks were then gently tapped to ensure cell detachment, and 
appropriate cell culture medium (10 mL) was added to inactivate the trypsin. The 
cell suspension was then centrifuged at 150 g for ten minutes. The cell pellet was 
re-suspended in 1 mL appropriate culture medium, and cells were counted using a 
haemocytometer as described in Section 2.2.9.4. The cell suspension was then 
adjusted to the appropriate cell density, and transferred to a T175 tissue culture 
flask with 20 mL fresh culture medium. Cell culture medium was replaced every 48 
hours until cells had reached approximately 80  - 90 % confluency and could be 
passaged again.  
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2.2.9.4 Cell counting and determination of cell viability 
In order to determine the viability of cells, trypan blue was added to cell 
suspensions prior to counting. Trypan blue is able to traverse the membranes of 
dead cells due to a loss of membrane potential, therefore dead cells microscopically 
appear blue while live cells appear transparent, enabling dead cells to be excluded 
from cell counts. To perform a cell count, cell suspension was diluted 1:10 mL in 
cell culture medium, and 20 µL cell suspension was added to 20 µL trypan blue (0.4 
%; w/v), and added to an Improved Neubauer haemocytometer. Viable cells were 
counted in 1 mm2 grids, which resulted in a typical cell count of between 100 – 300 
cells. The total number of cells.mL-1 suspension was calculated as follows: 
 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠. 𝑚𝐿−1 =  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠
𝑛
𝑥 104 𝑥 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
n = number of 1 mm2 grids used in cell count 
dilution factor = dilution of cells in Trypan blue (in this case dilution factor = 2) 
 
2.2.9.5 Cell cryopreservation 
Cells were harvested from flasks and a cell count performed as described in 
Section 2.2.9.3 and Section 2.2.9.4. Cells were re-suspended at a density of 1 x 
106.mL-1 in cryopreservation medium (appropriate cell culture medium containing 
10% (v/v) DMSO. Cell aliquots (1 mL) were transferred to cryovials, placed in 
cryofreezing chambers containing isopropanol, and frozen at -80 °C overnight. Cell 
cryovials were then transferred to liquid nitrogen for long term storage. 
2.2.10 Contact cytotoxicity testing 
Tissue samples (5 mm2) were attached to the centre of three wells of a six-well 
tissue culture plate using wound closure strips (SteriStrips). Cyanoacrylate contact 
adhesive and SteriStrips were used as positive and negative control wells 
respectively. Each well was washed three times with PBS (without Ca2+ or Mg2+) for 
ten minutes without agitation. L929 cells or BHK cells were adjusted to a 
concentration of 250,000 cells.mL-1 as described in Section 2.2.9.4 , and 2 mL cell 
suspension was added to each well. Plates were then incubated for 48 hours. 
Following incubation, the plates were examined microscopically using phase 
contrast microscopy. Cell culture medium was then aspirated, and the cell 
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monolayer washed gently with 2 mL PBS (without Ca2+ or Mg2+). Cells were then 
fixed by adding 2 mL 10% (v/v) NBF to each well, and incubating for 10 minutes at 
room temperature. NBF was then aspirated from each well, Giemsa stain (a 
differential cellular stain) was added to each well (enough to cover the cell 
monolayer), and plates were incubated for five minutes. Each well was then 
washed with running tap water until clear, before air-drying. Images of the wells 
were captured using an inverted Olympus IX71 microscope and Olympus XC50 
digital camera, under normal Köhler illumination. 
2.2.11 Statistical analysis 
2.2.11.1.1 Confidence limits 
Numerical data were analysed using Excel (Version 2013, Microsoft Incorporated 
Ltd) and presented as mean (n ≥ 3) ± 95 % confidence limits. The 95 % confidence 
limits were calculated using the descriptive statistics package in Excel.  
 
 












95 % 𝐶𝑜𝑛𝑓𝑖𝑑𝑒𝑛𝑐𝑒 𝑙𝑖𝑚𝑖𝑡𝑠 = 𝑚𝑒𝑎𝑛 ± 𝑡 𝑥 𝑆𝐸 
x = individual value 
n = sample number 
t = critical value 
Σ = Sum of  
2.2.11.1.2 Comparison of means 
Group means were analysed using GraphPad prism 7. A student’s t-test was used 
for the comparison of two means, and one or two-way analysis of variance 
(ANOVA) was used to compare the means of more than two groups. The individual 
differences between means were identified by calculating the minimum significant 
74 
difference (MSD) at p = 0.05. For two-way ANOVA analyses, Tukey’s post hoc 
testing was used to identify the location of significant differences. 
 
𝑀𝑆𝐷 = 𝑄 (𝑎[𝑘, 𝑣])𝑥 𝑆𝐸 
Q = critical value 
α = p = 0.05 
k = number of groups 
v = degrees of freedom (n – 1) 
2.2.11.1.3 Linear regression analysis 
GraphPad prism 7 was used for linear regression analyses of standard curves. The 
coefficient of determination (r2) value is the ratio of explained variation to total 
variation, and denotes the strength of the linear relationship between x and y, such 
that 0 < r2 < 1. This represents how accurately the regression line explains variation 
in the data (with 0 = no relationship and 1 = perfect relationship) and thus the 
accuracy with which unknown values could be interpolated from the regression. 
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3 Chapter 3: Decellularisation and characterisation of 
porcine peripheral nerves 
3.1 Introduction 
A number of methods have been documented for the decellularisation of allogeneic 
and xenogeneic peripheral nerve, including physical, chemical or enzymatic 
methods (Hiles, 1972; Sondell et al., 1998; Hudson et al., 2004a; Wang et al., 2016; 
Zilic et al., 2016). Physical methods that have been used in isolation to decellularise 
peripheral nerve include repetitive freeze-thaw cycles (Gulati, 1988; Ide et al., 
1998), and radiation (Hiles, 1972). Repetitive freeze thaw cycles, used to lyse cells 
within tissue, have been shown to result in insufficient removal of cellular debris and 
a fractured basement membrane in endoneurial tubes surrounding myelinated and 
unmyelinated axons in rat sciatic nerve (Zalewski and Gulati, 1982). Furthermore, 
when implanted in vivo in a rat sciatic nerve defect model these “decellularised” 
nerves induced an inflammatory response and consequently graft rejection. 
Similarly, the use of radiation to decellularise rat peripheral nerve also resulted in 
inadequate removal of cellular debris, and the treated nerve induced an 
inflammatory response upon implantation in a rat sciatic nerve defect model (Hiles, 
1972; Pollard and Fitzpatrick, 1973).  
Although physical methods are effective in lysing and detaching cells from the ECM 
and freeze-thaw cycles are often incorporated in peripheral nerve decellularisation 
processes, such methods are insufficient when applied in isolation due to the 
disruptive effects of repetitive freeze-thaw cycles on ECM structure and inadequate 
removal of cellular debris (Hudson et al., 2004a). Chemical decellularisation 
methods can overcome these limitations and are widely employed. Chemical 
decellularisation methods are often combined with physical and enzymatic methods 
to achieve sufficient decellularisation (Gilbert et al., 2006).  
Detergents are the predominant chemical method used for the decellularisation of 
peripheral nerve, and various protocols including ionic detergents, non-ionic and 
zwitterionic detergents have been developed (Sondell et al., 1998; Hudson et al., 
2004b; Zilic et al., 2016). Common ionic detergents that have been used include 
sodium dodecyl sulphate (SDS), and sodium deoxycholate (White et al., 2017). The 
non-ionic detergent Triton X-100 and zwitterionic detergent sulfobetaine have also 
been widely used (Hudson et al., 2004a; Gilbert et al., 2006).  
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Non-ionic detergents such as Triton X-100 have been used for the decellularisation 
of peripheral nerve due to their mild effects upon ECM architecture, and have been 
used in combination with ionic detergents to increase decellularisation efficacy 
(Hudson et al., 2004a; Seddon et al., 2004). Using a combination of 3 % (v/v) Triton 
X-100 and 4 % (v/v) sodium deoxycholate, Sondell et al. (1998) produced a 
decellularised rat nerve graft which was shown to support axon regeneration in vivo 
in a rat sciatic nerve defect model (Sondell et al., 1998). Analysis of the implanted 
graft after 10 days showed regenerating axons within endoneurial tubes and 
migration of recipient Schwann cells, which repopulated empty endoneurial tubes 
without excessive inflammation. However, the graft was unable to match the 
performance of autografts, even when pre-seeded with Schwann cells (Sondell et 
al., 1998; Frerichs et al., 2002). It was hypothesised that this was due to inadequate 
preservation of the basement membrane. Other studies that have used 3 % (v/v) 
Triton X-100 to decellularise peripheral nerves have reported a decrease in 
basement membrane proteins, including laminin and fibronectin (Hudson et al., 
2004b). A more recent study by Wang et al (2016) used 1 % (v/v) Triton X-100 
alone and in combination with 1 % (v/v) sodium deoxycholate to decellularise rat 
peripheral nerve, and reported preservation of laminin, fibronectin, collagen type I 
and collagen type IV (Wang et al., 2016). However, some structural irregularity of 
endoneurial tubes was observed, and axon density and maturity were significantly 
less than observed for autografts up to 24 weeks post implantation in vivo in a rat 
sciatic nerve defect model (Wang et al., 2016). 
A chemical decellularisation process developed by Hudson et al (2004) used Triton 
X-200 (0.14 % v/v) in combination with zwitterionic detergents sulfobetaine-10 (125 
mM) and sulfobetaine-16 (0.6 mM) to decellularise rat sciatic nerve (Hudson et al., 
2004a). This process was shown to achieve sufficient decellularisation, and 
demonstrated superior preservation of the ECM in comparison to the method 
developed by Sondell et al. (1998). Furthermore, analysis of the graft 28 days post 
implantation in a rat sciatic nerve defect model showed that axon density at the 
midpoint was not significantly different from isograft controls, and significantly 
higher than in the grafts produced using the method developed by Sondell et al. 
(1998) and in a decellularised graft produced using a repetitive freeze-thaw cycle 
process developed by Gulati et al. (1988). The graft was not subject to an adverse 
immune response in vivo, however macrophage infiltration into the graft was slightly 
higher than in the isograft controls (Hudson et al., 2004b). One potential 
explanation for this was that increased ECM porosity and open endoneurial tubes 
enabled greater macrophage infiltration.  
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The decellularisation process developed by Hudson et al. (2004) has been licenced 
by Axogen® Inc. to produce the Avance® graft, developed for human nerves with 
the addition of enzymatic digestion of chondroitin sulphate proteoglycan (CSPG), a 
known inhibitor of axon regeneration (Zuo et al., 2002). The Avance® graft has 
demonstrated superior clinical efficacy to NGCs when used to treat a range of 
nerve defect sizes (Karabekmez et al., 2009; Johnson et al., 2011). However, the 
Avance® graft has not yet demonstrated consistently superior clinical outcomes 
compared to autografts, even in small defects. A potential explanation for this could 
be that the decellularised nerve graft has diminished regenerative capacity as a 
consequence of ECM disruption (Whitlock et al., 2009). 
As discussed previously, the collagenous ECM of peripheral nerve is crucial to 
supporting the function of axons travelling within the nerve, maintaining an optimal 
microenvironment and providing protection from mechanical stress (Bell and 
Haycock, 2011; Topp and Boyd, 2012). ECM structures, including endoneurial 
tubes, provide topographic guidance and support to elongating axons and 
infiltrating cells, and determine the mechanical properties of the nerve. 
Furthermore, various basement membrane components in the endoneurium and 
perineurium, including collagen type IV, laminin and fibronectin have been shown to 
be critical for enabling the attachment and migration of perineurial cells, Schwann 
cells and neurons (De Luca et al., 2014). It has been hypothesised that inadequate 
preservation of ECM microstructures, such as endoneurial tubes and the basement 
membrane, impairs cellular infiltration and proliferation in a decellularised nerve 
graft (Bellamkonda, 2006; Whitlock et al., 2009). 
In comparison to other detergents, including Triton X-100, studies using SDS have 
demonstrated superior efficacy for the removal of cellular material, nuclear 
remnants and cytoplasmic proteins from a wide array of tissues, such as rat aortic 
valves, porcine aortic valves and porcine carotid arteries (Booth et al., 2002; 
Grauss et al., 2003; Dahl et al., 2003). SDS has previously been used for the 
decellularisation of peripheral nerve in combination with other detergents. A study 
by Wakimura et al (2015) used a combination of 1% (w/v) SDS and 1 % (v/v) Triton 
X-100 to decellularise rat peripheral nerve, and reported sufficient cell removal with 
the preservation of the overall ECM structure. Furthermore, in vivo analysis in a rat 
sciatic nerve defect model showed an abundance of axons and Schwann cells 
migrating through the implanted graft (Wakimura et al., 2015).  
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The use of ionic detergents such as SDS at high concentrations is known to 
denature ECM proteins, including collagen fibrils, through the disruption of protein-
protein interactions, affecting tissue architecture and mechanical strength (Faulk et 
al., 2014b; Ferng et al., 2017). At high concentrations, SDS has been shown to 
induce significant denaturation of ECM proteins; a study of decellularised porcine 
aorta reported extensive collagen disruption and increased ECM porosity when 
treated with 2 % (w/v) SDS, whereas minimal alterations were observed when 
treated with 0.1 % (w/v) SDS (Azhim et al., 2014). However, low concentration SDS 
(0.1 %; w/v) in combination with protease inhibitors to inhibit the activity of 
endogenous matrix metalloproteases, followed by the use of nuclease enzymes, 
has been shown to sufficiently remove cellular and nuclear material from several 
tissues, with minimal alterations to the ECM (Booth et al., 2002; Wilshaw et al., 
2012; Azhim et al., 2014).  
As discussed in Chapter 1, a collaborative partnership between the University of 
Leeds and the University of Sheffield resulted in the development of a 
decellularisation process for porcine peripheral nerve (Zilic et al., 2016). The 
process was adapted from the proprietary University of Leeds decellularisation 
process, and utilised low concentration SDS (0.1 %; w/v) plus protease inhibitors in 
combination with hypotonic and hypertonic buffers and nuclease treatment. The 
developed process was shown to achieve sufficient DNA content reduction and 
preserve several key basement membrane components including laminin and 
collagen type IV (Zilic et al., 2016). However, the decellularisation process resulted 
in structural changes to the perineurium and endoneurial tubes, and changes in the 
distribution of collagen fibrils, laminin and fibronectin (Zilic et al., 2016). Therefore, 
in this chapter the decellularisation process was further developed to maintain the 






3.2 Aims and objectives 
3.2.1 Aims: 
I. To further develop the decellularisation process previously developed for 
porcine peripheral nerves, maintaining the efficacy in terms of sufficient cell 
removal and DNA reduction, whilst improving the preservation of overall 
histioarchitecture and the major ECM structures responsible for maintaining 
axonal function and directing axon growth, including the endoneurium. 
II. To characterise the properties of native and decellularised porcine 
peripheral nerve, and assess the effects of decellularisation on biochemical 
composition and specific ECM components, including basement membrane 
components crucial for cell adhesion, survival and migration. 
 
3.2.2 Objectives: 
I. To determine the efficacy of various iterations of the Zilic et al. (2016)  
decellularisation protocol for porcine peripheral nerves using DAPI staining 
of tissue sections to assess cell removal, and to determine the effects of the 
various protocols on the histioarchitecture and major ECM structures using 
histology.   
II. To select an improved decellularisation process for porcine peripheral 
nerves based upon the results of Objective I.  
III. To investigate the efficacy of the improved decellularisation protocol by 
quantifying total and double stranded DNA content of the tissue.  
IV. To determine the biocompatibility of nerves decellularised using the 
improved protocol by contact culture using two distinct cell types, BHK and 
L929 cells. 
V. To determine the effects of the improved decellularisation protocol on 
specific ECM components and macroscopic structures, including the 
structure and distribution of collagens and elastin, by histological analyses. 
VI. To determine the effects of the improved decellularisation protocol on key 
basement membrane components, including collagen type IV, laminin, 
fibronectin and chondroitin sulphate using immunohistochemical analyses. 
VII. To determine the effects of the improved decellularisation protocol on the 
biochemical composition of porcine peripheral nerves, by quantification of 
collagen, denatured collagen, GAG and fat content. 
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3.3 Methods and experimental approach 
3.3.1 Experimental approach 
Various iterations of the original decellularisation protocol developed by Zilic et al. 
(2016) were applied to porcine peripheral nerves. The process was developed with 
the purpose of establishing a decellularisation protocol that would maintain the 
efficacy of decellularisation, with sufficient cell removal and reduction in DNA 
content, whilst ensuring the preservation of overall nerve histioarchitecture and 
important ECM structures, such as the endoneurium. Once an improved process 
had been developed, nerves that had been decellularised using the improved 
process were compared with native porcine peripheral nerves using various 
histological, immunohistochemical and biochemical analyses. 
3.3.2 Methods 
3.3.2.1 Development of the decellularisation process 
3.3.2.1.1 Decellularisation protocols 
The peripheral nerve plexus was dissected from the hind legs of 6 large white pigs, 
cut into 30 mm segments (approximately n = 30 segments per hind leg) and stored 
on PBS-moistened filter paper at -80 °C as described in Chapter 2 (Section 
2.2.2.2). A total of 24 nerve segments randomly selected from each hind leg were 
subject to each decellularisation protocol, described below. The decellularisation 
process was carried out aseptically, using aseptic technique in a class II safety 
cabinet. All decellularisation solutions were autoclaved prior to use, as described in 
Chapter 2 (Section 2.2.1.3). Following decellularisation, nerve segments were 
stored aseptically in PBS at 4 °C for up to one month.  
The original decellularisation process for porcine peripheral nerve segments  
developed by Zilic et al. (2016) is shown in Table 3.1. The decellularisation 
solutions used are described in Chapter 2 (Section 2.1.8).  
The original decellularisation protocol and four modified decellularisation protocols, 
utilising either one, or two, incubations in hypotonic buffer and / or SDS hypotonic 




Table 3.1 Decellularisation process for porcine peripheral nerve 
segments. Decellularisation process developed for porcine peripheral nerve by 
Zilic et al. (2016). Each step is shown in chronological order. For details of each 
solution, see Chapter 2 (Section 2.2.7). Each step was carried out in a 150 mL 
sterile pot, with 100 mL of each solution added, with horizontal agitation. Three 30 
mm nerve segments were added to each pot. 
 
Process step Time Temperature Agitation 
Thaw 30 minutes 37 °C  
Antibiotic solution (0.05 mg.mL-1 vancomycin, 0.5 
mg.mL-1 gentamicin, 0.2 mg.mL-1 polymyxin B), pH 
7.2 – 7.4 
30 minutes 37 °C 240 rpm 
EDTA solution (200 mM EDTA), pH 7.2 - 7.4 24 hours 4 °C 240 rpm 
Hypotonic buffer (10 mM tris, 2.7 mM EDTA, 10 
10000 KIU.mL-1 aprotinin), pH 8.0 – 8.2 
24 hours 42 °C 240 rpm 
SDS hypotonic buffer (0.1 % w/v SDS, 10 mM tris, 
2.7 mM EDTA, 10 10000 KIU.mL-1 aprotinin), pH 8.0 
- 8.2 
24 hours 42 °C  240 rpm 
Hypotonic buffer (10 mM tris, 2.7 mM EDTA, 10000 
KIU.mL-1 aprotinin), pH 8.0 – 8.2 
24 hours 42 °C 240 rpm 
PBS EDTA solution containing aprotinin (2.7 mM 
EDTA, 10 10000 KIU.mL-1 aprotinin), pH 7.2 - 7.4 
48-56 
hours 
4 °C 50 rpm 
Hypotonic buffer (10 mM tris, 2.7 mM EDTA, 10 
10000 KIU.mL-1 aprotinin), pH 8.0 – 8.2 
24 hours  42 °C 240 rpm 
PBS, pH 7.2 – 7.4 24 hours  42 °C 240 rpm 
Nuclease solution (50 mM Tris, 1 mM MgCl2.6H20, 1 
U.mL-1 benzonase), pH 7.5 – 7.7,  x 2 
3 hours 37 °C 50 rpm 
PBS, pH 7.2 – 7.4, ( x 3) 30 minutes 42 °C 240 rpm 
Hypertonic buffer (50 mM tris, 1.5 M NaCl), pH 7.5 -
7.7 
24 hours  42 °C 240 rpm 
PBS, pH 7.2 – 7.4, ( x 3) 30 minutes  42 °C 240 rpm 
Storage in PBS  4 °C  
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Table 3.2 Decellularisation protocols applied to porcine peripheral nerve 
segments. Number of hypotonic and SDS hypotonic buffer incubations used as part 
of the original and four modified decellularisation protocols applied to porcine 
peripheral nerve segments. Each incubation was for 24 hours at 42 °C, with agitation 
at 240 rpm, as described in Table 3.1. 
 
 
3.3.2.1.2 Histological analysis 
Porcine peripheral nerve segments decellularised using each protocol (n = 3) were 
evaluated and compared to native nerve segments (n = 3) using histology to assess 
the efficacy and reproducibility of each protocol. Decellularised nerve segments 
were cut into three 10 mm samples, in order to analyse both the middle and end 
areas of the nerve segment. Samples of native and decellularised tissue were fixed 
in 10 % (w/v) NBF, processed and embedded in paraffin wax as described in 
Chapter 2 (2.2.4.1). Wax blocks of native (n = 3), and middle (n = 3) and end (n= 3) 
regions of decellularised nerve were sectioned (5 µm thickness) as described in 
Chapter 2 (Section 2.2.4.2). Sections were then stained using H&E (n = 6) or DAPI 
(n = 6) as described in Chapter 2 (Sections 2.2.5.1 and 2.2.5.2 respectively). H&E 
staining was used to assess overall histioarchitecture and the preservation of major 
ECM structures, and DAPI staining was used to assess cell removal by visualising 
whole cell nuclei or nuclear remnants. Following histological analysis of nerve 
segments decellularised using the different protocols, Protocol (1), with a reduced 
agitation speed of 120 rpm, was identified as the improved process. Images 
presented are of the middle regions of native and decellularised nerve segments.  
Nerve segments (30 mm, n = 24) were decellularised using Protocol (1) with a 
reduced agitation speed of 120 rpm. These segments were used for further detailed 
analyses as described below. 
Protocol Number of hypotonic buffer 
incubations 
Number of SDS hypotonic 
buffer incubations 
Original 3 1 
1 1 1 
2 1 2 
3 2 1 
4 2 2 
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3.3.2.1.3 DNA content of native and decellularised porcine peripheral nerve 
segments  
The efficacy and reproducibility of decellularisation, in terms of sufficient reduction 
in DNA content, was determined in nerve samples decellularised using Protocol (1) 
with a reduced agitation speed of 120 rpm. Whole 30 mm segments of native (n = 
6) and decellularised (n = 6) nerve were lyophilised to a constant weight prior to 
DNA extraction and spectrophotometric quantification as described in Chapter 2 
(Sections 2.2.7.1 – 2.2.7.3). The double stranded DNA (dsDNA) content of the 
same DNA samples was also determined using the PicoGreen assay, as described 
in Chapter 2 (Section 2.2.7.4).  
3.3.2.1.4 Biocompatibility of decellularised porcine peripheral nerve  
The biocompatibility of porcine peripheral nerve tissue decellularised using Protocol 
(1) with a reduced agitation speed of 120 rpm was determined using a contact 
cytotoxicity assay, as described in Chapter 2 (Section 2.2.10), using BHK cells (n = 
3) and L929 cells (n = 3). Cyanoacrylate contact adhesive was used as a positive 
control for cytotoxicity, and surgical closure strips (SteriStrips) were used as a 
negative control. Biocompatibility was assessed by examining cell growth up to and 
in contact with the samples after 48 hours in culture. 
3.3.2.2 Characterisation of native and decellularised porcine 
peripheral nerve segments 
Various histological, immunohistochemical and biochemical analyses were used to 
characterise the properties of native (n = 6) and decellularised (n = 6) porcine 
peripheral nerve segments, and assess the effects of decellularisation Protocol (1) 
with a reduced agitation speed of 120 rpm on nerve histioarchitecture and specific 
ECM components. 
3.3.2.2.1 Histological analysis 
Native (n = 6) and decellularised (n = 6) nerve samples were cut into three 10 mm 
segments, fixed in 10 % (w/v) NBF, processed and embedded in paraffin wax as 
described in Chapter 2 (Section 2.2.4.1). Wax blocks were sectioned (5 µm 
thickness) as described in Chapter 2 (Section 2.2.4.2), and processed for 
histological analysis, or analysis by immunofluorescent labelling. Images presented 
are of the middle regions of native and decellularised nerve segments. 
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3.3.2.2.2 Histological stains 
Sections were stained using Sirius red / Miller’s elastin and Sirius red / Luxol fast 
blue, as described in Chapter 2 (Sections 2.2.5.3 and 2.2.5.4 respectively). Sirius 
red staining was used to assess overall collagen structure, and imaged under 
circularly polarised light to examine collagen fibril configuration and distribution. 
Miller’s stain was used to stain elastin, and Luxol fast blue was used to stain myelin. 
3.3.2.2.3 Immunofluorescent labelling of specific ECM components 
For immunofluorescent labelling, sections of native and decellularised nerve were 
labelled with primary antibodies specific for collagen IV, laminin, fibronectin and 
chondroitin sulphate, as described in Chapter 2 (Section 2.2.6), and counterstained 
with DAPI (Table 3.3). Sections of native and decellularised nerve were incubated 
with isotype control antibodies, and sections of native porcine artery or cartilage 















Table 3.3 Specific antibodies and solutions for immunofluorescent 
labelling of laminin, fibronectin, collagen type IV and chondroitin 
sulphate. Specific antibodies, antigen retrieval methods and blocking steps used for 
immunofluorescent labelling. For details of each antibody, see Chapter 2 (Section 
2.1.6). Isotype control antibodies were applied at the same protein concentration as 
the primary antibody. 
 







1); 1:500 dilution  
Polyclonal rabbit 
anti-fibronectin 
(4.9 g.L-1); 1:200 
dilution 
Monoclonal mouse 



























Mouse IgG1 Rabbit polyclonal 
IgG 
Mouse IgG1 Mouse IgM 
Antigen 
retrieval 
Proteinase K 20 
minutes 
Proteinase K 20 
minutes, Trypsin / 
EDTA 30 seconds 





None None None Goat serum (10 




3.3.2.2.4 Biochemical analysis 
The biochemical composition of native (n = 6) and decellularised (n = 6) nerve 
segments was determined using assays to quantify collagen, denatured collagen, 
fat and GAG content as described in Chapter 2 (Section 2.8).  
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3.4   Results 
3.4.1 Development of the decellularisation process 
3.4.1.1 Decellularisation protocols and histological analysis 
A number of different decellularisation protocols were applied to porcine peripheral 
nerve segments (Table 3.1). These included the original protocol, including one 
incubation in SDS hypotonic buffer and three incubations in hypotonic buffer, and 
four modified protocols. Protocols (1) and (2) included one and two incubations in 
hypotonic buffer respectively, and one incubation in SDS hypotonic buffer. 
Protocols (3) and (4) included one and two incubations in hypotonic buffer 
respectively, and two incubations in SDS hypotonic buffer. H&E staining of tissue 
sections was used to assess overall histioarchitecture and cell removal. DAPI 
staining of tissue sections was used to assess cell removal by visualising whole cell 
nuclei or nuclear remnants.  
Sections of native nerve stained with H&E and DAPI are shown in Figure 3.1 (A & 
G). Observations of the stained sections revealed regular shaped and sized 
endoneurial tubes, although the size and shape of fascicles varied. The perineurium 
surrounding each fascicle appeared as a discrete, concentric band, with little 
variation between fascicles. The inter-fascicular epineurium appeared loose and 
disorganised in comparison to the perineurium, forming irregular networks (Figure 
3.1 A). The endoneurium and perineurium appeared to have dense cell populations, 
forming aligned, flattened configurations around endoneurial tubes and along the 
perineurial border (Figure 3.1 A & G). The blood vessels in the inter-fascicular 
epineurium, the vasa nervorum, also contained dense cell populations, whereas 
cells in the inter-fascicular region were sporadically distributed (Figure 3.1 A & G).  
Observations of DAPI stained sections revealed that no whole nuclei were present 
following any of the decellularisation protocols (Figure 3.1 G & H). However, 
observations of H&E stained sections indicated differences in the histoarchitecture 
of decellularised nerve in comparison to native nerve. For nerves decellularised 
using any of the protocols, the endoneurium and epineurium appeared less dense, 
with irregular organisation compared to native nerve, and the perineurium appeared 
thinner but remained as an intact barrier between the fascicles and epineurium 
(Figure 3.1 A-F).   
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Figure 3.1 Images of sections of porcine peripheral nerve stained with 
H&E and DAPI before and after different decellularisation protocols. 
Representative images of native porcine peripheral nerve (A & G) and decellularised 
porcine peripheral nerve segments produced using the original decellularisation 
protocol (B) and Protocols 1 (C & H), 2 (D) 3 (E) and 4 (F). Sections stained with H&E 
(A – F) and DAPI (G & H). Labels added to H&E images to identify ECM structures, 
EN = endoneurium, IEP = inter-fascicular epineurium, P = perineurium, BV = blood 
vessels. Major ECM structures were well preserved following decellularisation, 
although greater ECM degradation corresponded with increased cycles of hypotonic 
and / or SDS hypotonic buffer. Images acquired under Köhler illumination using a x10 




























Observations of H&E stained sections showed that increased numbers of  
incubations in hypotonic and / or SDS hypotonic buffer appeared to correspond to  
greater ECM degradation, with an increasing loss of definition of the major ECM 
structures (Figure 3.1 B-F). In particular, Protocols (3) (Figure 3.1E)  and (4) (Figure 
3.1 F), incorporating two incubations in SDS hypotonic buffer and the original 
protocol, incorporating three incubations in hypotonic buffer (Figure 3.1 B), led to 
severe disruption to the major ECM structures, especially the endoneurium (Figure 
3.1 B, E & F).  
Protocol (1), the minimal protocol with one incubation in hypotonic buffer and one 
incubation in SDS hypotonic buffer, appeared to be an improved protocol. Sections 
of porcine peripheral nerve segments decellularised using Protocol (1) retained 
clear definition of the major ECM structures, although some structural damage was 
observed, particularly to the endoneurium (Figure 3.1 C).  However, since 
observations of  DAPI stained sections showed that no whole nuclei were present 
following any of the decellularisation protocols, the agitation speed used during 
incubations was reduced from 240 rpm to 120 rpm in an attempt to further minimise 
structural damage to the nerve (Figure 3.2). 
Two further groups of porcine peripheral nerve segments (n = 12 each) were 
decellularised using Protocol (1); one group using the original agitation speed of 
240 rpm and one group with a reduced agitation speed of 120 rpm. Both versions of 
Protocol (1) appeared to successfully remove cells from the nerve (Figure 3.2 B & 
D). However, reducing the agitation speed to 120 rpm appeared to enable better 
retention of ECM structures, particularly the endoneurium, and individual 
endoneurial tubes could be identified (Figure 3.2 A & C). Therefore, Protocol (1), 
incorporating one incubation in hypotonic buffer and SDS hypotonic buffer, with a 
reduced agitation speed of 120 rpm, was used to produce decellularised porcine 










Figure 3.2 Images of sections of native porcine peripheral nerve and 
nerve segments decellularised using Protocol (1) with agitation speeds 
of 120 and 240 rpm stained with H&E and DAPI. Representative images of 
sections of decellularised porcine peripheral nerve produced using Protocol 1, with an 
agitation speed of 240 rpm (A & B), and Protocol 1 with a reduced agitation speed of 
120 rpm (C & D). Sections stained with H&E (A & C) and DAPI (C & D). Cell nuclei 
were removed from the tissue using both agitation speeds, whilst a reduced agitation 
speed enabled better preservation of ECM structures, particularly the endoneurium. 
Labels added to H&E images to identify ECM structures, EN = endoneurium, IEP = 
inter-fascicular epineurium, P = perineurium, BV = blood vessels. Images acquired 
under Köhler illumination using a x10 objective. Scale bars = 100 µm. 
 
3.4.1.2 DNA content of native and decellularised porcine peripheral 
nerve 
The DNA content of native and decellularised porcine peripheral nerve was 
determined to assess the efficacy and reproducibility of Protocol (1) with a reduced 
agitation speed of 120 rpm. Following DNA extraction from the tissues, total DNA 
content was quantified using spectrophotometry, and double stranded DNA content 
quantified using a PicoGreen assay (Table 3.4). Calf thymus DNA was used to 
create a standard curve to assess the accuracy of the spectrophotometer (Figure 
3.3 A), and lambda DNA was used to create a standard curve to interpolate 














Using a Student’s t- test for each comparison, a significant difference was found 
between the total DNA content of native and decellularised nerves (p < 0.0001), 
and the double stranded DNA content of native and decellularised nerve (p < 
0.0001). 
Table 3.4 Quantification of the DNA content of native and decellularised 
nerve. Average total DNA content (ng.mg-1) and average double stranded DNA 





Figure 3.3 DNA content of calf thymus and lambda DNA standards. (A) 
Linear relationship between calf thymus DNA concentration and measured DNA 
content of calf thymus DNA standards. Data represented as mean (n = 3) ± 95 % 
confidence limits (B) Standard curve of lambda DNA concentration against 
fluorescence emitted. Data represented as mean (n = 3) ± 95 % confidence limits. 
 
 




Native nerve 379 ± 62 298 ± 75 
Decellularised nerve 15 ± 7 3 ± 1 
A B 
91 
3.4.1.3 Biocompatibility of decellularised porcine peripheral nerve 
The biocompatibility of decellularised porcine peripheral nerve was assessed using 
a contact cytotoxicity assay using two distinct cell lines, BHK and L929 (Figure 3.4). 
Cells cultured with cyanoacrylate, the positive control, were sparsely distributed, 
displayed a rounded morphology and were not adhered, indicating cell death 
(Figure 3.4 A & B). Both cell types cultured with SteriStrips, the negative control, 
and samples of decellularised nerve grew up to and in contact with the samples, 
and displayed normal morphological characteristics. L929 cells displayed an 
elongated, spindle morphology and BHK cells displayed a more rounded 
morphology and a denser population (Figure 3.4 C-F).  
 
Figure 3.4 Contact cytotoxicity assay of decellularised porcine 
peripheral nerve. BHK cells (A, C & E), and L929 cells (B, D, & F) were cultured 
with either cyanoacrylate adhesive (A & B) to serve as a positive control, SteriStrips 
(C & D) to serve as a negative control, or 5 mm2 segments of decellularised porcine 
peripheral nerve (n = 3) (E & F). White arrows indicate position of decellularised nerve 
(E & F). Both cell types grew up to and in contact with the tissue, and displayed 
normal morphological characteristics. Images acquired under brightfield illumination 






3.4.2 Characterisation of native and decellularised porcine 
peripheral nerve 
3.4.2.1 Histological analysis 
Picro-Sirius red was used to stain collagen fibres within sections of native and 
decellularised nerve, whilst Miller’s solution was used to stain elastin fibres (Figure 
3.5 A-D). The specific configuration and distribution of the collagen fibres was 
visualised using circularly polarized light microscopy, as collagen fibre diameter can 
be deduced based on the birefringence of the fibres under polarised light, with 
thicker fibrils appearing as yellow/red, and smaller fibrils appearing as green (Figure 
3.5 C & D) (Junqueira et al., 1979). Visualisation under normal Köhler illumination 
revealed fine collagen fibres forming the endoneurial tubes of native nerve, and 
slightly thicker, discrete bands forming the perineurium. The collagen appeared to 
form evenly interspersed networks between fascicles in the inter-fascicular 
epineurium, and a dense, thick layer in the external epineurium with crimped 
regions (Figure 3.5 A). In comparison to sections of native nerve, the collagen in the 
epineurium of sections of decellularised nerve appeared sparse and lacking 
network configurations. In addition, the collagen also appeared significantly thinner 
in the perineurium of decellularised nerve sections, and less defined within the 
endoneurium (Figure 3.5 B).  Under circularly polarized light, the collagen fibres in 
native nerve sections appeared to form tightly aligned configurations of red/yellow 
fibres along the perineurial borders and in the external epineurium, irregular 
networks of red/yellow fibrils in the inter-fascicular epineurium, and fine networks of 
green fibrils surrounding individual endoneurial tubes (Figure 3.5 D). Visualisation 
of decellularised nerve sections under circularly polarised light indicated the 
retention of these fine collagen fibril networks, and a similar distribution of red, 
yellow and green collagen fibres between native and decellularised nerve (Figure 
3.5 C & D). No elastin fibres were revealed within the native nerve sections, except 
within the blood vessels located in the inter-fascicular epineurium, the vasa 
nervorum, and these elastin fibres were retained in decellularised nerve sections 
(Figure 3.5 A & B).   
Luxol fast blue was used to stain the myelin in native and decellularised peripheral 
nerve sections, although staining was improved when used in conjunction with 
another stain to visualise myelin in the context of other ECM components. Picro-
Sirius red was used, as collagen is a ubiquitous component of peripheral nerve 
ECM, and haematoxylin was used as a counterstain to visualise cell nuclei (Figure 
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3.5 E & F). Myelin was only observed within the endoneurium of native nerve 
sections; however the myelin staining appeared fragmented and patchy within 
individual endoneurial tubes (Figure 3.5 E). Myelin was not observed in 
decellularised nerve sections, indicating that the decellularisation process may have 
removed the myelin from porcine peripheral nerves (Figure 3.5 F). 
 
Figure 3.5 Images of sections of native and decellularised porcine 
peripheral nerve stained with Sirius red / Miller’s elastin and Sirius red / 
Luxol Fast blue. Representative images of native (A, C & E) and decellularised (B, 
D & F) porcine peripheral nerve sections stained with Sirius red / Miller’s elastin (A – 
D) or Sirius red, Luxol Fast blue and haematoxylin (E & F). Sirius red imaged using 
normal Köhler illumination (A & B) or circularly polarised light (C & D). The structure 
and distribution of collagen appeared to be well preserved following decellularisation, 
and the decellularisation process appeared to remove myelin from the nerve. Labels 
added to H&E images to identify ECM structures, EN = endoneurium, IEP = inter-
fascicular epineurium, P = perineurium, BV = blood vessels. Images taken using a x 






























3.4.2.2 Immunofluorescent labelling of specific ECM components 
3.4.2.2.1 Immunofluorescent labelling of collagen type IV 
Sections of native and decellularised peripheral nerve were labelled with a primary 
monoclonal antibody against collagen type IV and a goat anti-mouse IgG secondary 
antibody (Figure 3.6). Collagen type IV was present within fascicles, located in both 
the endoneurium and perineurium, and in inter-fascicular blood vessels. In the 
endoneurium, collagen IV appeared to form discrete bands around individual 
endoneurial tubes, and in the perineurium collagen type IV appeared to form a thick 
layer surrounding each fascicle (Figure 3.6 C & D). Although labelling intensity was 
reduced following decellularisation, collagen type IV was still located in the 
endoneurium, perineurium and blood vessels of decellularised nerve (Fig 3.6 D). 
Intense labelling was observed in the smooth muscle and luminal regions of 
sections of porcine femoral artery, the positive control (Figure 3.6 A), and no 
labelling was observed in sections of native porcine peripheral nerve incubated with 
the isotype control antibody (Figure 3.6 B).  
 
Figure 3.6 Immunofluorescent labelling of collagen type IV in sections of 
porcine peripheral nerve. Representative images of sections of native porcine 
artery labelled with a primary monoclonal antibody to collagen IV (A), native nerve 
sections incubated with an isotype control antibody (B) and native (C) and 
decellularised (D) porcine peripheral nerve sections  labelled with a primary 
monoclonal antibody to collagen type IV, and counterstained with DAPI. Collagen 
type IV was present following decellularisation and labelling was most intense in the  
perineurium, as indicated by white arrows. Images taken using a x 10 and x 20 






3.4.2.2.2   Immunofluorescent labelling of laminin 
Sections of native and decellularised porcine peripheral nerve were labelled with a 
primary monoclonal antibody against laminin and a goat anti-mouse IgG secondary 
antibody (Figure 3.7). Labelling of native nerve sections revealed laminin in the 
endoneurium and perineurium. Within the endoneurium, where labelling was most 
prominent, there appeared to be discrete, fine bands of laminin forming each 
endoneurial tube, although some sporadic staining was observed within nerve 
fascicles (Figure 3.7 C & D). Laminin appeared visible in faint, thin bands along the 
perineurium, although labelling was not as intense as in the endoneurium. Labelling 
of decellularised peripheral nerve sections showed similar observations, indicating 
that laminin was present following decellularisation, but labelling appeared more 
dispersed when compared to native nerve sections (Figure 3.7 C & D).  Labelling 
was observed throughout the smooth muscle region of the porcine femoral artery 
positive control, with sporadic intense labelling located along the luminal region 
(Figure 3.7 A). No labelling was observed in sections of native porcine peripheral 
nerve incubated with the isotype control antibody (Figure 3.7 B).  
 
Figure 3.7 Immunofluorescent labelling of laminin in sections of porcine 
peripheral nerve. Representative images of native porcine artery sections labelled 
with a primary monoclonal antibody to laminin (A), native nerve sections incubated 
with an isotype control antibody (B), and native (C) and decellularised (D) porcine 
peripheral nerve sections  labelled with a primary monoclonal antibody to laminin, and 
counterstained with DAPI. Laminin was present following decellularisation and 
labelling was most intense in the  endoneurium, as indicated by white arrows. Images 





3.4.2.2.3 Immunofluorescent labelling of fibronectin 
Sections of native and decellularised porcine peripheral nerve were labelled with a 
primary antibody against fibronectin and a goat anti-rabbit IgG secondary antibody 
(Figure 3.8). Similarly to collagen type IV, fibronectin was located in both the 
endoneurium and perineurium, but labelling was most prevalent in the perineurium, 
appearing as a distinct band surrounding each fascicle (Figure 3.8 C & D). 
However, fibronectin labelling in the endoneurium was not as ubiquitous as 
collagen type IV, and fine bands of fibronectin were sporadically located around 
endoneurial tubes (Figure 3.8 C & D). Labelling of decellularised nerve sections 
revealed similar observations, with only a slight reduction in staining intensity, 
indicating that fibronectin was present following decellularisation (Figure 3.8 D). 
Labelling was observed ubiquitously along the smooth muscle region of the porcine 
femoral artery positive control, with intense labelling in the luminal region (Figure 
3.8 A). No labelling was observed in sections of native porcine peripheral nerve 
incubated with the isotype control antibody (Figure 3.8 D).  
 
Figure 3.8 Immunofluorescent labelling of fibronectin in sections of 
porcine peripheral nerve. Representative images of native porcine artery sections 
labelled with a primary antibody to fibronectin (A), native nerve sections incubated 
with an isotype control antibody (B), and native (C) and decellularised (D) porcine 
peripheral nerve sections  labelled with a primary antibody to fibronectin, and 
counterstained with DAPI. Fibronectin was present following decellularisation and 
labelling was most intense in the  perineurium, as indicated by white arrows. Images 





3.4.2.2.4 Immunofluorescent labelling of chondroitin sulphate 
Sections of native and decellularised porcine peripheral nerve were labelled with a 
primary monoclonal antibody against chondroitin sulphate and a rabbit anti-mouse 
IgG secondary antibody (Figure 3.9). Labelling of native nerve sections revealed 
chondroitin sulphate in the endoneurium and inter-fascicular blood vessels (Figure 
3.9 C). However, whereas intense labelling was observed within blood vessels, 
chondroitin sulphate was only located sporadically in the endoneurium (Figure 3.9 
C). Labelling of decellularised nerve sections only revealed chondroitin sulphate in 
the endoneurium, and labelling intensity was reduced compared to native tissue, 
indicating the decellularisation process may have reduced chondroitin sulphate and 
/ or affected its localisation (Figure 3.9 D). A characteristic zonal distribution of 
chondroitin sulphate was observed in sections of porcine cartilage labelled with the 
primary antibody (positive control), with intense labelling in the ECM of the deep 
region and cellular expression in the middle regions of the cartilage (Figure 3.9 A). 
No labelling was observed in sections of native porcine peripheral nerve incubated 
with the isotype control antibody (Figure 3.9 B). 
 
Figure 3.9 Immunofluorescent labelling of chondroitin sulphate in 
sections of porcine peripheral nerve. Representative images of native porcine 
cartilage labelled with a primary monoclonal antibody to chondroitin sulphate (A), 
native porcine nerve incubated with an isotype control antibody (B), and native (C) 
and decellularised (D) porcine peripheral nerve labelled with a primary monoclonal 
antibody to chondroitin sulphate and counterstained with DAPI. Chondroitin sulphate 
was still present following decellularisationLabels added to identify ECM structures, 
EN = endoneurium and BV = blood vessels. Images taken using a x 10 objective 










3.4.2.3 Biochemical analysis 
3.4.2.3.1 Quantification of collagen content 
The collagen content of native and decellularised porcine peripheral nerve samples 
was determined following tissue hydrolysis and hydroxyproline assay. 
Hydroxyproline content of hydrolysed samples was quantified using a linear 
regression of a trans-4-hydroxy-L-proline standard curve (Figure 3.10 A). The 
hydroxyproline content of native and decellularised nerve was 36.10 ± 5.89 and 
39.05 ± 11.43 µg.mg-1 dry weight respectively (Figure 3.10 B). These values were 
converted to estimate collagen content, using a previously determined conversion 
factor of 7.52. The collagen content of native and decellularised nerve was 271.45 ± 
44.29 µg.mg-1 and 293.68 ± 85.98 µg.mg-1 respectively. No significant difference 
was found between the collagen content of native and decellularised peripheral 









   
 
Figure 3.10  Collagen content of native and decellularised porcine 
peripheral nerve. (A) Standard curve of hydroxyproline concentration against 
absorbance at 570 nm. Data represented as mean (n = 3) ± 95 % confidence limits. 
(B) Estimated collagen content of native and decellularised porcine peripheral nerve. 






3.4.2.3.2 Quantification of denatured collagen content 
The denatured collagen content of native and decellularised porcine peripheral 
nerve samples was determined by selectively digesting denatured collagen with α-
chymotrypsin enzyme and collecting the supernatant for quantification using a 
hydroxyproline assay. Hydroxyproline content of the supernatants was quantified 
using a linear regression of a trans-4-hydroxy-L-proline standard curve (Figure 3.11 
A). The hydroxyproline content of the denatured collagen in native and 
decellularised peripheral nerve was 0.65 ± 0.24 and 0.93 ± 0.31 µg.mg-1 dry weight 
respectively, and these values were used to calculate the denatured content by 
using a conversion factor of 7.52 as described previously. The denatured collagen 
content of native and decellularised nerve was 4.96 ± 1.81 and 6.97 ± 2.37 µg.mg-1 
respectively (Figure 3.11 B). No significant difference was found between the 
denatured collagen content of native and decellularised peripheral nerve (Student` 
t-test; p>0.05). 
Figure 3.11 Denatured collagen content of native and decellularised 
porcine peripheral nerve. (A) Standard curve of hydroxyproline concentration 
against absorbance at 570 nm. Data represented as mean (n = 3) ± 95 % confidence 
limits. (B) Estimated denatured collagen content of native and decellularised porcine 






3.4.2.3.3 Quantification of fat content 
The fat content of native and decellularised nerve was determined by the extraction 
of fat in a known volume of ethanol. The concentration of fat in the extracts was 
used to determine the fat content of the nerve samples, using a linear regression of 
a standard curve of known fat concentrations (Figure 3.12 A). The fat content of 
native and decellularised nerve was 639.13 ± 40.72 and 667.68 ± 58.02 µg.mg-1 dry 
weight respectively (Figure 3.12 B). No significant difference was found between 
the fat content of native and decellularised peripheral nerve (Student`s t-test 
p>0.05). 
Figure 3.12 Fat content of native and decellularised porcine peripheral 
nerve. (A) Standard curve of fat concentration against absorbance at 540 nm. Data 
represented as mean (n = 3) ± 95 % confidence limits. (B) Estimated fat content of 
native and decellularised porcine peripheral nerve. Data represented as mean (n = 6) 







3.4.2.3.4 Quantification of GAG content 
The GAG content of native and decellularised nerve was determined by digestion of 
samples with papain and collection of the supernatant containing GAGs, followed 
by quantification using the dimethylene blue (DMMB) assay. The GAG content of 
the supernatants was quantified using a linear regression of a standard curve of 
chondroitin sulphate B (Figure 3.13 A). The GAG content of native and 
decellularised nerve was 10.16 ± 6.43 and 8.47 ± 6.27 µg.mg-1 dry weight 
respectively (Figure 3.13 B). No significant difference was found between the GAG 
content of native and decellularised peripheral nerve (Student`s t-test; p>0.05). 
Figure 3.13 GAG content of native and decellularised porcine peripheral 
nerve. (A) Standard curve of chondroitin B sulphate concentration against 
absorbance at 570 nm. Data represented as mean (n = 3) ± 95 % confidence limits. 
(B) Estimated GAG content of native and decellularised porcine peripheral nerve. 







Porcine peripheral nerves were decellularised using a combination of low 
concentration SDS (0.1 %; w/v), hypertonic and hypotonic buffers, Benzonase 
nuclease and protease inhibitors. The decellularisation protocol, described by Zilic 
et al. (2016) for porcine peripheral nerve decellularisation, was shown to sufficiently 
remove cellular and nuclear material and preserve key basement membrane 
components, however the decellularisation process resulted in structural damage to 
the endoneurium and perineurium. Therefore, the decellularisation process was 
further developed to minimise structural changes by varying the number of SDS 
hypotonic buffer and hypotonic buffer cycles and minimising the agitation speed 
during incubations.  
H&E and DAPI staining of sections of porcine peripheral nerve before and after 
decellularisation indicated that one cycle each of hypotonic buffer and SDS 
hypotonic buffer was sufficient to achieve decellularisation, as no whole cell nuclei 
or cellular remnants were observed. However, the decellularisation process was 
developed for 30 mm nerve segments, and the process may need further 
development for the decellularisation of longer segments for large grafts. Although 
overall ECM architecture was preserved, some structural damage was observed in 
comparison to native nerve. High agitation speeds used during tissue 
decellularisation protocols have been reported to disrupt ECM structure (Montoya 
and McFetridge, 2009b), with particularly damaging effects to soft tissues, and are 
typically used to enhance the perfusion of decellularisation solutions rather than as 
a primary decellularisation mechanism (Gilbert et al., 2006; Azhim et al., 2014). 
Therefore to minimise structural damage, the agitation speed was reduced from 
240 rpm to 120 rpm. H&E and DAPI staining of sections of tissues decellularised 
using the improved protocol at lower agitation speed indicated successful 
decellularisation and showed improved preservation of individual ECM structures; 
the epineurium, perineurium and endoneurial tubes. However, some structural 
differences were observed in the endoneurium in comparison to native nerve, with 
less definition of individual endoneurial tubes and a more irregular appearance.   
The implications of these structural alterations are unclear as the topography of 
endoneurial tubes, which provide physical guidance to elongating axons, is one of 
the key advantages of decellularised nerve grafts compared to NGCs and it has 
been hypothesised that the inability of decellularised nerve grafts to consistently 
match the regeneration rates of autografts in vivo is due to inadequate preservation 
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of these structures (Whitlock et al., 2009; Karabekmez et al., 2009; Szynkaruk et 
al., 2012). However, porcine peripheral nerve decellularised using the protocol 
described by Zilic et al. (2016) has been shown to support axon regeneration in vivo 
in a rat sciatic nerve defect model, and the histological results shown here 
demonstrate improved preservation of ECM structures following development of the 
decellularisation process. Furthermore, the structural changes were similar to those 
observed in other decellularised peripheral nerve grafts, including the Avance® 
graft (Inc, 2013). Chemical detergents, including SDS and Triton X-100 can disrupt 
ECM proteins, affecting histioarchitecture and biomechanical properties (White et 
al., 2017). Low concentration SDS was chosen here rather than Triton X-100, the 
principal detergent used to produce the Avance® graft, due to superior efficacy in 
the removal of cellular material, and low concentration SDS has previously been 
shown to cause less alteration to the biomechanical properties of soft tissues than 
Triton X-100 (Grauss et al., 2003; Liao et al., 2008).  
Following development of the decellularisation process, the DNA content of the 
decellularised nerve was quantified to further evaluate the efficacy of the process. 
Criteria for successful decellularisation previously proposed by Crapo et al. (2011)  
are widely employed and stipulate an upper threshold of 50 ng double stranded 
DNA per mg (dry weight) of decellularised tissue (Crapo et al., 2011). Other studies 
have used different criteria to determine decelularisation, including a reduction of 
greater than 90 % (w/v) of the native DNA content, which was used in a study of 
small diameter blood vessels (Fercana et al., 2014). Studies have reported no 
adverse immune responses to decellularised tissues containing trace amounts of 
DNA, and many clinically available decellularised tissue products have been found 
to contain small residual quantities of DNA, including the Oasis™ and Restore™ 
products, processed from porcine small intestine submucosa (Gilbert et al., 2009; 
Badylak, 2014). Based on these criteria, the decellularisation process developed 
here achieved acceptable levels of residual DNA content in the decellularised 
porcine peripheral nerve segments. 
In addition to ensuring sufficient DNA content reduction, the decellularisation 
process must result in a scaffold which is biocompatible, as residual traces of 
detergent, EDTA and aprotinin have shown cytotoxic effects (Booth et al., 2002; 
Phillips et al., 2004; Wilshaw et al., 2012). SDS has been shown to have cytotoxic 
effects when not sufficiently removed from decellularised tissues, and can impart a 
negative charge and denature proteins, which may inhibit cell attachment and 
viability (Rieder et al., 2004; Seddon et al., 2004). The decellularised nerves 
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developed here appeared to be biocompatible, with a contact cytotoxicity assay 
using BHK and L929 cells showing no changes in cell morphology and growth when 
cultured with the decellularised nerve.  
Further characterisation of the decellularised porcine peripheral nerve showed that 
the ECM histioarchitecture, specific ECM components and biochemical composition 
were well preserved in comparison to native tissue.  
Biochemical analysis showed that porcine peripheral nerve ECM is comprised of 
approximately 64 % (w/w) fat, 27 % (w/w) collagen, and 1 % (w/w) GAGs, with cell 
content also contributing to the residual weight. Quantification of fat content showed 
that fat is the main component of peripheral nerve ECM, and that the 
decellularisation process did not significantly alter the fat content. Although there 
has been little research into the function of adipose tissue in peripheral nerve ECM, 
it is thought that its primary function is to provide inter-fascicular protection from 
mechanical compression during movement (Topp and Boyd, 2012; Grinsell and 
Keating, 2014). Along with fat, collagens are the main components of peripheral 
nerve ECM, forming the overall architecture, defining the epineurium, perineurium 
and endoneurium, and providing mechanical strength to the nerve, protecting the 
axons from external stress and enabling the nerve to stretch under tension during 
movement (Topp and Boyd, 2012). Disruption to collagen structure and 
configuration can be caused by physical and / or chemical treatments, particularly 
the use of detergents which may denature collagen fibrils, and the removal of cells 
from tissue causes the ECM to loosen (Gilbert et al., 2006; White et al., 2017). 
Biochemical analysis revealed that approximately 30 % of the dry weight of native 
nerve was collagen, and that the decellularisation process did not significantly alter 
the collagen content. Furthermore, the denatured collagen content of decellularised 
peripheral nerve was not significantly different from native nerve.  
Histological evaluation of the decellularised porcine peripheral nerve sections did, 
however, reveal some alterations to collagen structures. In comparison to native 
nerve sections, the network configuration of collagen in the inter-fascicular 
epineurium appeared looser and more sporadic, similar to the results described by 
Zilic et al. (2016), although in contrast to the results reported by Zilic et al. (2016) 
the structural disruption of collagen appeared to be confined to the epineurium, with 
a clearly defined, tightly aligned perineurium and a less fragmented endoneurium 
(Zilic et al., 2015; Zilic et al., 2016). Furthermore, decellularisation did not appear to 
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affect the distribution of fine and thicker collagen fibril networks across the ECM 
layers.   
Depending on tissue type, a degree of structural disruption is often necessary to 
ensure sufficient cell removal during decellularisation, and the enhanced porosity of 
a loosened ECM may facilitate cellular infiltration and graft integration (Colen et al., 
2009; Faulk et al., 2014b; Koch et al., 2015). Although increased porosity in the 
epineurium of porcine peripheral nerve may be well tolerated upon implantation, the 
presence of individual endoneurial tubes confining myelinated and unmyelinated 
axons would ensure appropriate target innervation, and avoid axon deviation which 
can form whorls within the nerve and cause painful neuromas (Burnett and Zager, 
2004). As such, the development of NGCs often focuses on stimulating directional 
axon growth by optimising scaffold porosity and utilising patterning techniques 
within the conduit (Siemionow and Brzezicki, 2009; De Luca et al., 2014). However, 
similar to studies investigating recellularisation of the Avance® graft, which also 
reported alterations to the collagen structure, Zilic et al. (2016) demonstrated that 
the decellularised porcine peripheral nerve graft was able to support the attachment 
and migration of Schwann cells both in vitro and in vivo (Whitlock et al., 2009; 
Johnson et al., 2011).  
The basement membrane, located in the endoneurium and perineurium, facilitates 
cell-matrix interactions, enabling Schwann cell adhesion and promoting axon 
elongation and maturation in the endoneurium (Kerns, 2008). In addition, it has 
been shown that the basement membrane is required for Schwann cells to form 
Bands of Bungner, which rapidly switch phenotype and assemble into longitudinal 
bands following injury, serving as a conduit to guide regenerating axons (Gaudet et 
al., 2011; Allodi et al., 2012). Immunofluorescent labelling showed that the specific 
basement membrane components laminin, fibronectin and collagen type IV were 
preserved following decellularisation, however antibody labelling intensity was 
reduced in comparison to native nerve. 
Many of the methods used to decellularise peripheral nerve, including chemical and 
thermal decellularisation processes, have been shown to induce significant damage 
to the basement membrane (Sondell et al., 1998; Evans et al., 1998; Krekoski et al., 
2001). The decellularisation process developed by Sondell et al. (1998), which 
utilised 3 % (v/v) Triton X-100, has been shown to cause a reduction in the laminin 
and fibronectin content, whereas the milder detergent method developed by 
Hudson et al. (2004), licenced for the production of the Avance® graft, using 
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sulfobeteine 10 (125 mM) and sulfobetaine 16 (0.6 mM) in combination with 0.14 % 
(v/v) Triton X-200 has demonstrated superior preservation of the basement 
membrane (Sondell et al., 1998; Hudson et al., 2004a). A comparative study of 
these decellularisation processes showed superior axon regeneration using the 
Hudson method, with significantly higher axon densities, and this was attributed to 
the presence of an intact basement membrane (Hudson et al., 2004b). In addition, 
another study comparing nerve decellularised using the Hudson method and 
NeuraGen®, a clinically available collagen type I NGC, demonstrated a significantly 
greater axon regeneration rate using the decellularised nerve graft (Hudson et al., 
2004a; Karabekmez et al., 2009). As such, it is hypothesised that decellularised 
nerve grafts support axon regeneration through the provision of endoneurial tubes 
with an intact basement membrane. One of the main limitations to the currently 
available NGCs is the lack of ECM architecture and specific basement membrane 
components, and the development of NGCs often focuses on supplementation with 
basement membrane factors, such as the incorporation of laminin (Bellamkonda, 
2006; de Ruiter et al., 2009).  
The reduction in antibody labelling intensity for collagen IV, laminin and fibronectin 
following decellularisation may be explained by the alterations to the collagenous 
structure, through the disruption of collagenous basement membrane components. 
Similar alterations to the basement membrane have also been shown for various 
other tissues decellularised using the low concentration (0.1 %; w/v) SDS protocol 
patented by the University of Leeds (Wilshaw et al., 2012; Zilic et al., 2016; Helliwell 
et al., 2017; Jones et al., 2017). Studies of porcine pulmonary heart valves, dermis 
and human pulmonary and aortic valves have reported a reduction in labelling 
intensity for laminin and collagen type IV, however decellularised porcine aortic 
roots demonstrated functional biocompatibility and cellular repopulation in vivo in a 
sheep model (Paniagua Gutierrez et al., 2014).  
Glycosaminoglycans (GAGs) have various functions in peripheral nerve ECM, 
implicated in the maintenance of other ECM molecules, structural integrity and the 
regulation of cellular growth, and are located in the basement membrane (Krekoski 
et al., 2001; Zuo et al., 2002; Neubauer et al., 2007). The quantity and distribution 
of GAGs in peripheral nerve has not been characterised in detail, and biochemical 
analysis revealed only a small quantity of GAGs in native porcine peripheral nerve 
ECM and a reduction, although not significant, in GAG content following 
decellularisation. Immunofluorescent labelling of chondroitin sulphate, one of the 
main GAGs present in peripheral nerve, also showed a reduction in GAG content. A 
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reduction in GAG content is consistent with the findings of other studies of tissues 
decellularised using SDS. It is hypothesised that this is due to the ionic disruption of 
link protein interaction with hyaluronan, leading to the disaggregation of aggrecan 
and hyaluronan and thus increasing GAG mobility (Kheir et al., 2011). Chondroitin 
sulphate proteoglycans are the main proteoglycans involved in the inhibition of 
axonal growth, and are thought to be inhibitory to the regenerative process 
(Krekoski et al., 2001; Gao et al., 2013). Therefore, a reduction in GAG content may 
not be detrimental to the regenerative potential of the decellularised nerve graft, 
and many peripheral nerve decellularisation processes, including the method used 
to produce Avance®, include chondroitinase ABC to remove residual chondroitin 
sulphate (Zuo et al., 2002; Hudson et al., 2004a; Wang et al., 2012).  
Histological analysis indicated that myelin was removed from the nerve following 
decellularisation. In addition to chondroitin sulphate, myelin is thought to be 
inhibitory to the regenerative process (Burnett and Zager, 2004). Following 
peripheral nerve injury, the distal segment of the severed axon degenerates 
following a defined pathway, termed Wallerian degeneration. This involves the 
breakdown of axons and associated myelin, the recruitment of macrophages to the 
lesion and the subsequent phagocytosis of axon and myelin debris before axon 
regeneration can commence (Gaudet et al., 2011). Residual axon and myelin 
debris have been shown to inhibit axonal growth by prolonging the degenerative 
process, and evidence suggests axon regeneration is impaired by delayed 
Wallerian degeneration (Burnett and Zager, 2004). Therefore, the presence of 
myelin in a decellularised nerve graft may adversely affect axon regeneration, and 
several studies using other methods of decellularisation have shown incomplete 
removal of myelin. Peripheral nerve decellularised using thermal techniques, 
including repetitive freeze thaw and cold preservation have shown incomplete 
removal of cellular remnants, including myelin, and Wang et al (2016) reported 
residual traces of myelin sheath when rat sciatic nerve was decellularised using 1 
% (v/v) Triton-X 100 and 1 % (v/v) sodium deoxycholate both in isolation and in 





The porcine peripheral nerve decellularisation protocol described by Zilic et al. 
(2016) was further developed to minimise alterations to ECM architecture and 
composition. The developed protocol, using one cycle each of hypotonic and SDS 
hypotonic buffer, showed improved preservation of ECM architecture whilst meeting 
the criteria required for decellularisation. The decellularised peripheral nerve was 
biocompatible and retained the basement membrane components thought to be 
essential for supporting regeneration, providing a substrate to support cellular 
infiltration and growth. The decellularisation protocol developed here offers potential 
for translation to human peripheral nerves, and the development of a 

















4 Chapter 4: Decellularisation and characterisation of 
human femoral nerves 
4.1 Introduction 
Decellularised peripheral nerve grafts have been produced from both allogeneic 
tissue, and xenogeneic tissue from a range of species, including rat, pig and rabbit 
(Wood et al., 2014; Zilic et al., 2016; Wang et al., 2016). The use of porcine tissue 
as a source material offers considerable clinical potential as the ECM molecules, 
including collagens, are generally conserved from pig to human, and the use of 
porcine tissue ensures a consistent supply of high quality tissue (Badylak et al., 
2009; Badylak, 2014). However, preclinical and clinical evidence of axon 
regeneration only exists for decellularised allogeneic peripheral nerve grafts such 
as the Avance® graft, as discussed in Chapter 3 (Karabekmez et al., 2009; 
Szynkaruk et al., 2012). The use of xenogeneic tissue for decellularised tissue 
grafts also has several limitations, which have been discussed in Chapter 1.  
Although the Avance® graft has demonstrated superior clinical efficacy to NGCs 
when used to treat a range of defect sizes, clinical studies using the Avance® graft 
have not yet demonstrated consistently superior outcomes in comparison to 
autografts, even in small defects (up to 30 mm) (Karabekmez et al., 2009; 
Szynkaruk et al., 2012). As discussed in Chapter 3, a potential explanation for this 
could be that the decellularised nerve graft has diminished regenerative capacity as 
a consequence of ECM disruption resulting from the decellularisation process. It 
has been hypothesised that inadequate preservation of ECM structures, such as 
endoneurial tubes, and specific ECM components including laminin and collagen 
type IV, impairs cellular infiltration and proliferation in a decellularised nerve graft 
(Whitlock et al., 2009). 
The porcine peripheral nerve decellularisation process developed in Chapter 3 
achieved sufficient decellularisation, in terms of cell removal and DNA content 
reduction, and the decellularised tissue retained a native histioarchitecture, 
biochemical composition, and specific ECM components including collagen type IV, 
laminin and fibronectin. Therefore, in this chapter, the porcine peripheral nerve 
decellularisation protocol was translated to establish a decellularisation process for 
human femoral nerve.  
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4.2 Aims and objectives 
4.2.1 Aims: 
I. To develop a process for the decellularisation of human femoral nerve by 
translating the decellularisation process developed for porcine peripheral 
nerve, maintaining the efficacy of decellularisation in terms of sufficient cell 
removal and DNA reduction, whilst ensuring the preservation of overall 
histioarchitecture and major ECM structures.  
II. To characterise the properties of native and decellularised human femoral 
nerve, and assess the effects of decellularisation on the biochemical 
composition and specific ECM components, including basement membrane 
components crucial for cell adhesion, survival and migration. 
 
4.2.2 Objectives: 
I. To apply and develop the porcine peripheral nerve decellularisation protocol 
to human femoral nerve segments. 
II. To determine the efficacy of decellularisation of human femoral nerve 
segments using total DNA quantification and DAPI staining of tissue 
sections to assess cell removal, and determine the effects of 
decellularisation on histioarchitecture using H&E staining of tissue sections.  
III. To determine the biocompatibility of decellularised human femoral nerve 
segments by contact culture using two distinct cell types, BHK and L929 
cells.  
IV. To determine the effects of decellularisation on specific ECM components 
and macroscopic structures of human femoral nerve segments, including 
the structure and distribution of collagens, by histological analyses. 
V. To determine the effects of decellularisation on biochemical composition, by 
quantification of collagen, denatured collagen, fat and GAG content of native 






4.3 Methods and experimental approach 
4.3.1 Experimental approach 
The decellularisation protocol developed for porcine peripheral nerves described in 
Chapter 3 was initially applied to human femoral nerves (Protocol 1H). The process 
was further developed (Protocol 2H and 3H) to ensure sufficient decellularisation in 
terms of cell removal and DNA content reduction, and the preservation of overall 
nerve histioarchitecture and important ECM structures, such as the endoneurium. 
Once an improved process (Protocol 3H) had been developed, the decellularised 
tissue was compared with native human femoral nerve using various histological, 
immunohistochemical and biochemical analyses. 
4.3.2 Methods 
4.3.2.1 Development of a decellularisation protocol for human 
femoral nerve 
Human femoral nerves were acquired from the NHSBT TES with appropriate ethical 
approval and stored as described in Chapter 2 (2.2.3.1). All human tissues were 
stored, tracked and disposed of in accordance with the Human Tissue Act (2004) 
and HTA regulations as described in Chapter 2 (Section 2.2.3.2) 
4.3.2.1.1 Application of porcine peripheral nerve decellularisation protocol 
to human femoral nerve segments (Protocol 1H)  
Human femoral nerves were dissected from three femoral bundles, cut into 60 mm 
segments and stored on PBS moistened filter paper at -80 °C as described in 
Chapter 2 (Section 2.2.3.3). Human femoral nerve segments (n = 12) were subject 
to the decellularisation protocol developed for porcine peripheral nerve segments in 
Chapter 3, using the decellularisation solutions described in Chapter 2 (Section 
2.1.8), with the modification of using Cambridge antibiotic solution in place of the 
disinfection solution (Table 4.1) The decellularisation process was carried out 
aseptically, using aseptic technique throughout in a class II safety cabinet. All 
decellularisation solutions were autoclaved prior to use, as described in Chapter 2 
(Section 2.2.1.3). Following decellularisation, nerve segments were stored 
aseptically in PBS at 4 °C for up to one month. 
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Table 4.1 Decellularisation Protocol 1H  applied to human femoral 
nerve segments. Each step is shown in chronological order. For details of each 
solution, see Chapter 2 (Section 2.2.7). Each step was carried out in a 150 mL 
sterile pot with 100 mL of each solution added, with horizontal agitation, and each 
human femoral nerve segment (60 mm) was processed in an individual pot. 
 
Process step Time Temperature Agitation 
Antibiotic solution (Cambridge antibiotics) 1 hour 37 °C 120 rpm 
EDTA solution (200 mM EDTA), pH 7.2 – 7.4 24 hours 4 °C 120 rpm 
Hypotonic buffer (10 mM tris, 2.7 mM EDTA, 
10 10000 KIU.mL-1 aprotinin), pH 8.0 – 8.2 
24 hours 42 °C 120 rpm 
SDS hypotonic buffer (0.1 % w/v SDS, 10 
mM tris, 2.7 mM EDTA, 10 10000 KIU.mL-1 
aprotinin), pH 8.0 – 8.2 
24 hours 42 °C  120 rpm 
PBS, pH 7.2 – 7.4 ( x 3)  30 minutes 42 °C 120 rpm 
PBS EDTA solution containing aprotinin (2.7 
mM EDTA, 10 10000 KIU.mL-1 aprotinin), pH 
7.2 – 7.4 
48-56 hours 4 °C 50 rpm 
PBS pH 7.2 – 7.4 30 minutes 42 °C 120 rpm 
Nuclease solution (50 mM Tris, 1 mM 
MgCl2.6H20, 1 U.mL-1 benzonase), pH 7.5 – 
7.7,  (x 2) 
3 hours 37 °C 50 rpm 
PBS, pH 7.2 – 7.4 ( x 3) 30 minutes 42 °C 120 rpm 
Hypertonic buffer (50 mM tris, 1.5 M NaCl) 
(pH 7.5 – 7.7) 
24 42 °C 120 rpm 
PBS pH 7.2 – 7.4  ( x 3) 30 minutes 42 °C 120 rpm 






4.3.2.1.2 Further development of the decellularisation process for human 
femoral nerve segments  
Following histological analysis and total DNA quantification of human femoral nerve 
segments decellularised using Protocol 1H it was apparent that the process 
required further development. Two modified versions of the decellularisation 
protocol were therefore applied to human femoral nerve segments (n = 12  for each 
protocol, dissected from six femoral bundles as described previously). Protocol 2H 
included an additional nuclease solution incubation following the existing two 
nuclease solution incubations, and Protocol 3H included an additional hypertonic 
buffer incubation following the existing hypertonic buffer incubation (Table 4.2). 
Following histological analysis and DNA quantification, Protocol 3H, including an 
additional hypertonic buffer incubation, was identified as the improved process. 
Human femoral nerve segments (n = 48, dissected from 12 femoral bundles as 
described above), were decellularised using Protocol 3H, and subject to histological 
analysis, DNA quantification, immunohistochemical and biochemical evaluation. 
Table 4.2 Decellularisation protocols applied to human femoral nerve 
segments. Number of nuclease solution incubations and hypertonic buffer 
incubations used as part of decellularisation protocols 1H, 2H and 3H applied to 
human femoral nerve segments. Each nuclease solution incubation was for 3 hours at 
37 °C, with agitation at 50 rpm, and each hypertonic buffer incubation was for 24 
hours at 42 °C, with agitation at 240 rpm, as described in Table 4.1. 
 
4.3.2.1.3 Histological analysis 
Decellularised human femoral nerve segments subjected to each decellularisation 
protocol (n = 3) were evaluated and compared to native nerve (n = 3) using 
histology to assess the efficacy and reproducibility of the decellularisation protocol. 
Decellularised nerve segments were cut into three (20 mm) segments, in order to 
analyse both the middle and end areas of the nerve. Samples of native and 
decellularised nerve were fixed in 10 % (w/v) NBF, processed and embedded in 
paraffin wax as described in Chapter 2 (Section 2.2.4.1). Wax blocks of native (n = 
3), and middle (n = 3) and end (n = 3) regions of decellularised nerve were 
Protocol Number of nuclease solution 
incubations 
Number of hypertonic buffer 
incubations 
Protocol 1H 2 1 
Protocol 2H 3 1 
Protocol 3H 2 2 
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sectioned (5 µm thickness) as described in Chapter 2 (Section 2.2.4.2). Sections 
were stained using H&E (n = 3) or DAPI (n = 3) as described in Chapter 2 (Sections 
2.2.5.1 and 2.2.5.2 respectively). H&E staining was used to assess overall 
histioarchitecture and the preservation of major ECM structures, and DAPI staining 
to assess cell removal by visualising whole cell nuclei or cell remnants. Images 
presented are of the middle regions of native and decellularised nerve segments. 
4.3.2.1.4 DNA content of native and decellularised human femoral nerve 
segments  
The efficacy and reproducibility of decellularisation, in terms of sufficient reduction 
in DNA content, was determined by DNA extraction and quantification. Whole 
segments of native (n = 6) and decellularised (n = 6) nerve were lyophilised to a 
constant weight prior to DNA extraction and spectrophotometric quantification as 
described in Chapter 2 (Sections 2.2.7.1 – 2.2.7.3). The double stranded DNA 
(dsDNA) content the same DNA samples was also determined using the PicoGreen 
assay, as described in Chapter 2 (Section 2.2.8.4).  
4.3.2.1.5 Biocompatibility of decellularised human femoral nerve segments  
The biocompatibility of human femoral nerve segments decellularised using 
Protocol 3H was investigated using the contact cytotoxicity assay, as described in 
Chapter 2 (Section 2.2.10), using BHK cells (n = 3) and L929 cells (n = 3). 
Cyanoacrylate contact adhesive was used as a positive control for cytotoxicity, and 
surgical closure strips (SteriStrips) were used as a negative control. Biocompatibility 
was assessed by examining cell growth up to and in contact with the samples after 







4.3.2.2 Characterisation of native and decellularised human femoral 
nerve segments  
Various histological, immunohistochemical and biochemical analyses were used to 
characterise the properties of native (n = 6) and decellularised (n = 6) human 
femoral nerve segments, and assess the effects of decellularisation Protocol 3H on 
the ECM histioarchitecture and specific ECM components. 
4.3.2.2.1 Histological analysis 
Native (n = 3) and decellularised (n = 3) nerve segments were cut into three 20 mm 
segments as described previously, and fixed in 10 % (w/v) NBF, processed and 
embedded in paraffin wax as described in Chapter 2 (Section 2.2.4.1). Wax blocks 
were sectioned (5 µm thickness) as described in Chapter 2 (Section 2.2.4.2), and 
processed for histological analysis, or analysis by immunofluorescent labelling. 
Images presented are of the middle regions of native and decellularised nerve 
segments. 
4.3.2.2.2 Histological stains 
Sections were stained using Sirius red / Miller’s elastin and Sirius red / Luxol fast 
blue, as described in Chapter 2 (Sections 2.2.5.3 and 2.2.5.4 respectively). Sirius 
red staining was used to assess overall collagen structure, and imaged under 
circularly polarised light to examine collagen fibril configuration and distribution. 
Miller’s stain was used to stain elastin, and Luxol fast blue was used to stain myelin. 
4.3.2.2.3 Immunofluorescent labelling of specific ECM components 
For immunofluorescent labelling, sections of native and decellularised nerve were 
labelled with primary antibodies specific for collagen IV, laminin, fibronectin and 
chondroitin sulphate, as described in Chapter 2 (Section 2.2.6), and Chapter 3 
(Table 3.3). Sections of native and decellularised nerve were also incubated with 
isotype control antibodies, and sections of native human femoral artery were used 
as positive controls. Omission of primary antibodies served as negative controls. 
4.3.2.2.4 Biochemical analysis 
The biochemical composition of native (n = 6) and decellularised (n = 6) nerve 
segments was determined using assays to quantify collagen, denatured collagen, 
fat and GAG content as described in Chapter 2 (Section 2.2.8).  
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4.4     Results 
4.4.1 Development of a decellularisation protocol for human 
femoral nerve  
4.4.1.1 Application of Protocol 1H 
The decellularisation process developed for porcine peripheral nerve in Chapter 3, 
with one modification (use of Cambridge antibiotic solution; Table 4.1) was applied 
to human femoral nerve segments. H&E staining of native and decellularised tissue 
sections was used to assess overall histioarchitectue and cell removal. DAPI 
staining of native and decellularised tissue sections was used to assess cell 
removal by visualising whole cell nuclei or nuclear remnants.  
Sections of native human femoral nerve stained with H&E and DAPI are shown in 
Figure 4.1. Observations of the H&E stained sections revealed regular shaped and 
sized endoneurial tubes, although the size and shape of fascicles varied greatly 
(Figure 4.1 B). The perineurium surrounding each fascicle appeared as dense, 
concentric bands with little variation. The inter-fascicular epineurium appeared 
loose and disorganised, containing inter-fascicular blood vessels (vasa nevorum). 
The endoneurium, perineurium and inter-fascicular blood vessels contained dense, 
evenly distributed cell populations, whereas cells in the inter-fascicular epineurium 
were sporadically distributed (Figure 4.1 B). Observations of DAPI stained tissue 
sections showed that no whole nuclei were present following decellularisation 
(Figure 4.1 A & C). However, observations of H&E stained sections indicated 
differences in the decellularised nerve in comparison to native nerve (Figure 4.1 B 
& D). The endoneurium appeared less dense, with a more irregular structure 
compared to native nerve, however individual endoneurial tubes could still be 
observed. The perineurium of decellularised nerve appeared thinner, but remained 







Figure 4.1 Images of sections of human femoral nerve stained with H&E 
and DAPI before and after decellularisation with protocol 1H. 
Representative images of sections of native human femoral nerve (A & B) and human 
femoral nerve decellularised using Protocol 1H (C & D). Sections stained with H&E (A 
& C) and DAPI (B & D). Labels added to H&E images to identify ECM structures, EN 
= endoneurium, IEP = inter-fascicular epineurium, P = perineurium, BV = blood 
vessels. Major ECM structures were well preserved following decellularisation, and no 
whole cell nuclei were observed. H&E images acquired under Köhler illumination 
using a x10 objective, and DAPI images acquired using DAPI & GFP filters using a 
x10 objective. Scale bars = 100 µm. 
 
4.4.1.1.1 DNA content of native and decellularised human femoral nerve  
The DNA content of native and decellularised human femoral nerve was 
determined to assess the efficacy and reproducibility of decellularisation Protocol 
1H . Following extraction, total DNA content was quantified using 
spectrophotometry. 
The total DNA content of native and decellularised nerve was 346 ± 53 and 62 ± 45 
ng.mg-1 respectively. Since the total DNA content of the decellularised nerves was 
high and inconsistent, ranging from 17 - 107 ng.mg-1, the decellularisation process 













4.4.1.2 Further development of the decellularisation protocol 
Two modified versions of the decellularisation process were also applied to human 
femoral nerves; Protocol 2H and Protocol 3H. Protocol 2H included an additional 
nuclease solution incubation following the existing two nuclease solution 
incubations, and Protocol 3H included an additional hypertonic buffer incubation 
following the existing hypertonic buffer incubation.  
Sections of human femoral nerves decellularised using Protocol 2H or 3H were 
assessed using H&E and DAPI staining (Figure 4.2). Observations of H&E stained 
sections showed that nerve decellularised using either Protocol 2H or 3H retained 
overall histioarchitecture and major ECM structures (Figure 4.3), with similar 
observations to nerve decellularised using Protocol 1H (Figure 4.1).  
 
Figure 4.2 Images of sections of human femoral nerve decellularised 
using Protocols 2H and 3H stained with H&E and DAPI. Representative 
images of sections of decellularised human femoral nerve produced using Protocol 
2H (A & B) and Protocol 3H (C & D). Sections stained with H&E (B & D) and DAPI (A 
& C). Labels added to H&E images to identify ECM structures, EN = endoneurium, 
IEP = inter-fascicular epineurium, P = perineurium, BV = blood vessels. Major ECM 
structures were well preserved following decellularisation, and no whole cell nuclei 
were observed. Images acquired under Köhler illumination using a x10 objective. 













The total DNA content and double stranded DNA content of native nerve and nerve 
decellularised using Protocols 1H, 2H and 3H was quantified. The results are 
presented in Table 4.3. Calf thymus DNA was used to create a standard curve to 
assess the accuracy of the spectrophotometer (Figure 4.3 A), and lambda DNA was 
used to create a standard curve to interpolate unknown values to quantify double 
stranded DNA (Figure 4.3 B). 
Statistical analysis of total DNA content by one-way ANOVA with Tukey’s post hoc 
test showed that there were significant differences between the mean total DNA 
content of native nerve and nerve decellularised using protocols 1H, 2H and 3H (p 
< 0.0001). However, there were no significant differences between the mean total 
DNA content of nerve decellularised using protocols 1H, 2H and 3H (p > 0.05).  
Statistical analysis of average double stranded DNA content by one-way ANOVA 
showed that there was a significant difference between the average double 
stranded DNA content of native nerve and nerve decellularised using protocol 2H (p 
< 0.0001) and between the average double stranded DNA content of native nerve 
and nerve decellularised using protocol 3H (p < 0.0001). However, there was no 
significant difference between the average double stranded DNA content of nerve 
decellularised using protocol 2H or 3H (p > 0.05). 
Human femoral nerve segments decellularised using Protocol 3H were found to 
have a lower total and double stranded DNA content than nerve decellularised 
using Protocols 1H or 2H with less variability (Table 4.3). Therefore, Protocol 3H 
was identified as the improved process, and human femoral nerve segments  









Table 4.3 Quantification of the DNA content of native and decellularised 
nerve. Mean total DNA content (ng.mg-1) and mean double stranded DNA (dsDNA) content 
(ng.mg-1) of native nerve (n = 6) and nerve decellularised using Protocol 1H, 2H or 3H (n = 6 
each). Data is presented as the mean ± 95% confidence limits. Statistical analysis content 
was by one-way ANOVA with Tukey’s post hoc test (p < 0.05).   
 
* Mean dsDNA content of nerve decellularised using Protocol 1H was not quantified as the 
total DNA content was high and inconsistent 
 
Figure 4.3 DNA content of calf thymus and lambda DNA standards. Linear 
relationship between calf thymus DNA concentration and measured DNA content of 
calf thymus DNA standards. (B) Standard curve of lambda DNA concentration against 
fluorescence emitted. Data represented as mean (n = 3) ± 95 % confidence limits. 
 




Native nerve 357 ± 58 244 ± 33 
Protocol 1H 69 ± 37  * 
 Protocol 2H  43 ± 16 3 ± 1 
 Protocol 3H  26 ± 5 2 ± 1 
A B 
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4.4.1.3 Biocompatibility of decellularised human femoral nerve 
The biocompatibility of human femoral nerve decellularised using Protocol 3H was 
assessed using a contact cytotoxicity assay with two distinct cell lines, BHK and 
L929 (Figure 4.4). Cells cultured with cyanoacrylate adhesive, the positive control, 
were sparsely distributed and most cell were not adhered, indicating cell death 
(Figure 4.4 A & B). Both BHK and L929 cells cultured with SteriStrips, the negative 
control, and samples of decellularised nerve grew up to and in contact with the 
samples, and displayed normal morphological characteristics. L929 cells displayed 
an elongated, spindle morphology and BHK cells displayed a more rounded 
morphology and a denser population (Figure 4.4 C-F).  
 
Figure 4.4 Contact cytotoxicity assay of decellularised human femoral nerve. 
BHK cells (A, C & E), and L929 cells (B, D, & F) were cultured with either cyanoacrylate 
adhesive (A & B) to serve as a positive control, SteriStrips (C & D) to serve as a negative 
control, or 5 mm2 segments of decellularised human femoral nerve (n = 3) (E & F). White 
arrows indicate position of decellularised nerve (E & F). Both cell types grew up to and in 
contact with the tissue, and displayed normal morphological characteristics. Images 






4.4.2 Characterisation of native and decellularised human 
femoral nerve 
4.4.2.1 Histological analysis 
Picro-sirius red was used to stain collagen fibres within sections of native and 
decellularised nerve, whilst Miller’s solution was used to stain elastin fibres (Figure 
4.5 A – D). Visualisation under normal Kohler illumination revealed fine collagen 
fibres forming the endoneurial tubes of native nerve, and thicker, discrete bands 
forming the perineurium (Figure 4.5 A). The collagen appeared to form dense, 
regular networks in the inter-fascicular epineurium.  
In comparison to native nerve, the collagen in the inter-fascicular epineurium of the 
native nerve appeared more disorganised and fragmented, and the collagen 
forming the perineurium appeared thinner, although remaining as a discrete band 
surrounding the fascicle (Figure 4.5 B). The collagen in endoneurial tubes appeared 
thinner and slightly less defined, although individual endoneurial tubes were still 
observed. Visualisation of decellularised nerve under circularly polarised light 
indicated the retention of fine collagen fibril networks in the endoneurium, and a 
similar distribution of red, yellow and green collagen fibres between native and 
decellularised nerve (Figure 4.5 A & B). No elastin fibres were revealed within the 
native nerve, except within the blood vessels located in the inter-fascicular 
epineurium, and these elastin fibres were retained in decellularised nerve (Figure 
4.5 A & B). 
Luxol fast blue was used to stain the myelin in native and decellularised nerve, in 
conjunction with Picro-sirius red to stain collagen and haematoxylin to visualise cell 
nuclei (Figure 4.5 E & F). Myelin was only observed in the endoneurium of native 
nerve, within most individual endoneurial tubes (Figure 4.5 E). Myelin was not 
observed in decellularised nerve, indicating that the decellularisation process may 
have removed the myelin from human femoral nerve (Figure 4.5 F).  
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Figure 4.5 Images of sections of native and decellularised human 
femoral nerve stained with Sirius red / Miller’s elastin and Sirius red / 
Luxol fast blue. Representative images of sections of native (A, C & E) and 
decellularised (B, D & F) nerve stained with Sirius red / Miller’s elastin (A – D) or 
Sirius red, Luxol fast blue and haematoxylin (E & F). Sirius red imaged using normal 
Köhler illumination (A & B) or circularly polarised light (C & D). The structure and 
distribution of collagen appeared to be well preserved following decellularisation, and 
the decellularisation process appeared to remove myelin from the nerve. Labels 
added to H&E images to identify ECM structures, EN = endoneurium, IEP = inter-
fascicular epineurium, P = perineurium, BV = blood vessels. Images taken using a x 



























4.4.2.2 Immunofluorescent labelling of specific ECM components 
4.4.2.2.1 Immunofluorescent labelling of collagen type IV 
Sections of native and decellularised human femoral nerve were labelled with a 
primary monoclonal antibody against collagen type IV and a goat anti-mouse IgG 
secondary antibody (Figure 4.6). Collagen type IV was located within the 
endoneurium, perineurium and blood vessels of native nerve. Collagen type IV 
appeared to form fine, discrete bands around individual endoneurial tubes, and 
dense layers in the perineurium surrounding each fascicle (Figure 4.6 C). Collagen 
type IV was still located in the endoneurium, perineurium and blood vessels of 
decellularised nerve, although labelling intensity appeared slightly reduced (Figure 
4.6 D). Intense labelling was observed in the smooth muscle region of the human 
femoral artery positive control (Figure 4.6 A), and no labelling was observed in 
sections of native human femoral nerve labelled with the isotype control antibody 
(Figure 4.6 B).  
 
Figure 4.6 Immunofluorescent labelling of collagen type IV in sections of 
native and decellularised human femoral nerve. Representative images of 
sections of native human artery (A), native human femoral nerve incubated with an 
isotype control antibody (B), and native (C) and decellularised (D) human femoral 
nerve labelled with a primary monoclonal antibody against collagen type IV and 
counterstained with DAPI. Collagen type IV was still present following 
decellularisation and labelling was most intense in the endoneurium and perineurium. 
Labels added to identify ECM structures, EN = endoneurium and P = perineurium. 










4.4.2.2.2   Immunofluorescent labelling of laminin 
Sections of native and decellularised human femoral nerve were labelled with a 
primary monoclonal antibody against laminin, and a goat anti-mouse IgG secondary 
antibody (Figure 4.7). Similarly to collagen type IV, laminin was located in the 
endoneurium, perineurium and blood vessels of native nerve, although labelling 
was most intense in the endoneurium (Figure 4.7 C). Laminin appeared to form 
fine, discrete bands surrounding individual endoneurial tubes, although some 
dense, sporadic staining was also observed in the endoneurium. In the perineurium, 
laminin appeared as faint, thin bands surrounding fascicles. Laminin was still 
located in the endoneurium, perineurium and blood vessels of decellularised nerve, 
with clear definition of endoneurial tubes, and labelling intensity did not appear to 
be reduced in comparison to native nerve (Figure 4.7 D). Laminin was observed in 
the smooth muscle and luminal regions of the human femoral artery positive control 
(Figure 4.7 A), and no labelling was observed in sections of native human femoral 
nerve labelled with the isotype control antibody (Figure 4.7 B). 
 
Figure 4.7 Immunofluorescent labelling of laminin in sections of native 
and decellularised human femoral nerve. Representative images of sections of 
native porcine artery sections (A), native nerve sections incubated with an isotype 
control antibody (B), and native (C) and decellularised (D) porcine peripheral nerve 
sections  labelled with a primary monoclonal antibody against laminin, and 
counterstained with DAPI. Fibronectin was still present following decellularisation and 
labelling was most intense in the  endoneurium, as indicated by white arrows. Images 






4.4.2.2.3 Immunofluorescent labelling of fibronectin 
Sections of native and decellularised human femoral nerve were labelled with a 
primary antibody against fibronectin and a goat anti-rabbit IgG secondary antibody 
(Figure 4.8). Fibronectin was located in the endoneurium, perineurium and blood 
vessels of native nerve, although labelling was most intense in the perineurium. 
Fibronectin appeared as a dense, discrete band in the perineurium surrounding 
each fascicle, whereas in the endoneurium fibronectin was sporadically located 
(Figure 4.8 C). Labelling of decellularised nerve showed similar observations, with 
fibronectin still located in the endoneurium, perineurium and blood vessels (Figure 
4.8 D). Labelling was observed ubiquitiously along the smooth muscle region of the 
human femoral artery positive control, with sporadic labelling in the luminal region 
(Figure 4.8 A). No labelling was observed in sections of native human femoral 
nerve labelled with the isotype control antibody (Figure 4.8 B) 
 
Figure 4.8 Immunofluorescent labelling of fibronectin in sections of 
native and decellularised human femoral nerve. Representative images of 
sections of native human artery (A), native human femoral nerve incubated with an 
isotype control antibody (B), and native (C) and decellularised (D) human femoral 
nerve labelled with a primary antibody against fibronectin and counterstained with 
DAPI. Fibronectin was still present following decellularisation and labelling was most 
intense in the perineurium, indicated by white arrows. Images taken using a x 10 







4.4.2.2.4 Immunofluorescent labelling of chondroitin sulphate 
Sections of native and decellularised human femoral nerve were labelled with a 
primary monoclonal antibody against chondroitin sulphate and a rabbit anti-mouse 
IgG secondary antibody (Figure 4.9). Chondroitin sulphate was observed in the 
endoneurium and blood vessels of native nerve, although labelling was most 
intense in the blood vessels. Intense labelling was observed within the lumen of 
blood vessels of native nerve, whereas labelling was faint and sporadically located 
in the endoneurium (Figure 4.9 C). Chondroitin sulphate was still observed in the 
endoneurium and blood vessels of decellularised nerve, although labelling intensity 
was reduced in comparison to native nerve (Figure 4.9 D). Chondroitin sulphate 
was observed in both the smooth muscle and luminal regions of the human femoral 
artery positive control (Figure 4.9 A), and no labelling was observed in sections of 
native human femoral nerve labelled with the isotype control antibody (Figure 4.9 
B).  
 
Figure 4.9 Immunofluorescent labelling of chondroitin sulphate in 
sections of native and decellularised human femoral nerve. Representative 
images of sections of native human artery (A), native human femoral nerve incubated 
with an isotype control antibody (B), and native (C) and decellularised (D) human 
femoral nerve labelled with a primary monoclonal antibody against chondroitin 
sulphate and counterstained with DAPI. Chondroitin sulphate was still present 
following decellularisation and labelling was most intense in the endoneurium, 
perineurium and blood vessels. Labels added to identify ECM structures, EN = 
endoneurium, P = perineurium and BV = blood vessels. Images taken using a x 10 











4.4.2.3 Biochemical analysis 
4.4.2.3.1 Quantification of collagen content 
The collagen content of native and decellularised human femoral nerve was 
determined following tissue hydrolysis and hydroxyproline assay. Hydroxyproline 
content was quantified using a linear regression of a trans-4-hydroxy-L-proline 
standard curve (Figure 4.10 A). The hydroxyproline content of native and 
decellularised nerve was 36.11 ± 2.75 and 38.12 ± 1.64 µg.mg-1 dry weight 
respectively. These values were converted to estimate collagen content, using a 
previously determined conversion factor of 7.52. The collagen content of native and 
decellularised nerve was 271.48 ± 20.75 and 286.53 ± 12.29 µg.mg-1 dry weight 
respectively (Figure 4.10 B). No significant difference was found between the 
collagen content of native and decellularised nerve (Student’s t-test; p> 0.05). 
 
Figure 4.10 Collagen content of native and decellularised human femoral 
nerve. (A) Standard curve of hydroxyproline concentration against absorbance at 
570 nm. Data represented as mean (n = 3) ± 95 % confidence limits. (B) Estimated 
collagen content of native and decellularised human femoral nerve. Data represented 





4.4.2.3.2 Quantification of denatured collagen content 
The denatured collagen content of native and decellularised human femoral nerve 
nerve was determined by selectively digesting denatured collagen with α-
chymotrypsin enzyme and collecting the supernatant containing denatured collagen 
prior to quantification using a hydroxyproline assay. Hydroxyproline content was 
quantified using a linear regression of a trans-4-hydroxy-L-proline standard curve 
(Figure 4.11 A). The hydroxyproline content of the denatured collagen in native and 
decellularised nerve was 0.51 ± 0.16 and 0.48 ± 0.15 µg.mg-1 dry weight 
respectively, and these values were used to calculate the denatured content by 
using a conversion factor of 7.52 as described previously. The denatured collagen 
content of native and decellularised nerve was 3.84 ± 1.22 and 3.66 ± 1.15 µg.mg-1 
dry weight respectively (Figure 4.11 B). No significant difference was found 
between the denatured collagen content of native and decellularised nerve 
(Student’s t-test; p>0.05). 
 
Figure 4.11 Denatured collagen content of native and decellularised 
human femoral nerve. (A) Standard curve of hydroxyproline concentration against 
absorbance at 570 nm. Data represented as mean (n = 3) ± 95 % confidence limits. 
(B) Estimated denatured collagen content of native and decellularised human femoral 





4.4.2.3.3 Quantification of fat content 
The fat content of native and decellularised human femoral nerve was determined 
by the extraction of fat in a known volume of ethanol. The concentration of fat in the 
extracts was used to determine the fat content of the nerve samples, using a linear 
regression of a standard curve of known fat concentrations (Figure 4.12 A). The fat 
content of native and decellularised nerve was 529.71 ± 19.85 and 567.82 ± 39.84 
µg.mg-1 dry weight respectively (Figure 4.12 B). No significant difference was found 
between the fat content of native and decellularised nerve (Student`s t-test p>0.05). 
 
Figure 4.12 Fat content of native and decellularised human femoral 
nerve. (A) Standard curve of fat concentration against absorbance at 540 nm. Data 
represented as mean (n = 3) ± 95 % confidence limits. (B) Estimated fat content of 
native and decellularised human femoral nerve. Data represented as mean (n = 6) ± 








4.4.2.3.4 Quantification of GAG content 
The GAG content of native and decellularised human femoral nerve was 
determined by digestion of samples with papain and collection of the supernatant 
containing GAGs, followed by quantification using the dimethylene blue (DMMB) 
assay. The GAG content was quantified using a linear regression of a standard 
curve of chondroitin sulphate B (Figure 4.13 A). The GAG content of native and 
decellularised nerve was 2.25 ± 0.38 and 0.69 ± 0.43 µg.mg-1 dry weight 
respectively (Figure 4.13 B). Statistical analysis revealed a significant difference 
between the GAG content of native and decellularised nerve (Student’s t-test, 
p<0.0001) 
 
Figure 4.13 GAG content of native and decellularised human femoral 
nerve. (A) Standard curve of chondroitin B sulphate concentration against 
absorbance at 570 nm. Data represented as mean (n = 3) ± 95 % confidence limits. 
(B) Estimated GAG content of native and decellularised human femoral nerve. Data 







The decellularisation protocol developed using 30 mm segments of porcine 
peripheral nerve in Chapter 3 was applied to 60 mm segments of human femoral 
nerve (Protocol 1H). Although 30 mm segments of decellularised nerve are 
generally used for both in vitro and in vivo studies of axon regeneration, 30 mm 
segments were considered inappropriate for human femoral nerves with the 
potential to be used in the clinic (Zilic et al., 2016; Lovati et al., 2018). Therefore, 
based on advice from collaborators within NHSBT TES, 60 mm segments of human 
femoral nerve were decellularised. The only other change to the protocol was the 
use of Cambridge antibiotic solution instead of disinfection solution, in order to 
comply with Good Manufacturing Practice (GMP) standards for human tissue 
processing. 
H&E and DAPI staining of sections of human femoral nerve before and after 
decellularisation indicated that Protocol 1H achieved sufficient decellularisation, as 
no whole cell nuclei or cellular remnants were observed. However, the DNA content 
of decellularised nerve was found to be high, with a high degree of variability, 
indicating that the decellularisation process was not consistently removing the 
majority of the DNA from the tissue. This was likely due to the increase in nerve 
segment size, from 30 mm to 60 mm, reducing the efficacy of the decellularisation 
process. As H&E and DAPI staining of sections of decellularised nerve did not show 
any whole cell nuclei or cell remnants, the high DNA content of the decellularised 
nerve produced using Protocol 1H was thought to be due to insufficient removal of 
residual DNA fragments from the tissue. Therefore, the decellularisation process 
was developed further to facilitate the removal of DNA fragments from the tissue, 
and ensure consistent DNA content reduction. Two modified versions of the 
decellularisation protocols were developed, including (1) an additional nuclease 
treatment to digest fragments of residual DNA (Protocol 2H), and (2) an additional 
hypertonic buffer incubation to dissociate DNA-protein complexes within the tissue 
(Protocol 3H) (Gilbert et al., 2006). Statistical analysis showed that there were no 
significant differences between the total and double stranded DNA content of 
decellularised nerve produced using Protocols 1H, 2H or 3H. However, the mean 
total and double stranded DNA content of nerve decellularised using Protocol 3H 
was the lowest (26 ng.mg-1) and importantly showed very little variability between 
the replicates, and was therefore identified as a more robust decellularisation 
process.  
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The biocompatibility of decellularised human femoral nerve was assessed, as 
residual traces of detergent, EDTA and aprotinin have been shown to have 
cytotoxic effects, as discussed in Chapter 3 (Rieder et al., 2004; Seddon et al., 
2004). The decellularised human femoral nerves developed here were 
biocompatible, with the contact cytotoxicity assay using BHK and L929 cells 
showing no changes in cell morphology and growth when cultured with the 
decellularised human femoral nerve.  
Histological analysis of decellularised human femoral nerve showed that overall the  
ECM histioarchitecture and major ECM structures were preserved, although some 
structural differences were observed in comparison to native nerve. The 
endoneurium of decellularised nerve appeared more irregular in comparison to 
native nerve, with less definition of individual endoneurial tubes. The implications of 
these structural alterations are unclear, as the presence of a native ECM 
microenvironment is one of the key advantages of decellularised nerve grafts 
compared to NGCs (Bellamkonda, 2006; Karabekmez et al., 2009; Szynkaruk et al., 
2012; Spivey et al., 2012). The Avance® nerve graft has demonstrated consistently 
superior clinical outcomes to NGCs, and this is thought to be due to the provision of 
a native microenvironment, particularly endoneurial tubes, and it has been 
hypothesised that the inability of decellularised nerve grafts to consistently match 
the regeneration rates of autografts in vivo is due to inadequate preservation of 
endoneurial tubes (Whitlock et al., 2009; Moore et al., 2011; Johnson et al., 2011). 
However, although some structural differences were observed in the endoneurium 
of the decellularised human femoral nerve compared to the native tissue, individual 
endoneurial tubes could still be identified. Furthermore, based on the histological 
results presented in this chapter, the endoneurial structure of the decellularised 
human femoral nerve may be better preserved than the endoneurial structure of the 
Avance® graft, with more regular, clearly defined endoneurial tubes.    
Another key advantage of decellularised nerve grafts in comparison to NGCs is the 
provision of specific basement membrane components, as discussed in Chapter 3 
(Burnett and Zager, 2004; de Ruiter et al., 2009; Gaudet et al., 2011). Laminin is a 
major component of the basement membrane, with axon-growth promoting activity 
and providing the adhesive stimulus for axon regeneration (Chen et al., 2000; De 
Luca et al., 2014). Immunofluorescent labelling of laminin in decellularised human 
femoral nerve showed that laminin was preserved following decellularisation, 
primarily located in the endoneurium. Similar to results demonstrated here, studies 
of the Avance® decellularised nerve graft have shown that laminin is preserved 
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following decellularisation, and a study by Yang et al. (2011) demonstrated the 
preservation of laminin in human peripheral nerves decellularised using Triton X-
100 (46 mM) and sodium deoxycholate (96 mM) (Yang et al., 2011; Wood et al., 
2014). Immunofluorescent labelling of native and decellularised human femoral 
nerve showed that basement membrane components collagen type IV and 
fibronectin were also preserved following decellularisation, located in the 
endoneurium and perineurium. Collagen type IV is a highly glycosylated collagen in 
the basement membrane, providing binding sites for key moieties, including 
laminins, enabling the cellular processes of Schwann cells and axons (Chernousov 
et al., 2008; Yurchenco, 2011). Fibronectin is a glycoprotein component of the 
basement membrane, enabling the binding of cell surface proteins, such as 
integrins, and has been shown to stimulate Schwann cell proliferation and migration 
(Ahmed et al., 2003; Mosahebi et al., 2003). However, studies of the Avance® 
decellularised nerve graft, and the decellularised nerve graft produced by Yang et 
al. (2011) discussed previously, have not assessed the effect of decellularisation on 
collagen type IV or fibronectin (Yang et al., 2011; Wood et al., 2014).  
Biochemical analysis showed that native human femoral nerve ECM was comprised 
of approximately 55 % (w/w) fat, 30 % (w/w) collagen, and 0.2 % (w/w) GAGs, 
similar to the biochemical composition of native porcine peripheral nerve as 
described in Chapter 3. However, porcine peripheral nerve contained approximately 
10 % (w/w) more fat, likely due to the young age of porcine tissue in comparison to 
human tissue, and that pigs are commercially reared for rapid weight gain. 
Biochemical analysis also showed that the decellularisation process did not 
significantly alter the fat or collagen content of human femoral nerve. Furthermore, 
the denatured collagen content of decellularised human femoral nerve was not 
significantly different from native nerve. However, histological analysis of 
decellularised human femoral nerve showed some differences in collagen structure. 
In comparison to native nerve, the collagen in the inter-fascicular epineurium 
appeared more disorganised and fragmented, and the collagen forming the 
perineurium appeared thinner following decellularisation. The alterations to collagen 
structure were similar to those observed in decellularised porcine peripheral nerve, 
described in Chapter 3, and the results described by Zilic et al. (2016), although in 
contrast to the results reported by Zilic et al. (2016) the collagen disruption 
appeared to be confined to the epineurium and perineurium (Zilic et al., 2016). As 
the alterations to the collagen structure of decellularised human nerve were 
confined to the epineurium and perineurium, this may not necessarily impair the 
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directional regeneration of axons in individual endoneurial tubes (Colen et al., 2009; 
Koch et al., 2015; White et al., 2017).  
Quantification of GAG content showed that there was a significant difference 
between the GAG content of native and decellularised human femoral nerve. 
Immunofluorescent labelling of chondroitin sulphate, one of the main GAGs present 
in human peripheral nerve, showed a reduction in staining intensity in sections of 
decellularised human femoral nerve compared to native nerve. However, as 
discussed in Chapter 3, no significant difference was found between the GAG 
content of native and decellularised porcine peripheral nerve. A reduction in GAG 
content is consistent with the findings of other studies of tissues decellularised 
using SDS, as discussed in Chapter 3. It is hypothesised that this is due to the ionic 
disruption of link protein interaction with hyaluronan, leading to the disaggregation 
of aggrecan and hyaluronan and thus increasing GAG mobility. Hypertonic buffer 
dissociates negatively charged DNA from proteins, and as GAGs are also 
negatively charged, hypertonic buffer may facilitate the removal of mobile GAGs 
from tissue. Therefore, as Protocol 3H included an additional hypertonic buffer 
incubation, this may explain the significant reduction in GAG content in 
decellularised human femoral nerve compared to native tissue.  
Chondroitin sulphate proteoglycans (CPSGs) are the main GAGs involved in the 
inhibition of axonal growth, as discussed in Chapter 3 (Krekoski et al., 2001). 
Several studies have shown that CPSGs bind to and inhibit the growth promoting 
activity of endoneurial laminin, and are rapidly upregulated following nerve injury, 
providing a non-permissive substrate for axonal growth (Zuo et al., 2002; Neubauer 
et al., 2007). However, during the degenerative process, CPSGs are subsequently 
degraded. As such, it has also been suggested that the degradation of CPSGs may 
represent a mechanism by which the growth-promoting properties of laminin may 
be restored, thus promoting axonal regeneration (Krekoski et al., 2001; Wang et al., 
2012). The decellularistion process used to produce the Avance® graft includes 
treatment with chondroitinase ABC, a bacterial enzyme that degrades the 
disaccharide side-chains of CPSGs, and it has been shown that chondroitinase 
ABC does not affect the basement membrane or displace laminin (Braunewell et 
al., 1995). Furthermore, it has been shown that degradation of CPSGs enhances 
axon regeneration in decellularised rat nerve grafts in a rat sciatic injury model, and 
the regeneration of axons following transection repair in a rat sciatic nerve 
(Krekoski et al., 2001; Zuo et al., 2002). Therefore, the significant reduction in GAG 
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content in decellularised human femoral nerve may be beneficial to promoting 
axonal regeneration. 
Following nerve injury, Schwann cells become activated, dissociate myelin and 
migrate extensively. The myelin sheath fragments and associated debris are 
removed by phagocytosis, and residual myelin debris has been shown to inhibit 
axonal growth by delaying the degenerative process, as discussed in Chapter 3 
(Gaudet et al., 2011; Salzer, 2012). Similar to decellularised porcine peripheral 
nerve, the decellularisation process was shown to remove myelin from human 
femoral nerves, which may promote axonal regeneration (Burnett and Zager, 2004). 
However, other studies of decellularised human nerves, including the Avance® 
graft and the study of Yang et al. (2011), have not assessed the removal of myelin 
(Neubauer et al., 2010; Wolford and Rodrigues, 2011; Yang et al., 2011; Wood et 















The porcine peripheral nerve decellularisation protocol developed in Chapter 3 was 
further developed for human femoral nerves. The improved process was shown to 
achieve sufficient decellularisation, in terms of cell removal and DNA content 
reduction, and preserve ECM histioarchitecture. The decellularised nerve was 
biocompatible and retained the basement membrane components essential for 
supporting axon regeneration, providing a substrate to support cellular infiltration 
and migration. The ability of the decellularised nerve to support cellular infiltration, 










5 Chapter 5: Dorsal Root Ganglion (DRG) cell interaction 
with decellularised human femoral nerve 
5.1 Introduction 
The provision of a native microenvironment to support axon elongation and 
Schwann cell infiltration is believed to be one of the key advantages of 
decellularised nerve grafts in comparison to NGCs (Whitlock et al., 2009; Khaing 
and Schmidt, 2012; Faroni et al., 2015). Despite the development of a diverse array 
of NGCs aiming to replicate complex ECM properties, such as endoneurial 
topography, the majority of currently available NGCs are simple conduits with either 
a hollow or homogenous structure, and these NGCs have not demonstrated 
equivalent performance to autografts, even for the repair of small defects (up to 30 
mm) (Kehoe et al., 2012; Faroni et al., 2015; Silva et al., 2017). Recent 
experimental advances in the design of NGCs have included the development of 
highly aligned, porous scaffolds, intraluminal fillers with axially aligned channels, 
and the inclusion of ECM components, adhesion molecules and neurotrophic 
factors to provide a permissive environment for Schwann cell infiltration and axon 
regeneration (Gerth et al., 2015; Dalamagkas et al., 2016; Mobini et al., 2017). 
NeuraGen® was the first FDA approved NGC to incorporate a luminal filler to 
provide three-dimensional guidance to regenerating axons and Schwann cells 
(Dalamagkas et al., 2016). NeuraGen® is a type I collagen conduit with a luminal 
filler of collagen type I and axially aligned porosity to provide topographic guidance 
to migrating cells (Kehoe et al., 2012; Dalamagkas et al., 2016). However, a 
comparative study using both the Avance® graft and NeuraGen® for the repair of 
14 mm and 28 mm rat sciatic nerve defects reported a significantly greater axon 
regeneration rate using the decellularised nerve graft (Whitlock et al., 2009). 
Currently, autografts remain the gold standard intervention, particularly for the 
repair of longer nerve gap defects (over 30 mm) (Whitlock et al., 2009; Mobini et al., 
2017). It is hypothesised that this is due to the presence of Schwann cells, and that 
the efficacy of decellularised nerve grafts and NGCs is limited to shorter distances 
(up to 30 mm) due to insufficient host Schwann cell migration to sustain axon 
regeneration (Szynkaruk et al., 2012; Gerth et al., 2015; Busuttil et al., 2017). As 
discussed in Chapter 1, Schwann cells are essential for axonal survival and 
function, and serve a pivotal role in orchestrating peripheral nerve repair (Jessen et 
al., 2015; Jessen and Mirsky, 2016; López-Leal and Diaz, 2018). Following 
peripheral nerve injury, distal myelinating and non-myelinating Schwann cells 
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undergo large scale changes in gene expression and rapidly switch to a transient 
repair (Bungner) phenotype to support the survival of injured neurons and axonal 
regeneration (Jessen and Mirsky, 2016; Poplawski et al., 2018; Wagstaff, 2018). 
The repair Schwann cells have several functions, including the up-regulation of a 
number of neurotrophic factors and surface proteins to promote axon survival, and 
pro-inflammatory cytokines to recruit macrophages to the site of injury (Jessen and 
Mirsky, 2016; Wagstaff, 2018). In addition, the repair Schwann cells adopt an 
elongated morphology, rapidly migrate and align in columns (bands of Bungner) 
inside endoneurial tubes, providing essential substrate and guidance cues to 
enable the elongation of regenerating axons towards the distal stump (Jessen and 
Mirsky, 2016; Ronchi and Raimondo, 2017; Wong et al., 2017). However, the ability 
of Schwann cells and neurons to sustain axon regeneration is influenced by 
distance, and progressively fails over time if axon contact is not re-established due 
to deterioration of the distal nerve stump. This involves a decrease in Schwann cell 
numbers and the trophic factors initially upregulated by Schwann cells following 
injury (Ronchi and Raimondo, 2017; Wagstaff, 2018).   
Currently, there is no in vitro model of peripheral nerve, and peripheral nerve 
regeneration cannot be replicated in vitro. The majority of in vitro studies of axonal 
regeneration and Schwann cell survival, migration and interaction with 
decellularised nerve grafts or NGCs have been performed using short-term cultures 
of dissociated rat primary cells, either in isolation or in co-cultures (Geuna et al., 
2016; Mobini et al., 2017). Sensory neurons dissociated from rat dorsal root 
ganglion (DRG) explants are most commonly used, as they are easily isolated and 
sprout neurites in vitro. Sensory neurons can be co-cultured with primary Schwann 
cells to represent an in vitro model of peripheral nerve regeneration (De Luca et al., 
2015; Geuna et al., 2016; Neto et al., 2017). However, primary neuron cultures do 
not survive for a prolonged period of time in the absence of a permissive 
environment, which consists of a heterogeneous population of cells, including glial 
cells and fibroblasts (De Luca et al., 2015; Geuna et al., 2016).  
Rat DRG explant organotypic cultures have also been used for in vitro studies of 
peripheral nerve regeneration, as rat DRGs can be easily isolated and inserted into 
scaffolds, and enable quantification of neurite outgrowth from the body of the DRG 
explant. DRG explants are also considered to be more physiologically relevant for 
studies of neuron interactions, because the in vivo three-dimensional architecture, 
ECM organisation, and the complex niche involving a heterogeneous population of 
neurons, mature Schwann cells and glial cells is preserved (Morano et al., 2014; 
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Geuna et al., 2016; Neto et al., 2017). Furthermore, the appropriate spatial 
arrangement, connectivity and cell-cell communication between neurons, Schwann 
cells and glial cells is not disrupted in rat DRG explant cultures (Neto et al., 2017). 
Although many studies of peripheral nerve regeneration have used embryonic DRG 
explants, extrapolation from embryonic to adult DRGs is limited since embryonic 
neurons differ from adult neurons in terms of axonal survival, outgrowth and gene 
expression (Allodi et al., 2011; Neto et al., 2017). Therefore, adult DRG explant 
cultures may better represent an in vitro model for the regeneration of mature axons 
(Fornaro et al., 2008; Allodi et al., 2011; Neto et al., 2017).   
DRG explants also contain satellite glial cells (SGCs) that form sheaths around the 
neuronal cell body. SGCs are thought to participate in peripheral nerve repair, 
however, the interaction between SGCs and decellularised nerve grafts or NGCs 
has not been studied (Geuna et al., 2016; Kastriti and Adameyko, 2017; George et 
al., 2018). SGCs have been described as being similar to astrocytes in the central 
nervous system, since they modulate neuronal activity through recycling glutamate, 
a neurotransmitter also involved in neuron metabolism, by converting glutamate to 
glutamine (Hanani, 2005; Costa and Moreira Neto, 2015; Kastriti and Adameyko, 
2017). Glutamine synthetase (GS), an enzyme involved in the glutamate recycling, 
has previously been described as a unique marker for rat SGCs (George et al., 
2018). Rat SGCs have also been shown to exhibit an activated state and undergo 
enhanced proliferation in response to injury (George et al., 2018; Dubový et al., 
2019). Rat SGCs have been shown to be highly plastic and can differentiate into a 
range of cell types including oligodendrocytes and Schwann cells, and it has been 
proposed that SGCs may be a population of multipotent cells that could differentiate 
to replace neurons in the DRG (Svenningsen et al., 2004; Hanani, 2005; Weider et 
al., 2015). Furthermore, the notion that SGCs may not be fully differentiated cells is 
supported by the expression of the transcription factor, Sox2 in the nuclei of SGCs, 
which has been described as a stem cell marker (Koike et al., 2015; Weider et al., 
2015).  
It is hypothesised that SGCs represent a population of developmentally arrested 
Schwann cells (George et al., 2018). SGCs have been shown to express a number 
of markers associated with Schwann cell precursors, including adhesion molecule 
cadherin-19 (CDH19), which has previously been described as a unique marker for 
Schwann cell precursors, even in adult DRGs (George et al., 2018). SGCs have 
been shown to differentiate into Schwann cell-like cells, transcriptionally and 
morphologically similar to Schwann cells, when cultured independently in vitro, and 
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are also capable of migrating and myelinating embryonic axons in vitro (George et 
al., 2018). Therefore, it is thought that SGCs are a population of cells within the 
Schwann cell lineage whose further differentiation appears to be arrested by 
contact with the DRG neuronal soma, and are capable of differentiating into multiple 
cell types, including Schwann cell-like cells in response to injury (Weider et al., 
2015; Koike et al., 2015; George et al., 2018).  
In order to investigate the ability of human decellularised nerve to support axon 
regeneration in vitro, primary adult rat DRG explants were cultured in segments of 
decellularised human nerve. The effects of decellularised human nerve on DRG cell 
viability and migration up to 28 days in culture was assessed, and neurite growth 
was assessed using the neuron marker neurofilament-200 (NF-200). SGCs within 
the DRG were also investigated by assessing changes in the expression of Sox2 
and GS over 28 days in culture. In addition, Schwann cells within the DRG were 
also studied by assessing changes in the expression of the mature myelinating 
Schwann cell marker myelin basic protein (MBP) and the non-myelinating Schwann 
cell marker neural cell adhesion molecule-1 (NCAM-1).  
As discussed previously, the linear microarchitecture of endoneurial tubes is 
believed to be one of the key advantages of decellularised nerve grafts in 
comparison to NGCs (Khaing and Schmidt, 2012; Faroni et al., 2015). Previous 
research investigating sterilisation strategies for decellularised porcine peripheral 
nerve grafts (JDR Holland, unpublished data) showed that lyophilisation of porcine 
peripheral nerve resulted in physical damage to endoneurial structure, whilst 
preserving the basement membrane components laminin and collagen type IV. 
Therefore, lyophilised decellularised human nerve was investigated as a potential 
variable to assess the importance of endoneurial architecture, and DRG explants 
were also cultured in segments of lyophilised decellularised human nerve. In 
addition, DRG explants were also cultured with rat tail type I collagen hydrogels to 
represent a non-aligned control scaffold, and compared to DRG explants cultured in 






5.2 Aims and objectives 
5.2.1 Aims: 
I. To culture primary adult rat DRG explants in decellularised human femoral 
nerve in vitro, and determine the effects of decellularised nerve on cell 
viability, cell migration, neurite outgrowth and the expression of SGC and 
Schwann cell markers 
II. To investigate the importance of endoneurial structure by culturing primary 
rat DRG explants in lyophilised decellularised human femoral nerve, and 
compare the effects on cell viability, cell migration, neurite outgrowth and 
the expression of SGC and Schwann cell markers with decellularised 
human femoral nerve. 
III. To culture primary rat DRG explants in collagen type 1 hydrogels, to 
represent a non-aligned control, and compare the effects on cell viability, 
cell migration, neurite outgrowth and the expression of SGC and Schwann 




I. To lyophilise decellularised human femoral nerve and determine the effects 
on nerve histioarchitecture and the specific basement membrane 
components collagen type IV and laminin by histological and 
immunofluorescent analyses. 
II. To establish a culture system for primary rat DRG explants with 
decellularised nerve segments in vitro.  
III. To establish a culture system for primary rat DRG explants in collagen type 
1 hydrogels in vitro 
IV. To determine cell viability at various time points in the culture systems 
developed in Objectives II and III using the ATP lite™ assay and TUNEL 
staining to detect apoptotic cells 
V. To investigate cell migration and neurite outgrowth at various time points in 
the culture systems developed in Objectives II and III by immunofluorescent 
labelling of Neurofilament-200 (NF-200) 
VI. To investigate the expression of satellite glial cell markers Sox2 and GS, 
and Schwann cell markers NCAM-1 and MBP at various time points in the 
culture systems developed in Objective II using immunofluorescent labelling. 
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5.3 Methods and experimental approach 
5.3.1 Experimental approach 
Decellularised human femoral nerves were lyophilised and rehydrated to 
structurally damage the endoneurium, in order to assess the importance of 
endoneurial structure on cell viability and migration when they were used to culture 
primary rat DRG explants. The histioarchitecture and specific basement 
components laminin and collagen type IV of lyophilised decellularised nerve were 
analysed by histology and immunofluorescent labelling. Decellularised human 
femoral nerve segments and lyophilised decellularised human femoral nerve 
segments were then cultured with primary rat DRG explants for 1, 7, 14, 21 or 28 
days. Primary rat DRG explants were also cultured in collagen hydrogels to 
represent non-aligned scaffold controls, for 1, 7, 14, 21 or 28 days in order to 
compare cell viability and migration with DRGs cultured in decellularised and 
lyophilised decellularised nerve. At each time point in culture, cell viability was 
assessed using the ATP lite™ assay, and apoptosis was assessed using the 
terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labelling (TUNEL) 
assay. Immunofluorescent labelling was also used to assess cell migration and 
determine the expression of Neurofilament-200, Sox2, GS, MBP and NCAM-1 at 
each time point in culture. At each time point in culture, DRGs cultured with 
decellularised nerve and DRGs cultured with lyophilised decellularised nerve were 
analysed by histology to visualise migrating cells.  
5.3.2 Methods 
5.3.2.1 Decellularisation of human femoral nerves 
Human femoral nerves were dissected from 16 femoral bundles, cut into 60 mm 
segments and stored on PBS moistened filter paper at -80 °C as described in 
Chapter 2 (Section 2.2.3). Human femoral nerve segments (n = 72) were 
decellularised using decellularisation Protocol 3H developed for human femoral 
nerves, as described in Chapter 4. The decellularisation process was carried out 
aseptically, using aseptic technique in a class II safety cabinet. All decellularisation 
solutions were autoclaved prior to use, as described in Chapter 2 (Section 2.2.1.3). 
Following decellularisation, nerve segments were stored aseptically in PBS at 4 °C 
for up to one month. 
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5.3.2.2 Lyophilisation and rehydration of decellularised human 
femoral nerves 
Decellularised human femoral nerve segments (n = 36) were weighed three times 
and a mean wet weight calculated. Samples were placed in a freeze dryer at -50 
°C, 0.15 – 0.2 mbar, and the weight measured every 24 hours until constant (48 -72 
hours). Once samples were lyophilised to a constant weight, samples were 
immersed in PBS at 4 °C until rehydrated to the initial wet weight calculated for 
each sample (24 – 48 hours). Samples were then were stored aseptically in PBS at 
4 °C for up to one month. 
5.3.2.3 Histological analysis of lyophilised decellularised human 
femoral nerve 
Native (n = 3), decellularised and lyophilised decellularised (n = 3) human femoral 
nerve segments were cut into three 20 mm samples as described previously, and 
fixed in 10 % (w/v) NBF, processed and embedded in paraffin wax as described in 
Chapter 2 (Section 2.2.4.1). Wax blocks were sectioned (5 µm thickness) as 
described in Chapter 2 (Section 2.2.4.2) and processed for histological analysis, or 
analysis by immunofluorescent labelling. 
5.3.2.3.1 Histological stains 
Sections of native, decellularised and lyophilised decellularised human femoral 
nerve were stained using Sirius red / Miller’s elastin, as described in Chapter 2 
(Section 2.2.5.3). Sirius red staining was used to assess overall collagen structure, 
and stained sections were imaged under circularly polarised light to examine 
collagen fibril configuration and distribution. Miller’s stain was used to stain elastin. 
5.3.2.3.2 Immunofluorescent labelling of collagen type IV and laminin 
For immunofluorescent labelling, sections of native, decellularised and lyophilised 
decellularised human femoral nerve were labelled with primary antibodies specific 
for collagen IV and laminin, as described in Chapter 2 (Section 2.2.6), and 
counterstained with DAPI. Specific antibodies and concentrations are detailed in 
Chapter 3 (Table 3.3). Sections of native and lyophilised decellularised nerve were 
also incubated with isotype control antibodies, and sections of native human 
femoral artery were used as positive controls. Omission of primary antibodies 
served as negative controls. 
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5.3.2.4 Isolation of primary rat DRG explants 
All procedures involving animals were performed in accordance with the UK Home 
Office Animals (Scientific Procedures) Act 1986. Adult Wistar rats (approximately 
45 days, male and female) were sacrificed by Schedule 1 asphyxiation in a rising 
concentration of CO2 (to 100%; v/v) for 5 minutes. Following asphyxiation, rats were 
exsanguinated by incision through the carotid artery to confirm death.  
DRG explants were isolated aseptically. The rat body was sprayed with 70 % (v/v) 
ethanol, and scissors were used to cut through the skin horizontally at the base of 
the back of the neck and then vertically along the length of the spine. Connective 
tissues and muscles either side of the spine were removed, and the spine was 
excised from the body by cutting through the spinal column at the cervical and 
lumbar ends, removing the ribs, remaining muscle and fascia. The spinal column 
was cut into three segments using scissors, and stored in cold Hanks balanced salt 
solution (HBSS) in a 50 mL Falcon tube on ice prior to dissection. Using small 
scissors, the spinal column segment was dissected in half along the sagittal plane, 
and the spinal cord was exposed. Using fine tweezers, the spinal cord was gently 
peeled away from the spinal column to reveal the nerve roots, which could be 
traced to locate the DRG of each vertebrae (Figure 5.1). Individual DRGs were 
removed by pulling the axon bundles either side of the DRG with fine tweezers. 
Each DRG was placed in a petri dish containing cold naked DMEM on ice, and the 
meninges were removed using 3 mm spring-back scissors under a dissection 
microscope. DRGs were then cut in half, and stored in petri dishes containing cold 
DMEM on ice until all DRGs were dissected. 
 
Figure 5.1 Dissection of Dorsal Root Ganglion (DRG) explants from 
adult rat spinal column. The rat spinal column segment is dissected into two 
halves by cutting along the dorsal and ventral sides of the vertebral column. The 
spinal cord is peeled away to reveal the DRGs located in small cavities along the 












5.3.2.5 Cryo-embedding freshly isolated primary rat DRG explants 
Freshly isolated DRGs (n = 3) were placed into individual plastic histology cassettes 
with an inner mesh cage. Samples were fixed by immersion in 50 mL 4 % (v/v) 
paraformaldehyde (PFA) solution in sterile 100 mL pots for one hour. Following 
fixation, samples were immersed in 100 mL PBS for 10 minutes, then immersed in 
50 mL 15 % (w/v) sucrose in PBS for 24 hours at 4 °C. Samples were then 
immersed in 50 mL 30 % (w/v) sucrose in PBS for 24 hours at 4 °C, and transferred 
to small plastic cryo-moulds. Optimal cutting temperature (OCT) compound was 
added to each mould to cover the sample, and allowed to equilibrate for three hours 
at room temperature. Samples were then transferred to fresh plastic cryo-moulds, 
covered in OCT compound and cryo-embedded by placing in a metal tray filled with 
dry ice and 100 % (v/v) ethanol. Once samples were frozen, they were stored at -80 
°C in an air tight container until use. 
5.3.2.6 Development of a culture method for primary rat DRG 
explants with decellularised and lyophilised decellularised 
human femoral nerve 
5.3.2.6.1 Solutions 
5.3.2.6.1.1 Agarose (4 %; w/v) 
Agarose (4 g) was added to 100 mL distilled water. The solution was autoclaved, as 
described in Chapter 2 (Section 2.2.1.3), and stored at room temperature for up to 
one month. Prior to use, the solution was heated in a microwave until re-melted. 
5.3.2.6.1.2 NGF stock solution (1 mg.mL-1 NGF) 
HBSS (1 mL) was added to a 1 mg vial of nerve growth factor (NGF) to reconstitute. 
The stock solution was stored in 50 µL aliquots in sterile Eppendorf tubes at -20 °C 
for up to two years. 
5.3.2.6.1.3 DRG culture medium (10 % v/v FBS, 2 mM L-glutamine, penicillin/ 
streptomycin 100 U / 100 µg.mL-1, 0.1 µg.mL-1 NGF) 
To make up the DRG culture medium, 20 mL foetal bovine serum (FBS), 2 mL L-
glutamine (200 mM), and 4 mL penicillin/ streptomycin (penicillin 5000 U.mL-1; 
streptomycin 5 mg.mL-1) was added to 87 mL Hams F12  and 87 mL DMEM. The 
medium was stored at 4 °C for up to one week. Immediately before use, 20 µL NGF 
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stock solution (1 mg.mL-1) was added, and the medium was pre-warmed to 37 °C in 
a water bath. 
5.3.2.6.2 Culture method 
Culture plates were prepared aseptically by coating the base of each well of a 6-
well tissue culture plate with 4 mL melted 4 % (w/v) agarose solution in a class II 
safety cabinet. Once the agarose solution had set at room temperature, each plate 
was wrapped in Parafilm and stored at 4 °C for up to one week. Prior to use, the 
plates were allowed to equilibrate to room temperature.  
Decellularised (n = 30) or lyophilised decellularised (n = 30) nerve segments (20 
mm) were adhered to the base of agarose coated plates by pinning each end into 
the agarose using 3 mm sterile stainless steel pins (Figure 5.2). A small incision 
was made in the top of each segment, and one half of a primary rat DRG  was 
inserted into the cavity of each segment. DRG culture medium (4 mL) was added to 
each well, and the plates were cultured at 37 °C in 5 % CO2 (v/v) in air, for up to 28 
days. DRG culture medium was aspirated and replaced with 4 mL fresh culture 
medium every 48 hours. DRGs were cultured for either 1, 7, 14, 21 or 28 days. 
At each time point (days 1, 7, 14, 21 and 28), six segments were removed from 
culture and processed for ATP lite™ assay (n = 3), as described in Section 5.3.2.12 
below, or processed for cryoembedding (n =3), as described in Section 5.3.2.8 
below. 
 
Figure 5.2 Culture design for culturing primary rat DRGs in 
decellularised and lyophilised decellularised human femoral nerve 
segments. Individual wells of 6 – well culture plates were coated with agarose (4 % 
w/v) and segments of decellularised or lyophilised decellularised nerve (20 mm) were 
pinned into position using stainless steel pins (11 x 3 mm). DRG explants were 
halved, and one half was inserted into each segment in a small cavity snipped in the 
top. DRG culture medium (4 mL) was added to each well. 
 
DRG explant 






5.3.2.7 Culture of primary rat DRG explants in collagen type I 
hydrogels 
5.3.2.7.1 Solutions 
5.3.2.7.1.1 Sodium hydroxide (1.94 M NaOH) 
NaOH pellets (7.76g) were dissolved in 100 mL distilled water using a magnetic 
stirrer and stirrer bar. The solution was stored for up to six months at room 
temperature. 
5.3.2.7.2 Culture method 
Collagen hydrogels (n = 30) were made according to the following composition: 80 
% (v/v) rat tail type I collagen (2.06 mg.mL-1 stock solution), 10 % (v/v) 10 X minimal 
essential medium (MEM), 5.8 % (v/v) NaOH solution, and 4.2 % (v/v) DRG culture 
medium. All reagents were kept on ice to slow down the gelation process, and all 
work was performed aseptically in a class II safety cabinet.   
Rat tail type I collagen (80 % v/v of final volume, final concentration 1.65 mg.mL-1) 
and MEM solution (10 % v/v of final volume) were added to a sterile 30 mL 
universal tube. The solution was neutralised by the addition of NaOH solution 
dropwise, until the colour of the solution changed from yellow to rose pink, 
indicating neutralisation. Following neutralisation, DRG cell culture medium (4.2 % 
v/v of final volume) was added, and the gel solution was pipetted into individual 
wells of a 48-well culture plate (300 µL per well). Prior to complete gelation, one half 
of a primary rat DRG was added to each well to suspend the half DRG within the 
gel. Once gelation was complete, gels were transferred to individual wells of 6-well 
culture plates, 4 mL DRG culture medium was added to each well, and the gels 
were cultured at 37 °C in 5 % CO2 (v/v) in air, for up to 28 days. DRG culture 
medium was aspirated and replaced with 4 mL fresh culture medium every 48 
hours. DRGs were cultured for either 1, 7, 14, 21 or 28 days. 
At each time point (days 1, 7, 14, 21 and 28), six gels were removed from culture 
and processed for ATP lite™ assay (n = 3), as described in Section 5.3.2.12 below, 
or processed for cryoembedding (n = 3), as described in Section 5.3.2.9 below.  
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5.3.2.8 Cryo-embedding cultured decellularised human femoral nerve 
segments 
Decellularised nerve segments (n = 3) and lyophilised decellularised nerve 
segments (n = 3) were removed from culture at each time point, and transferred to 
plastic histology cassettes. Samples were fixed by immersion in 50 mL 4 % (v/v) 
paraformaldehyde (PFA) solution in sterile 100 mL pots for one hour. Following 
fixation, samples were immersed in 100 mL PBS for 10 minutes, then immersed in 
50 mL 15 % (w/v) sucrose in PBS for 24 hours at 4 °C. Samples were then 
immersed in 50 mL 30 % (w/v) sucrose in PBS  for 24 hours at 4 °C, and 
transferred to large plastic cryo-moulds. OCT compound was added to each mould 
to cover the sample, and allowed to equilibrate for three hours at room temperature. 
Samples were then transferred to fresh large plastic cryo-moulds, covered in OCT 
compound and cryo-embedded by placing in a metal tray filled with dry ice and 100 
% (v/v) ethanol. Once samples were frozen, they were stored at -80 °C in an air 
tight container until use. 
5.3.2.9 Cryo-embedding primary rat half DRGs in collagen hydrogels 
DRG culture medium was aspirated from each gel (n = 3 per time point), and gels 
were fixed by adding 1 mL 4 % (v/v) PFA solution to each well and incubating at 
room temperature for one hour. Following fixation, the PFA solution was aspirated 
from each well, and 1 mL PBS was added to each well and incubated for 10 
minutes. PBS was aspirated from the wells, then 1 mL 15 % (w/v) sucrose in PBS 
was added to each well and incubated for 24 hours at 4 °C. Gels were then 
immersed in 1 mL 30 % (w/v) sucrose solution in PBS and incubated for 24 hours at 
4 °C. Gels were then transferred to large plastic cryo moulds, covered in OCT 
compound and cryo-embedded by placing in a metal tray filled with dry ice and 100 
% (v/v) ethanol. Once samples were frozen, they were stored at -80 °C in an air 
tight container until use. 
5.3.2.10 Cryo-sectioning and slide preparation 
Freshly isolated DRGs (n = 3), cryo-embedded decellularised nerve segments and 
lyophilised decellularised nerve segments cultured with DRGs from each time point 
(n = 3 per time point) and DRGs cultured in collagen gels from each time point (n = 
3 per time point) were sectioned using a cryotome at a temperature of -30 °C. Each 
block was serially sectioned, with sections cut at a thickness of 10 µm. The sections 
were transferred to Superfrost Plus slides, and each slide was numbered and left to 
dry at room temperature for 30 minutes. Slides were stored in plastic slide storage 
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boxes at -20 °C until staining. Prior to staining, slides were thawed at room 
temperature for 30 minutes. 
Numbered slides from each block of DRGs cultured with decellularised nerve 
segments were systematically separated for TUNEL assay (n = 3 slides, numbers 
1, 6 and 11), immunofluorescent labelling with Sox2 and GS (n = 3 slides, numbers 
2, 7 and 12) MBP and NCAM-1 (n = 3 slides, numbers 3, 8 and 13), and NF-200 (n 
= 3 slides, numbers 4, 9 and 14) and Masson’s trichrome staining (n = 3 slides, 
numbers 5, 10 and 15). This process was repeated for the numbered slides from 
each block of DRGs cultured with lyophilised decellularised nerve segments.  
Numbered slides from each block of collagen hydrogels cultured with DRGs were 
systematically separated for TUNEL assay (n = 3 slides, numbers 1, 6 and 11), 
immunofluorescent labelling with Sox2 and GS (n = 3 slides, numbers 2, 7 and 12) 
MBP and NCAM-1 (n = 3 slides, numbers 3, 8 and 13), and NF-200 (n = 3 slides, 
numbers 4, 9 and 14). Sections of collagen hydrogels cultured with DRGs were not 
stained with Masson’s Trichrome as it was not found to be technically possible, as 
sections would not adhere to slides during staining. 
5.3.2.11 Histological analysis 
5.3.2.11.1 Masson’s trichrome staining 
Cryosections of DRGs cultured with decellularised nerve (n = 3 per time point) and 
DRGs cultured with lyophilised decellularised nerve (n = 3 per time point) were 
stained with Masson’s trichrome as described in Chapter 2 (Section 2.2.5.5). 
Masson’s trichrome staining was used to visualise collagen (light green), nuclei 
(dark brown) and cytoplasm (red), assess the positioning of the DRGs and visualise 
migrating cells in the decellularised nerve or lyophilised decellularised nerve  
5.3.2.11.2 TUNEL staining 
Cryosections of freshly isolated DRGs (n = 3), DRGs cultured with decellularised 
nerve (n = 3 per time point), DRGs cultured with lyophilised decellularised nerve (n 
= 3 per time point) and DRGs cultured in collagen hydrogels (n = 3 per time point) 






 DeadEnd™ Fluorometric TUNEL 
system 
 
 Sodium chloride solution (0.85 %; w/v 
NaCl) 
0.85 g NaCl 
100 mL distilled water 
 Methanol free formaldehyde solution 
(4 %; w/v in PBS) 
20 mL 16 % methanol free 
formaldehyde 
60 mL PBS 
 Proteinase K buffer solution (100 mM 
Tris-HCl, 50 mM EDTA), pH 8.0 
788 mg Tris-HCl  
930.5 mg EDTA 
50 mL distilled water 
 Proteinase K stock solution (10 
mg.mL -1) 
10 mg Proteinase K 
1 mL proteinase K buffer solution 
 Proteinase K working solution (20 
µg.mL-1) 
2 µL Proteinase K stock solution 
998 µL PBS 
 Benzonase solution (1 U.mL-1) 1 µL Benzonase (250 U.µL-1) 
250 mL Nuclease solution (see 
Chapter 2 Section 2.1.8.6) 
 Terminal deoxynucelotidyl 
transferease (recombinant) (rTdT) 
reaction mix 
44 µL Equilibration buffer 
5 µL nucleotide mix 
1 µL rTdT enzyme 
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 rTdT-free negative control mix 44 µL Equilibration buffer 
5 µL Nucleotide mix 
1 µL sterile nuclease free water
  
 2X SSC solution 4 mL 20 x SSC solution 
36 mL distilled water 
 
5.3.2.11.2.2 Method 
Cryo-sections were thawed for 30 minutes, then immersed in running tap water for 
3 minutes. Sections were then immersed in sodium chloride solution for 5 minutes, 
followed by PBS for 5 minutes. Sections were then fixed by immersion in methanol 
free formaldehyde solution for 15 minutes at room temperature. Sections were 
immersed twice in PBS for 5 minutes each at room temperature. Each section was 
circled with a hydrophobic marker, washed for 3 minutes with PBS, and incubated 
with 100 µL Proteinase K working solution for 10 minutes at room temperature. 
Sections were washed twice with PBS, for 3 minutes each. Sections were fixed 
again by immersion in methanol free formaldehyde solution for 5 minutes at room 
temperature. Sections were washed twice with PBS for 3 minutes each. Positive 
control sections were incubated with 100 µL Benzonase solution for 5 minutes at 37 
°C, and washed twice in PBS for 2 minutes each. Sections were incubated in 50 µL 
equilibration buffer for 10 minutes at room temperature. Test sections and positive 
control sections were incubated in 50 µL rTdT reaction mix, and negative control 
sections were incubated in 50 µL negative control mix for one hour at 37 °C in a 
humidified chamber in the dark. Plastic coverslips were added to each slide to 
prevent sections drying. Plastic coverslips were then removed, and sections were 
immersed in 2 X SCC solution for 15 minutes at room temperature in the dark. 
Sections were washed three times in PBS in the dark, for 5 minutes each. Sections 
were immersed in DAPI working solution (Chapter 2 Section 2.2.5.2) for 10 minutes 
at room temperature in the dark. Sections were washed three times in PBS for 5 
minutes each in the dark, and mounted using a glass coverslip and fluorescent 
mounting medium. Sections were kept in the dark 4°C for a maximum of 24 hours 
until visualised using an upright fluorescent microscope and a DAPI filter (460 nm) 
and fluorescein filter (520 nm ± 20 nm). 
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5.3.2.11.3 Immunofluorescent labelling 
For immunofluorescent labelling, cryosections of freshly isolated DRGs (n = 3), 
DRGs cultured with decellularised nerve (n = 3 per time point), DRGs cultured with 
lyophilised decellularised nerve (n = 3 per time point) and DRGs cultured in 
collagen hydrogels (n = 3 per time point) were labelled with primary antibodies 
specific for neurofilament-200 (NF-200), Sox2, GS, MBP and NCAM-1 as described 
in Chapter 2 (Section 2.2.6) and Table 5.1 below. Sections were also incubated 
















Table 5.1 Specific antibodies and solutions for immunofluorescent 
labelling of NF-200, Sox2, GS, MBP and NCAM-1. Specific antibodies, antigen 
retrieval methods and block steps used for immunofluorescent labelling. For details of 
each antibody, see Chapter 2 (Section 2.1.6). Isotype control antibodies were applied 
at the same concentration as the primary antibody. GS = Glutamine Synthetase, MBP 
= Myelin Basic Protein, NCAM-1 = Neural Cell Adhesion Molecule-1, NF-200 = 
Neurofilament-200, RT = Room temperature, TBS = Tris buffered Saline.  
 




































































pH 6, 1 hour at 
RT 
Citrate buffer, 
pH 6, 1 hour 
at RT 
Citrate buffer, 
pH 6, 1 hour at 
RT 
Citrate buffer, 
pH 6, 1 hour 
at RT 
Proteinase 





(10 %; w/v 
serum, 0.1 %; 
w/v Triton X-
100 in TBS) for 
1 hour 
Goat serum 
(10 %; w/v 
serum, 0.1 %; 
w/v Triton X-
100 in TBS) 
for 1 hour 
Goat serum 
(10 %; w/v 
serum, 0.1 %; 
w/v Triton X-
100 in TBS) for 
1 hour 
Goat serum 
(10 %; w/v 
serum, 0.1 %; 
w/v Triton X-
100 in TBS) 
for 1 hour  
Goat serum 
(10 %; w/v 
serum, 0.1 
%; w/v Triton 
X-100 in 






5.3.2.11.4 Image capture 
Sections of DRGs cultured in decellularised nerve, lyophilised decellularised nerve 
and collagen hydrogels subject to TUNEL assay or labelled with NF-200, Sox2, GS, 
MBP or NCAM-1 were visualised using an upright fluorescent microscope and 
appropriate filters, as described in Chapter 2 (Section 2.2.1.2). Images acquired for 
analysis were taken using x 10 magnification, and the whole DRG was captured 
within the field of view. 
5.3.2.11.5 Image analysis 
5.3.2.11.5.1 Quantification of TUNEL staining 
Images of sections of DRGs cultured in decellularised nerve, lyophilised 
decellularised nerve and collagen hydrogels subject to TUNEL assay (n = 3 per 
time point) were analysed using FIJI Is Just ImageJ (FIJI) software program to 
quantify the number of apoptotic cells in each image.  
Each fluorescent multi-channel image was separated into single channel images of 
TUNEL staining (green channel) and DAPI staining (blue channel). Single channel 
images were then analysed using FIJI. The “Local Auto Threshold” plugin was used 
to threshold background fluorescence and generate binary images. The use of a 
local threshold produces a binary image according to the local image characteristics 
within a radius of each pixel, rather than a global calculation of the image. The 
'Phansalkar' Auto Local Threshold method was selected. The binary images were 
analysed using the “Analyse Particles” tool, which automates the detection and 
measurement acquisition of objects in a binary image. The number of cells was 
determined by the “count” output measure. 
The number of apoptotic cells (determined from green channel image) and the total 
number of cells (determined from blue channel image) were used to quantify the 
number of apoptotic cells in the original multi-channel image. The number of 
apoptotic cells was represented as a percentage of the total number of cells in each 
image. 
5.3.2.11.5.2 Quantification of fluorescent labelling 
Images of sections of DRGs cultured in decellularised nerve, lyophilised 
decellularised nerve and collagen hydrogels labelled with NF-200 (n = 3 per time 
point), Sox2 and GS (n = 3 per time point) and MBP and NCAM-1 (n = 3 per time 
point) were analysed using FIJI software program to quantify fluorescent labelling. 
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Each fluorescent multi-channel image was separated into single channel images 
(red, green or blue channels). Single channel images were then analysed using FIJI 
as described in Section 1.3.2.11.4.1. The 'Phansalkar' Auto Local Threshold 
method was selected to threshold background fluorescence and generate binary 
images. The binary images were analysed using the “Analyse Particles” tool, and 
the “total area (µm2)” output measure was used to quantify fluorescent labelling. 
The total area (µm2) of DAPI staining and the total area (µm2) of fluorescent 
labelling determined from single-channel images were used to quantify fluorescent 
labelling in the original multi-channel image. Fluorescent labelling of NF-200, Sox2, 
GS, MBP and NCAM-1 was represented as a percentage of the total area of DAPI 
staining in each multi-channel image. 
5.3.2.11.5.3 Quantification of maximum cell migration distance 
Images of sections of DRGs cultured in decellularised nerve (n = 3 per time point), 
lyophilised decellularised nerve (n = 3 per time point), and collagen hydrogels (n = 3 
per time point) labelled with NF-200 were analysed using FIJI software program to 
quantify the maximum cell migration distance in each image. With each image, the 
“Measure” tool was used to draw a line and determine the distance (µm) between x 
and y coordinates. The centre of the DRG explant was used as the x coordinate, 
and a migrating cell was used as the y-coordinate. A separate line was drawn for 
each migrating cell. The maximum cell migration distance (µm) for each image was 
determined. 
5.3.2.12 ATPLite-M™ cell viability assay 
Cell viability was determined using the ATP-lite M™ assay kit to quantify adenosine 
triphosphate (ATP) levels. The ATP present in the cells reacts with ᴅ-luciferin in the 
presence of luciferase to emit light proportional to ATP concentration.   
5.3.2.12.1.1 ATP lite™ assay of DRG explants cultured in decellularised nerve, 
lyophilised decellularised nerve and collagen hydrogels 
DRGs cultured with decellularised nerve segments (n = 3 per time point), DRGs 
cultured with lyophilised decellularised nerve segments (n = 3 per time point), and 
DRGs cultured in collagen gels (n = 3 per time point) were removed from culture, 
placed in individual wells of a 6-well tissue culture plate and macerated using a 
scalpel. Mammalian cell lysis solution (500 µL) was added to each sample, and 
incubated for 15 minutes with agitation at 700 rpm at room temperature. Following 
incubation, 50 µL from each sample was added to individual wells of a 96-well 
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Optiplate™ along with 50 µL substrate solution. The plate was covered in adhesive 
foil and incubated for 15 minutes with agitation at 700 rpm in the dark at room 
temperature. The luminescence of each well was then determined using a Top 



















5.4     Results 
5.4.1 Lyophilisation of decellularised human femoral nerve 
The effects of lyophilisation and rehydration on the histioarchitecture of 
decellularised human femoral nerve segments was assessed histologically using 
Sirius red/Miller’s elastin staining. Picro-sirius red was used to stain collagen fibres 
within sections of native nerve, decellularised nerve and lyophilised decellularised 
nerve, whilst Miller’s solution was used to stain elastin fibres (Figure 5.3). 
Visualisation under normal Kohler illumination showed that the histioarchitecture of 
lyophilised decellularised nerve was severely damaged in comparison to native and 
decellularised nerve (Figure 5.3 A, C & E). The collagen in the inter-fascicular 
epineurium and in the perineurial layers surrounding each fascicle appeared more 
disorganised and fragmented in comparison to native nerve, although the 
perineurium remained as a discrete band surrounding each fascicle. In comparison 
to native nerve, the endoneurium appeared more fragmented, and individual 
endoneurial tubes could no longer be identified. However, visualisation under 
circularly polarised light indicated a similar distribution of red, yellow and green 




Figure 5.3 Images of sections of native, decellularised and lyophilised 
decellularised human femoral nerve stained with Sirius red / Miller’s 
elastin. Representative images of native (A & B), decellularised (C & D) and 
lyophilised decellularised (E & F) human femoral nerve sections stained with Sirius 
red / Miller’s elastin. Sirius red imaged using normal Köhler illumination (A & C) or 
circularly polarised light (B & D). Major structural alterations were observed in the 
endoneurium of freeze dried decellularised nerve in comparison to native nerve. 
Images taken using a x 10 objective. Scale bars 100 μm. 
 
The effects of lyophilisation and rehydration on specific basement membrane 
components collagen type IV and laminin in decellularised human nerve were 
assessed using immunofluorescent labelling (Figures 5.4 and 5.5 respectively).  
Sections of native nerve, decellularised nerve and lyophilised decellularised human 
femoral nerve were labelled with a primary monoclonal antibody against collagen 
type IV and a goat anti-mouse IgG secondary antibody (Figure 5.4). Collagen type 
IV was located in the endoneurium and perineurium of lyophilised decellularised 
nerve, although labelling intensity appeared slightly reduced in comparison to native 
nerve (Figure 5.4 C & E). Intense labelling was observed in the smooth muscle 
region of the human femoral artery positive control (Figure 5.4 A), and no labelling 







Figure 5.4 Images of immunofluorescent labelling of collagen type IV in 
sections of native, decellularised and lyophilised decellularised human 
femoral nerve. Representative images of sections of native human artery (A), 
native human femoral nerve incubated with an isotype control antibody (B), and native 
(C), decellularised (D) and lyophilised decellularised (E) human femoral nerve labelled 
with a primary monoclonal antibody against collagen type IV and counterstained with 
DAPI. Collagen type IV was present in freeze dried decellularised nerve, located in 
the endoneurium and perineurium. Images taken using a x 10 objective using DAPI 
and FITC filters. Scale bars 50 μm (A, C & D) and 100 μm (B). 
 
Sections of native nerve, decellularised nerve and lyophilised decellularised human 
femoral nerve were also labelled with a primary monoclonal antibody against 
laminin and a goat anti-mouse IgG secondary antibody (Figure 5.5). Similarly to 
collagen type IV, laminin was located in the endoneurium and perineurium of 
lyophilised decellularised nerve, although labelling intensity appeared slightly 
reduced in comparison to native nerve (Figure 5.5 C & E). Laminin was observed in 
the smooth muscle and luminal regions of the human femoral artery positive control 








Figure 5.5 Images of immunofluorescent labelling of laminin in sections 
of native, decellularised and lyophilised decellularised human femoral 
nerve. Representative images of sections of native human artery (A), native human 
femoral nerve incubated with an isotype control antibody (B), and native (C), 
decellularised (D) and lyophilised decellularised (E) human femoral nerve labelled 
with a primary monoclonal antibody against laminin and counterstained with DAPI. 
Laminin was still present in freeze dried decellularised nerve, located in the 
endoneurium and perineurium. Images taken using a x 10 objective using DAPI and 










5.4.2 Masson’s Trichrome staining of DRGs cultured in 
decellularised nerve and lyophilised decellularised nerve 
Sections of primary rat DRGs cultured in decellularised and lyophilised 
decellularised human femoral nerve segments at days 1, 7, 14, 21 and 28 in culture 
were assessed histologically using Masson’s Trichrome staining (Figure 5.6). At 
day 1 in culture, visual observation of sections showed few migrating cells from the 
body of the DRG explants in DRGs cultured in decellularised nerve (Figure 5.6 A) 
and lyophilised decellularised nerve (Figure 5.6 F). However, from day 7 onwards, a 
greater number of cells migrating from the body of the DRG explants were 
observed in DRGs cultured in decellularised nerve (Figure 5.6 B – E) and 
lyophilised decellularised nerve (Figure 5.6 G – J). From day 7 onwards, cells 
migrating from the body of DRG explants cultured in decellularised nerve and 
lyophilised decellularised nerve appeared to be sporadically distributed (Figure 5.6 




Figure 5.6 Masson’s Trichrome staining of DRGs cultured in 
decellularised nerve and lyophilised decellularised nerve. Representative 
images of DRGs cultured in decellularised nerve (A-E), and lyophilised decellularised 
nerve (F-J) at time points day 1 (A & F), day 7 (B & G), day 14 (C & H), day 21 (D & I) 
and day 28 (E & J) stained with Masson’s Trichrome. Sections imaged using normal 
Köhler illumination. Images taken using a x 10 objective and a x 4 objective. Scale 








5.4.3 Cell viability of DRGs cultured in decellularised and 
lyophilised decellularised human femoral nerve and 
collagen hydrogels 
5.4.3.1 ATP content of DRG cultures over time  
Cell viability of DRG explants cultured in decellularised nerve, lyophilised 
decellularised nerve and collagen hydrogels at days 1, 7, 14, 21 and 28 in culture 
was determined using ATP lite™ assay (Figure 5.7). DRG cells remained viable up 
to 28 days in culture for all conditions (Figure 5.7).  
 
Figure 5.7 ATP content of primary rat DRGs cultured in decellularised 
and, lyophilised decellularised human femoral nerve and collagen 
hydrogels. ATP content of DRGs cultured in decellularised nerve, lyophilised 
decellularised nerve and collagen hydrogels at days 1, 7, 14, 21 and 28 in culture. 
Data is expressed as the mean counts per second (n = 3 per time point) ± 95 % 
confidence limits. Data was analysed by two-way ANOVA with Tukey’s post hoc test 
(p< 0.05). The asterisk indicates a significant difference (p< 0.05) between the ATP 
content of DRGs cultured collagen hydrogels and decellularised nerve at day 28. 
The data was analysed by two-way ANOVA (culture type vs time) with Tukey’s post 
hoc test and this revealed no significant differences between the ATP content of 
DRGs cultured in decellularised nerve, lyophilised decellularised nerve or collagen 
hydrogels at days 1, 7, 14, or 21. At day 28 in culture, there was no significant 
difference between the ATP content of DRGs cultured in decellularised nerve and 
the ATP content of DRGs cultured in collagen hydrogels, and no significant 
difference between the ATP content of DRGs cultured in decellularised nerve and 
the ATP content of DRGs cultured in lyophilised decellularised nerve. However, at 
day 28 in culture the ATP content of DRGs cultured in lyophilised decellularised 
nerve were was significantly lower than the ATP content of DRGs cultured in 
collagen hydrogels (p < 0.05). Although there was an apparent decrease in the ATP 
content of DRGs cultured in decellularised nerve and lyophilised decellularised 
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nerve between day 21 and 28 in culture, this was not found to be significantly 
different (Figure 5.7). 
5.4.3.2 Apoptotic cells in freshly isolated DRGs and DRGs cultured in 
decellularised nerve, lyophilised decellularised nerve and 
collagen hydrogels 
Sections of freshly isolated primary rat DRGs were subject to a TUNEL assay to 
detect apoptotic cells (Figure 5.8). Relatively few apoptotic cells were observed in 
sections of freshly isolated DRGs, and these appeared to be mainly at the edges 
(Figure 5.8 A). A greater number of apoptotic cells were observed in benzonase 
treated DRGs, the positive control, and these were more evenly distributed across 
the tissue section (Figure 5.8 B). No apoptotic cells were detected in the negative 
control DRG section (Figure 5.8 C).  
 
Figure 5.8 Apoptotic cells in freshly isolated primary rat DRGs. 
Representative images of TUNEL assay of sections of freshly isolated DRGs (A), 
freshly isolated DRGs treated with benzonase (B) as positive controls, and freshly 
isolated DRGs treated as negative controls (C). Apoptotic cells shown as green. 
Images acquired using a x 10 objective and DAPI and fluorescein filters. Scale bars 
100 μm. 
Apoptotic cells within primary rat DRGs cultured in decellularised nerve, lyophilised 
decellularised nerve and collagen hydrogels at days 1, 7, 14, 21 and 28 in culture 
were detected using the TUNEL assay (Figure 5.9). Apoptotic cells were observed 
in sections of DRGs cultured in decellularised nerve, lyophilised decellularised 
nerve and collagen hydrogels at all time points in culture (Figure 5.9). At day 1 in 
culture, apoptotic cells were mainly located along the edges of the DRG, with few 





5.9 A), lyophilised decellularised nerve (Figure 5.9 F), and collagen hydrogels 
(Figure 5.9 K). However, from day 7 onwards in culture, apoptotic cells appeared 
more evenly distributed within the DRG body, and a greater number of migrating 
apoptotic cells were observed in DRGs cultured in decellularised nerve, (Figure 5.9  
B – E), lyophilised decellularised nerve (Figure 5.9 G - J) and collagen hydrogels 
(Figure 5.9 L – O).  
The percent apoptotic cells (total number of apoptotic cells represented as a 
percentage of total cells) within primary rat DRGs cultured in decellularised nerve, 
lyophilised decellularised nerve and collagen hydrogels at days 1, 7, 14, 21 and 28 
in culture are shown in Figure 5.10. The percent apoptotic cells in sections of DRGs 
cultured in collagen hydrogels increased slightly with prolonged culture time, from 6 
% at day 1 to 11 % at day 28 in culture (Figure 5.10). There was little change in the 
percent apoptotic cells in sections of DRGs cultured in decellularised nerve 
between day 1 (9 %) and day 21 (10 %), however at day 28 the percent apoptotic 
cells had increased to 18 % (Figure 10). The percent apoptotic cells in DRGs 
cultured in lyophilised decellularised nerve increased from day 7 to day 28 in 
culture, and the percent apoptotic cells had increased to 31 % by day 28 (Figure 
5.10).  
No major differences were observed between the percent apoptotic cells in sections 
of DRGs cultured in decellularised nerve, lyophilised decellularised nerve and 
collagen hydrogels at day 1, 7, and 14 in culture (Figure 5.10). In addition, no major 
differences were observed between the percent apoptotic cells in sections of DRGs 
cultured in decellularised nerve and collagen hydrogels at day 21 or 28 in culture 
(Figure 5.10). However, the percent apoptotic cells in sections of DRGs cultured in 
lyophilised decellularised nerve was greater than the percent apoptotic cells in 
sections of DRGs cultured in decellularised nerve or collagen hydrogels at day 21 




Figure 5.9 Apoptotic cells in sections of primary rat DRGs cultured in 
decellularised and lyophilised decellularised human femoral nerve 
segments and collagen hydrogels. Representative images of TUNEL assay of 
sections of DRGs cultured in decellularised nerve (A-E), lyophilised decellularised 
nerve (F-J) or collagen hydrogels (K-O). TUNEL assay was performed at time points 
day 1 (A, F & K), day 7 (B, G & L), day 14 (C, H & M), day 21 (D, I & N) and day 28 
(E, J & O). Apoptotic cells shown as green. Images acquired using a x 10 objective 
and DAPI and fluorescein filters. Scale bars 100 μm. 
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Figure 5.10 Quantification of apoptotic cells in primary rat DRGs 
cultured in decellularised and  lyophilised decellularised human femoral 
nerve sections  and collagen hydrogels. Percent apoptotic cells (number of 
apoptotic cells represented as a percentage of total number of cells) in sections of 
DRGs cultured in decellularised and lyophilised decellularised human femoral nerve 
segments and collagen hydrogels at days 1, 7, 14, 21 and 28 in culture. Number of 
cells calculated from images of TUNEL assay of sections of DRGs cultured in 
decellularised nerve, lyophilised decellularised nerve and or collagen hydrogels using 









5.4.4 Expression of NF-200 in DRGs cultured in decellularised 
nerve, lyophilised decellularised nerve and collagen 
hydrogels 
Sections of native human femoral nerve and freshly isolated primary rat DRGs were 
labelled with a primary antibody against neurofilament-200 (NF-200) and a goat 
anti-rabbit IgG secondary antibody (Figure 5.11) to visualise neurofilaments. 
Neurofilament was observed within native human femoral nerve, confined to 
individual fascicles and appearing to form tightly aligned filaments corresponding 
with individual endoneurial tubes. However, labelling was fragmented and 
neurofilament did not appear to be ubiquitously expressed in the endoneurium 
(Figure 5.11 A). Neurofilament expression was observed within the freshly isolated 
DRGs, appearing as small, fragmented filaments tightly packed within the centre of 
the explanted tissue (Figure 5.11 B). No staining was observed in the isotype 
control sections (Figure 5.11 C). 
 
Figure 5.11 Immunofluorescent labelling of NF-200 in sections of native 
human femoral nerve and freshly isolated primary rat DRGs. 
Representative images of sections of native human femoral nerve (A) and freshly 
isolated DRGs (B) labelled with a primary monoclonal antibody against NF-200 
(green) and counterstained with DAPI (white), and freshly isolated DRGs incubated 
with an isotype control antibody (C). Images acquired using a x 10 objective and DAPI 





Sections of primary rat DRGs cultured in decellularised and lyophilised 
decellularised human femoral nerve segments and collagen hydrogels at days 1, 7, 
14, 21 and 28 in culture were labelled with a primary antibody against 
neurofilament-200 (NF-200) and a goat anti-rabbit IgG AF488 secondary antibody 
(Figure 5.12). The percent total area of neurofilament labelling (total area of 
neurofilament labelling (µm2) represented as a percentage of the total area of DAPI 
staining (µm2)) in sections of DRGs cultured in decellularised and lyophilised 
decellularised human femoral nerve segments and collagen hydrogels at days 1, 7, 
14, 21 and 28 in culture is shown in Figure 5.13. 
Sections of DRGs cultured in decellularised nerve showed that neurofilament 
expression appeared to gradually increase with prolonged culture time (Figure 5.12 
A – E). Quantification of the percent total area of neurofilament labelling in DRGs 
cultured in decellularised nerve confirmed these observations, as the percent total 
area of neurofilament labelling increased over time from 20 % at day 1 to 40 % at 
day 28 (Figure 5.13). Sections of DRGs cultured in lyophilised decellularised nerve 
also showed that neurofilament expression appeared to gradually increase with 
prolonged culture time (Figure 5.12 F & G). Quantitative data corroborated these 
observations, as the percent total area of neurofilament labelling in DRGs cultured 
in lyophilised decellularised nerve increased from 12 % at day 1 to 20 % at day 28 
(Figure 5.13). Neurofilament expression in sections of DRGs cultured in collagen 
hydrogels appeared to remain consistent, with no major differences observed at 
any time point (Figure 5.12 K – O). These observations were confirmed by 
quantification as the percent total area of neurofilament labelling in DRGs cultured 
in collagen hydrogels remained relatively consistent, from 42 % at day 1 to 45 % at 
day 28 (Figure 5.13). 
Overall, the percent total area of neurofilament labelling in DRGs cultured in 
decellularised nerve was greater than in DRGs cultured in lyophilised decellularised 
nerve throughout the culture period (Figure 5.13). The percent total area of 
neurofilament labelling in DRGs cultured in collagen hydrogels was greater than in 
decellularised nerve and lyophilised decellularised nerve up to day 21 in culture. 
However, at day 28 no major differences were observed in the percent total area of 
neurofilament labelling in DRGs cultured in decellularised nerve (40 %) and 





Figure 5.12 Immunofluorescent labelling of NF-200 in DRGs cultured in 
decellularised nerve, lyophilised decellularised nerve and collagen 
hydrogels. Representative images of DRGs cultured in decellularised nerve (A-E), 
lyophilised decellularised nerve (F-J) and collagen hydrogels (K-O) at time points 
points day 1 (A, F & K), day 7 (B, G & L), day 14 (C, H & M), day 21 (D, I & N) and 
day 28 (E, J & O) labelled with a primary monoclonal antibody against NF-200 (green) 
and counterstained with DAPI (white). Images taken using a x 10 objective using 
DAPI and FITC filters. Scale bars 100 μm. 
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Figure 5.13 Quantification of immunofluorescent labelling of sections for 
NF-200 in primary rat DRGs cultured in decellularised and  lyophilised 
decellularised human femoral nerve sections  and collagen hydrogel. 
Percent total area of neurofilament labelling (total area of neurofilament labelling 
(µm2) represented as a relative percentage of the total area of DAPI staining (µm2)) in 
sections of DRGs cultured in decellularised and lyophilised decellularised human 
femoral nerve segments and collagen hydrogels at days 1, 7, 14, 21 and 28 in culture. 
Total area (µm2) of neurofilament labelling and DAPI staining calculated from images 
of sections of DRGs cultured in decellularised nerve, lyophilised decellularised nerve 
and collagen hydrogels labelled with NF-200 using Fiji software. Data represented as 
mean (n = 3 per time point) ± standard deviation. 
 
Sections of DRGs cultured in decellularised and lyophilised decellularised human 
femoral nerve segments and collagen hydrogels at 28 days were also scanned and 
the scanned images tiled to present an overview of neurofilament expression and 
cell migration in the sections (Figure 5.14). Sections of DRGs cultured in 
decellularised nerve, lyophilised decellularised nerve and collagen hydrogels at 28 
days showed neurofilament expression in cells migrating from the body of the DRG 
(Figure 5.14). Sections of DRGs cultured in collagen hydrogels showed 
neurofilament expression in migrating cells, although expression was sporadic, and 
neurofilament expression was mainly confined to the body of the DRG (Figure 5.14 
A). However, sections of DRGs cultured in decellularised nerve showed 
neurofilament expression in migrating cells, and lower neuroflament expression in 
the body of the DRG (Figure 5.14 B). Furthermore, sections of DRGs cultured in 
lyophilised decellularised nerve also showed neurofilament expression in migrating 
cells, although overall neurofilament expression was lower than observed in DRGs 
cultured in collagen hydrogels or decellularised nerve (Figure 5.14 C). 
Some differences were also observed in the orientation and distribution of migrating 
cells at day 28 (Figure 5.14). Sections of DRGs cultured in collagen hydrogels 
showed that cells were migrating from the body of the DRG, with no discernible 
alignment (Figure 5.14 A). However, sections of DRGs cultured in decellularised 
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nerve and lyophilised decellularised nerve showed aligned columns of migrating 
cells, although some sporadic migrating cells were observed (Figure 5.14 B & C). 
 
 
Figure 5.14 Images of immunofluorescent labelling of sections for NF-
200 in primary rat DRGs cultured in decellularised and  lyophilised 
decellularised human femoral nerve sections  and collagen hydrogels at 
day 28 in culture. Representative images of tile scans of sections of DRGs cultured 
in collagen hydrogels (A), decellularised nerve (B) and lyophilised decellularised 
nerve (C) at time point day 28 labelled with a primary monoclonal antibody against 
NF-200 (green) and counterstained with DAPI (white). Images taken using a x 10 
objective using DAPI and FITC filters. Tile scans were created by scanning whole 





5.4.5 Cell migration of DRGs cultured in decellularised nerve, 
lyophilised decellularised nerve and collagen hydrogels 
Maximum cell migration distance was quantified by image analysis of sections of 
DRGs cultured in decellularised nerve, lyophilised decellularised nerve and 
collagen hydrogels at days 1, 7, 14, 21 and 28 in culture labelled with NF-200. The 
calculated maximum cell migration distances for each time point are shown in 
Figure 5.15. The data was analysed by two-way ANOVA with Tukey’s post hoc test 
(p<0.05). 
The maximum cell migration distance of DRGs cultured in collagen gels, 
decellularised nerve and lyophilised decellularised nerve increased with prolonged 
culture time, with increases observed at day 7, 14, 21 and 28 in culture (Figure 
5.15). At day 1 in culture, there were no significant differences between the 
maximum cell migration distance of DRGs cultured in collagen hydrogels, 
decellularised nerve or lyophilised decellularised nerve (Figure 5.15). At day 7, 14, 
21 and 28 in culture, the maximum cell migration distance of DRGs cultured in 
collagen hydrogels was significantly greater than the maximum cell migration 
distance for DRGs cultured in decellularised nerve (Figure 5.15). At day 7, 14, 21 
and 28 in culture, the maximum cell migration distance of DRGs cultured in 
collagen hydrogels was also significantly greater than the maximum cell migration 
distance of DRGs cultured in lyophilised decellularised nerve (Figure 5.15). At day 
7, 14 and 21 in culture, there were no significant differences between the maximum 
cell migration distance of DRGs cultured in decellularised nerve and lyophilised 
decellularised nerve (Figure 5.15). However, at day 28 in culture, the maximum cell 
migration distance for DRGs cultured in decellularised nerve was significantly 
greater than the maximum cell migration distance of DRGs cultured in lyophilised 
decellularised nerve (Figure 5.15).  
175 
 
Figure 5.15 Maximum cell migration distance of primary rat DRGs 
cultured in decellularised and  lyophilised decellularised human femoral 
nerve segments and collagen hydrogels. Maximum cell migration distance 
(µm) of DRGs cultured in decellularised nerve, lyophilised decellularised nerve and 
collagen hydrogels at days 1, 7, 14, 21 and 28 in culture. Cell migration distances 
(µm) calculated from images of sections of DRGs cultured in decellularised nerve, 
lyophilised decellularised nerve and collagen hydrogels labelled with NF-200 using 
ImageJ. Data represented as mean (n = 3 per time point) ± 95 % confidence limits. 
Statistical analysis was by two-way ANOVA with Tukey’s post hoc test(p < 0.05). 
Asterisks indicate a significant difference (p< 0.05) between the maximum cell 
migration distance of DRGs cultured in collagen hydrogels and decellularised nerve at 
day 7, day 14, day 21 and day 28. Hashtags indicate a significant difference (p< 0.05) 
between the maximum cell migration distance of DRGs cultured in collagen hydrogels 
and lyophilised decellularised nerve at day 7, day 14, day 21 and day 28. The caret 
indicates a significant difference between the maximum cell migration distance of 






5.4.6 Expression of satellite glial cell markers Sox2 and GS in 
primary rat DRGs cultured in decellularised and lyophilised 
decellularised human femoral nerve segments and collagen 
hydrogels 
Sections of freshly isolated DRGs were labelled with primary antibodies against 
Sox2 and GS, a goat anti-mouse IgG AF647 secondary antibody and a goat anti-
rabbit IgG AF488 secondary antibody (Figure 5.16). Sections of freshly isolated 
DRGs showed that a small number of Sox2 expressing cells were located 
sporadically in the body of the DRG (Figure 5.16 A). A greater number of GS 
expressing cells than Sox2 expressing cells were observed, and GS expressing 
cells appeared to form larger, circular structures in the body of the DRG (Figure 
5.16 A). In addition, GS expressing cells appeared to form clusters of these circular 
structures (Figure 5.16 A). No labelling was observed in the native human nerve 
section labelled with an isotype control antibody (Figure 5.16 B).  
 
Figure 5.16 Immunofluorescent labelling of Sox2 and GS in sections of 
freshly isolated primary rat DRGs. Representative images of freshly isolated 
DRGs labelled with primary antibodies against Sox2 (red) and GS (green) (A) and 
freshly isolated DRGs incubated with isotype control antibodies (B) and 
counterstained with DAPI (blue). Images taken using a x 10 objective using DAPI and 
FITC filters. Scale bars 100 μm. 
 
Sections of DRGs cultured in decellularised nerve, lyophilised decellularised nerve 
and collagen hydrogels at days 1, 7, 14, 21 and 28 in culture were also labelled with 
primary antibodies against Sox2 and GS, a goat anti-mouse IgG AF647 secondary 
antibody and a goat anti-rabbit IgG AF488 secondary antibody (Figure 5.17). The 
percent total area of Sox2 labelling (total area of Sox2 labelling (µm2) represented 
as a percentage of the total area of DAPI staining (µm2)) in sections of DRGs 
cultured in decellularised and lyophilised decellularised human femoral nerve 
segments and collagen hydrogels at days 1, 7, 14, 21 and 28 in culture is shown in 
A B 
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Figure 5.18. The percent total area of GS labelling (total area of GS labelling (µm2) 
represented as a percentage of the total area of DAPI staining (µm2)) in sections of 
DRGs cultured in decellularised and lyophilised decellularised human femoral nerve 
segments and collagen hydrogels at days 1, 7, 14, 21 and 28 in culture is shown in 
Figure 5.19. 
Sox2 expression was observed in sections of DRGS cultured in decellularised 
nerve, lyophilised decellularised nerve and collagen hydrogels at all time points 
(Figure 5.17). Sox2 expressing cells were sporadically located, and the number of 
Sox2 expressing cells was low and highly variable (Figure 5.17). Quantification of 
Sox2 labelling showed that the percent total area of Sox2 labelling in DRGs 
cultured in decellularised and lyophilised decellularised nerve segments and 
collagen hydrogels varied between circa 1% and 8% at all time points in culture, 
and no major differences were observed over time in culture (Figure 5.18). 
GS expression was also observed in sections of DRGs cultured in decellularised 
nerve, lyophilised decellularised nerve and collagen hydrogels at all time points 
(Figure 5.17). Sections of DRGS cultured in decellularised nerve, lyophilised 
decellularised nerve and collagen hydrogels showed that the expression pattern of 
GS changed with prolonged culture time. At day 1, GS expressing cells formed 
larger circular structures clustered together in the body of the DRG (Figure 5.17 A, 
F & K). At days 7, 14, 21, and 28 in culture these circular structures were absent, 
with sporadic cellular expression of GS, although some clustering of GS expressing 
cells was still observed (Figure 5.17 B-E, G-J & K-O).   
Sections of DRGs cultured in collagen hydrogels showed that little change was 
observed in GS expression with prolonged culture time (Figure 5.17 K-O). The 
percent total area of GS labelling in DRGs cultured in collagen hydrogels decreased 
slightly from 48 % at day 1 to 37 % at day 28 in culture, however high variation was 
observed (Figure 5.19). Sections of DRGs cultured in decellularised nerve showed 
that GS expression appeared to decrease with increased time in culture (Figure 
5.17 A-E). Quantification confirmed visual observations, as the percent total area of 
GS labelling in DRGs cultured in decellularised nerve changed from 46 % at day 1 
to 9 % at day 28 (Figure 5.19). Sections of DRGs cultured in lyophilised 
decellularised nerve also showed that GS expression decreased with prolonged 
culture time, although not to the same extent as DRGs cultured in decellularised 
nerve (Figure 5. F-J). The percent total area of GS labelling in DRGs cultured in 
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lyophilised decellularised nerve decreased between day 1 (43 %) and day 28 (22 
%) supporting visual observations (Figure 5.19). 
Quantification of GS labelling showed no major differences between the percent 
total area of GS labelling in DRGs cultured in collagen hydrogels, decellularised 
nerve or lyophilised decellularised nerve at day 1 or day 7 (Figure 5.19). However, 
from day 7 onwards the percent total area of GS labelling in DRGs cultured in 
collagen hydrogels was greater than the percent total area of GS labelling in DRGs 
cultured in decellularised nerve or lyophilised decellularised nerve (Figure 5.19). 
From day 14 onwards, the percent total area of GS labelling in DRGs cultured in 
decellularised nerve was greater than the percent total area of GS labelling in 
DRGs cultured in lyophilised decellularised nerve (Figure 5.19). 
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Figure 5.17 Immunofluorescent labelling of Sox2 and GS in sections of 
DRGs cultured in decellularised nerve, lyophilised decellularised nerve 
and collagen hydrogels. Representative images of sections of DRGs cultured in 
decellularised nerve (A-E), lyophilised decellularised nerve (F-J) and collagen 
hydrogels (K-O) at time points day 1 (A, F & K), day 7 (B, G & L), day 14 (C, H & M), 
day 21 (D, I & N) and day 28 (E, J & O) labelled with primary antibodies against Sox2 
(red) and GS (green) and counterstained with DAPI (blue). Images taken using a x 10 
objective using DAPI and FITC filters. Scale bars 100 μm. 
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Figure 5.18 Quantification of immunofluorescent labelling of sections 
for Sox2 in primary rat DRGs cultured in decellularised and  
lyophilised decellularised human femoral nerve sections  and collagen 
hydrogels. Percent total area of Sox2 labelling (total area of Sox2 labelling (µm2) 
represented as a relative percentage of the total area of DAPI staining (µm2)) in 
sections of DRGs cultured in decellularised and lyophilised decellularised human 
femoral nerve segments and collagen hydrogels at days 1, 7, 14, 21 and 28 in 
culture. Total area (µm2) of Sox2 labelling and DAPI staining calculated from 
images of sections of DRGs cultured in decellularised nerve, lyophilised 
decellularised nerve and collagen hydrogels labelled with Sox2 using Fiji software. 
Data represented as mean (n = 3 per time point) ± standard deviation. 
 
Figure 5.19 Quantification of immunofluorescent labelling of sections 
for GS in primary rat DRGs cultured in decellularised and  lyophilised 
decellularised human femoral nerve sections  and collagen hydrogels. 
Percent total area of GS labelling (total area of GS labelling (µm2) represented as a 
percentage of the total area of DAPI staining (µm2)) in sections of DRGs cultured in 
decellularised and lyophilised decellularised human femoral nerve segments and 
collagen hydrogels at days 1, 7, 14, 21 and 28 in culture. Total area (µm2) of GS 
labelling and DAPI staining calculated from images of sections of DRGs cultured in 
decellularised nerve, lyophilised decellularised nerve and collagen hydrogels 
labelled with GS using Fiji software. Data represented as mean (n = 3 per time 
point) ± standard deviation. 
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5.4.7 Expression of Schwann cell markers MBP and NCAM-1 in 
DRGs cultured in decellularised nerve, lyophilised 
decellularised nerve and collagen hydrogels 
Sections of freshly isolated DRGs were labelled with primary antibodies against 
MBP and NCAM-1, a goat anti-mouse IgG AF647 secondary antibody and a goat 
anti-rabbit IgG AF488 secondary antibody (Figure 5.20). Sections of freshly isolated 
DRGs showed that NCAM-1 expressing cells were mainly located along the edges 
of the body of the DRG, and the expression of NCAM-1 did not appear to co-
localise with the expression of MBP (Figure 5.20 A). MBP expression was observed 
in sections of freshly isolated DRGs, and appeared to form clusters of elongated 
tubes in the centre of the DRG (Figure 5.20 A). No labelling was observed in the 
isotype control (Figure 5.20 B).  
 
Figure 5.20 Immunofluorescent labelling of MBP and NCAM-1 in sections 
of freshly isolated DRGs. Representative images of sections of freshly isolated 
DRGs labelled with primary antibodies against MBP (green) and NCAM-1 (red) (A) 
and freshly isolated DRGs incubated with isotype control antibodies (B) and 
counterstained with DAPI (blue). Images taken using a x 10 objective using DAPI and 
FITC filters. Scale bars 100 μm. 
Sections of DRGs cultured in decellularised nerve, lyophilised decellularised nerve 
and collagen hydrogels at days 1, 7, 14, 21 and 28 in culture were also labelled with 
primary antibodies against MBP and NCAM-1, a goat anti-mouse IgG AF647 
secondary antibody and a goat anti-rabbit IgG AF488 secondary antibody (Figure 
5.21). The percent total area of NCAM-1 labelling (total area of NCAM-1 labelling 
(µm2) represented as a percentage of the total area of DAPI staining (µm2)) in 
sections of DRGs cultured in decellularised and lyophilised decellularised human 
femoral nerve segments and collagen hydrogels at days 1, 7, 14, 21 and 28 in 
culture is shown in Figure 5.22. The percent total area of MBP labelling (total area 
of MBP labelling (µm2) represented as a percentage of the total area of DAPI 
staining (µm2)) in sections of DRGs cultured in decellularised and lyophilised 
decellularised human femoral nerve segments and collagen hydrogels at days 1, 7, 
14, 21 and 28 in culture is shown in Figure 5.23. 
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Sections of DRGs cultured in cultured in decellularised nerve, lyophilised 
decellularised nerve and collagen hydrogels showed NCAM-1 expression at all time 
points in culture (Figure 5.21). However, at day 1 in culture NCAM-1 expression 
appeared to have increased in DRGs cultured in decellularised nerve, lyophilised 
decellularised nerve or collagen hydrogels (Figure 5.21 A, F & K) in comparison to 
freshly isolated DRGs (Figure 5.20 A).  
No major differences in NCAM-1 expression were observed in sections of DRGs 
cultured in decellularised nerve, lyophilised decellularised nerve or collagen 
hydrogels between day 1 and day 7 in culture (Figure 5.21 A – B, F – G & K – L). 
From day 14 onwards, NCAM-1 expression appeared to decrease in sections of 
DRGs cultured in decellularised nerve, lyophilised decellularised nerve and 
collagen hydrogels (Figure 5.21 C – E, H – J, M – O). However, the percent total 
area of NCAM-1 labelling in DRGs cultured in collagen hydrogels gradually 
decreased from 25 % at day 1 to 5 % at day 28 (Figure 5.22). The percent total 
area of NCAM-1 labelling in DRGs cultured in decellularised nerve and lyophilised 
decellularised nerve also decreased between day 1 and day 28, although this 
decrease was not as great as in the collagen gels (Figure 5.22). The percent total 
area of NCAM-1 labelling in DRGs cultured in decellularised nerve decreased from 
26 % at day 1 to 18 % at day 28, and the percent total area of NCAM-1 labelling in 
DRGs cultured in lyophilised decellularised nerve decreased from 27 % at day 1 to 
19 % at day 28 (Figure 5.22). 
At day 1 in culture, no major differences were observed in the percent total area of 
NCAM-1 labelling in DRGs cultured in decellularised nerve, lyophilised 
decellularised nerve or collagen hydrogels (Figure 5.22). However, the percent total 
area of NCAM-1 labelling in DRGs cultured in collagen hydrogels was lower than 
the percent total area of NCAM-1 labelling in DRGs cultured in decellularised nerve 
or lyophilised decellularised nerve from day 7 onwards (Figure 5.22). No major 
differences were observed in the percent total area of NCAM-1 labelling in DRGs 
cultured in decellularised nerve or lyophilised decellularised nerve at any time point 
in culture (Figure 5.22). 
Sections of DRGS cultured in decellularised nerve, lyophilised decellularised nerve 
and collagen hydrogels showed that the expression pattern of MBP changed with 
prolonged culture time. At day 1 in culture, MBP appeared to form clusters of 
elongated tubes in the body of the DRG (Figure 5.21 A, F & K). However, from day 
7 onwards, MBP expression appeared fragmented and distributed further away 
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from the centre of the DRG, with some sporadic cellular MBP expression also 
observed (Figure 5.21 B-E, G-J & L-O). 
Sections of DRGs cultured in collagen hydrogels showed that MBP expression 
decreased with prolonged culture time, with almost no MBP expression observed 
by day 28 in culture (Figure 5.21 K-O). The percent total area of MBP labelling in 
DRGs cultured in collagen hydrogels also decreased with a prolonged culture time, 
although percent total area of MBP labelling remained relatively consistent from 38 
% at day 1 to 36 % at day 7, and decreased from day 7 onwards to 7 % by day 28 
(Figure 5.23). Sections of DRGs cultured in decellularised nerve and lyophilised 
decellularised nerve also showed that MBP expression decreased with prolonged 
culture time, although some MBP expression was still observed at day 28 (Figure 
5.21 A – E & F - J). The percent total area of MBP labelling in DRGs cultured in 
decellularised nerve decreased from 51 % at day 1 to 38 % at day 14, and 
remained consistent from day 14 onwards to 37 % by day 28 (Figure 5.23). The 
percent total area of MBP labelling in DRGs cultured in lyophilised decellularised 
nerve decreased from day 39 % at day 1 to 20 % at day 28, with decreases 
observed at each time point (Figure 5.23). 
The percent total area of MBP labelling in DRGs cultured in decellularised nerve 
was greater than in DRGs cultured in lyophilised decellularised nerve or collagen 
hydrogels throughout the culture period (Figure 5.23). From day 7 onwards, the 
percent total area of MBP labelling in DRGs cultured in lyophilised decellularised 
nerve was also greater than in DRGs cultured in collagen hydrogels (Figure 5.23). 
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Figure 5.21 Immunofluorescent labelling of NCAM-1 and MBP in sections 
of DRGs cultured in decellularised nerve, lyophilised decellularised 
nerve and collagen hydrogels. Representative images of sections of DRGs 
cultured in decellularised nerve (A-E), lyophilised decellularised nerve (F-J) and 
collagen hydrogels (K-O) at time points points day 1 (A, F & K), day 7 (B, G & L), day 
14 (C, H & M), day 21 (D, I & N) and day 28 (E, J & O) labelled with primary 
antibodies against NCAM-1 (red) and MBP (green) (A) and counterstained with DAPI 
(blue). Images taken using a x 10 objective using DAPI and FITC filters. Scale bars 
100 μm. 
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Figure 5.22 Quantification of immunofluorescent labelling of sections 
for NCAM-1 in primary rat DRGs cultured in decellularised and  
lyophilised decellularised human femoral nerve sections  and collagen 
hydrogels. Percent total area of NCAM-1 labelling (total area of NCAM-1 labelling 
(µm2) represented as a relative percentage of the total area of DAPI staining (µm2)) 
in sections of DRGs cultured in decellularised and lyophilised decellularised human 
femoral nerve segments and collagen hydrogels at days 1, 7, 14, 21 and 28 in 
culture. Total area (µm2) of NCAM-1 labelling and DAPI staining calculated from 
images of sections of DRGs cultured in decellularised nerve, lyophilised 
decellularised nerve and collagen hydrogels labelled with NCAM-1 using Fiji 
software. Data represented as mean (n = 3 per time point) ± standard deviation. 
 
Figure 5.23 Quantification of immunofluorescent labelling of sections 
for MBP in primary rat DRGs cultured in decellularised and  lyophilised 
decellularised human femoral nerve sections  and collagen hydrogels. 
Percent total area of MBP labelling (total area of MBP labelling (µm2) represented 
as a relative percentage of the total area of DAPI staining (µm2)) in sections of 
DRGs cultured in decellularised and lyophilised decellularised human femoral nerve 
segments and collagen hydrogels at days 1, 7, 14, 21 and 28 in culture. Total area 
(µm2) of MBP labelling and DAPI staining calculated from images of sections of 
DRGs cultured in decellularised nerve, lyophilised decellularised nerve and collagen 
hydrogels labelled with MBP using Fiji software. Data represented as mean (n = 3 





Decellularised human femoral nerve segments were cultured with primary rat DRG 
explants in vitro for up to 28 days, in order to assess long-term biocompatibility and 
neurite outgrowth. Primary adult rat DRGs were chosen as they can be easily 
isolated and inserted into scaffolds, as discussed previously, and sprout neurites in 
vitro. The presence of a complex native ECM microenvironment, with intact 
endoneurial tubes, is believed to be the main advantage of decellularised nerve 
grafts in comparison to NGCs. In order to investigate the importance of a native 
ECM microenvironment, DRG explants were also cultured with rat tail type I 
collagen hydrogels, as a non-aligned control scaffold (Whitlock et al., 2009; Khaing 
and Schmidt, 2012; Faroni et al., 2015). Furthermore, it is hypothesised that 
inadequate preservation of the linear architecture of endoneurial tubes impairs axon 
regeneration and cellular infiltration in a decellularised nerve graft (Whitlock et al., 
2009). Lyophilised decellularised human nerve was identified as a potential variable 
scaffold in which the linear architecture of endoneurial tubes is disrupted. 
Histological analysis of lyophilised decellularised human nerve showed that the 
endoneurial architecture was severely damaged in comparison to native nerve, and 
individual endoneurial tubes could no longer be identified. However, basement 
membrane components laminin and collagen type IV were preserved. Therefore, 
lyophilisation was selected as a method to disrupt endoneurial architecture, and 
primary DRG explants were also cultured with lyophilised decellularised nerve as a 
disrupted variable to assess the importance of endoneurial architecture. 
The in vitro culture experiments presented in this chapter were limited to a small 
number of replicates per time point. Three replicates was the maximum practicable 
number of replicates, due to limited availability of human femoral nerves, and the 
limited number of DRGs that could be isolated. Statistical analysis was only 
performed on parametric data, therefore quantitative image analysis data, of 
immunofluorescent labelling and TUNEL assay, was not statistically analysed.  
It is essential for decellularised nerve grafts and NGCs to support the long-term 
adhesion and viability of Schwann cells to support axon regeneration, as axon 
regeneration has been reported to be slow (approximately 1 mm per day) and 
progressively fails over distance and time due to deterioration of the distal nerve 
stump and declining Schwann cell numbers (Ronchi and Raimondo, 2017; 
Wagstaff, 2018; López-Leal and Diaz, 2018). Collagen type I is commonly used for 
the fabrication of NGCs, as it is highly biocompatible and the smooth 
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microgeometry and transmural permeability (100, 000 D) enable nutrient diffusion 
through collagen type I matrices (Khaing and Schmidt, 2012; Kehoe et al., 2012). 
Although decellularised human femoral nerve was shown to be biocompatible and 
retain a native ECM architecture, as discussed in Chapter 4, the architecture of 
native peripheral nerve ECM is less porous than homogenous collagen type I 
scaffolds, which may result in lower diffusion rates and adversely affect cell viability 
(Sun et al., 2008; Zilic et al., 2016). However, analysis of cell viability by ATPlite 
assay showed that there were no significant differences between the ATP content 
of DRGs cultured in collagen hydrogels and decellularised human femoral nerve up 
to day 28 in culture, indicating that decellularised human femoral nerve is also a 
suitable substrate for long-term cell viability. Furthermore, quantification of TUNEL 
staining supported these findings, as no major differences were observed between 
the percent apoptotic cells in DRGs cultured in decellularised nerve and collagen 
hydrogels at all time points in culture, although high variation was observed.  
Analysis of cell viability by ATPlite assay showed that the ATP content of DRGs 
cultured in lyophilised decellularised nerve was significantly lower than the ATP 
content of DRGs cultured in decellularised nerve and collagen hydrogels at day 28 
in culture, although no significant differences were found at earlier culture times. 
Quantification of TUNEL staining showed that there were no major differences 
between the percent apoptotic cells in DRGs cultured in decellularised nerve, 
lyophilised decellularised nerve and collagen hydrogels up to day 14 in culture, 
however, the percent apoptotic cells in DRGs cultured in lyophilised decellularised 
nerve was greater than the percent apoptotic cells in DRGs cultured in 
decellularised nerve and collagen hydrogels at both day 21 and day 28 in culture. 
These differences may be due to variability between DRGs, as high variation was 
observed in the data, but may also be due to an increase in the number of 
apoptosing cells producing ATP at day 21 in culture. Apoptosis, the process of 
programmed cell death, is a highly regulated, energy intensive cellular breakdown 
process, and is contingent upon the availability of intracellular ATP.    
These results suggest that although initial cell viability is not affected, the disruption 
of endoneurial architecture adversely affects long-term cell viability in decellularised 
nerve. This may be due to impaired cell migration, or cell adhesion and the 
establishment of cell-matrix interactions required for long-term survival (Gilmore et 
al., 2009). However, lyophilisation of decellularised nerve may also physically 
damage ECM proteins and collapse the delicate internal structure, which may have 
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contributed to this and also adversely affected long-term cellular adhesion and 
viability. 
Collagen type 1 matrices, including hydrogels and aligned sponges, have 
previously been shown to support neurite outgrowth of primary rat DRG explants 
within 24 hours in vitro (Dalamagkas et al., 2016; Geuna et al., 2016; Neto et al., 
2017; Bozkurt et al., 2007). Quantification of immunofluorescent labelling of NF-200 
showed that the percent total area of NF-200 labelling in DRGs cultured in collagen 
hydrogels was greater than the percent total area of NF-200 labelling in 
decellularised nerve or lyophilised nerve up to day 21 in culture. Furthermore, 
neurofilament expression was observed at day 1 in vitro, and did not appear to 
significantly increase with prolonged culture time, suggesting that neurite outgrowth 
was rapidly established in DRGs cultured in collagen hydrogels. However, at day 28 
in culture, no major differences were observed between the percent total area of 
NF-200 labelling in DRGs cultured in collagen hydrogels and decellularised nerve. 
One potential explanation for this could be that the homogenous, non-aligned 
permeable structure of collagen hydrogels enables rapid neurite outgrowth and 
permits neurite outgrowth and cell migration in all directions, whereas only 
endoneurial tubes of decellularised nerve ECM are permissive to neurite outgrowth 
and thus alignment with linear endoneurial tubes is required (Stang et al., 2005; 
Whitlock et al., 2009; Kehoe et al., 2012). As discussed previously, it is 
hypothesised that inadequate preservation of endoneurial tubes impairs axon 
regeneration and cellular infiltration in a decellularised nerve graft (Whitlock et al., 
2009). The percent total area of NF-200 labelling was lower in DRGs cultured in 
lyophilised decellularised nerve than in DRGs cultured in decellularised nerve by 
day 28 in culture, supporting this hypothesis and suggesting that disruption to 
endoneurial architecture adversely affects neurite outgrowth in a decellularised 
nerve graft. 
The non-aligned, homogenous structure of the collagen hydrogels may also explain 
the differences observed in cellular migration distance and orientation (Bozkurt et 
al., 2007; Dalamagkas et al., 2016). The maximum cell migration distance was 
significantly greater in DRGs cultured in collagen hydrogels than in DRGs cultured 
in decellularised nerve or lyophilised decellularised nerve from day 7 onwards in 
culture, however in collagen hydrogels cell migration was radial around the DRG, 
and no columnar alignment was observed. Collagen type I matrices are often 
manufactured as complex linear structures with highly aligned channels and parallel 
oriented pores to promote oriented axon regeneration, as discussed in Chapter 1 
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(Bozkurt et al., 2007; Khaing and Schmidt, 2012). Various techniques have been  
used to form aligned scaffolds with a specific pore size, including electrospinning, 
cross-linking and unidirectional freezing (Stang et al., 2005; Kehoe et al., 2012). A 
study by Bozkurt et al. (2007) used unidirectional freezing followed by lyophilisation 
to produce a highly aligned collagen type I scaffold, and compared this scaffold to a 
non-aligned fibrin scaffold by culture with DRG explants for up to 21 days in vitro. 
The study reported random and irregular cellular migration in the non-aligned 
scaffold, as opposed to columnar oriented migrating cells in the aligned collagen 
scaffold, and found that neurite distance was significantly greater when associated 
with columnar oriented cells, including Schwann cells (Bozkurt et al., 2007). Other 
studies have also reported random and irregular Schwann cell alignment and 
reduced neurite outgrowth of DRG explants when cultured with non-aligned 
scaffolds (Gnavi et al., 2018; Khan et al., 2002). Although the maximum cell 
migration distance was significantly lower in DRGs cultured in decellularised nerve 
or lyophilised decellularised nerve than in collagen hydrogels from day 7 onwards in 
culture, columnar oriented cell migration was observed in sections of DRGs 
cultured in decellularised nerve and lyophilised nerve. Therefore, these results 
suggest that the presence of a native ECM architecture promotes columnar 
oriented cell migration, which may be beneficial for promoting neurite outgrowth 
(Bozkurt et al., 2007).  
Although several studies of DRGs cultured with various scaffolds in vitro have 
reported columnar oriented cell migration in aligned scaffolds, as opposed to 
random cell migration in non-aligned scaffolds, only a small number of the migrating 
cells were found to be Schwann cells and changes in the expression of Schwann 
cell markers were not assessed (Bozkurt et al., 2007; Gnavi et al., 2018). Neural 
cell adhesion molecule-1 (NCAM-1) is a marker of non-myelinating Schwann cells, 
which closely associate with neurons and modulate neuron activity (Jessen et al., 
2015). NCAM-1 is involved in neuron-neuron adhesion, neurite fasciculation and 
the early stages of neurite development (Takeda et al., 2001). Myelin basic protein 
(MBP) is produced by myelinating Schwann cells, which form the myelin sheath 
surrounding axons (Jessen et al., 2015).  
Quantification of immunofluorescent labelling of NCAM-1 showed that the percent 
total area of NCAM-1 labelling decreased in DRGs cultured in decellularised nerve, 
lyophilised decellularised nerve and collagen hydrogels over culture time, however 
the percent total area of NCAM-1 labelling decreased more in DRGs cultured in 
collagen hydrogels from day 7 onwards. This may be due to non-myelinating 
190 
Schwann cells responding to a loss of axonal contact or it may be due to neurite 
development, as NCAM-1 is expressed in the early stages (Takeda et al., 2001). 
However, as discussed previously, no differences in neurofilament expression were 
observed between DRGs cultured in decellularised nerve and collagen hydrogels 
by day 28.  
Quantification of immunofluorescent labelling of MBP showed that the percent total 
area of MBP labelling decreased with prolonged culture time in DRGs cultured in 
collagen hydrogels, decellularised nerve and lyophilised decellularised nerve. 
However, the percent total area of MBP labelling in DRGs cultured in collagen 
hydrogels was lower than the percent total area of MBP labelling in DRGs cultured 
in decellularised nerve or lyophilised decellularised nerve at all time points in 
culture. Therefore, stimuli from the native ECM of decellularised nerve, including 
topographical, ECM protein or basement membrane cues, may be influencing 
Schwann cell phenotype and function, or the interaction of migrating Schwann cells 
with developing neurites in endoneurial tubes maintained the stimuli for NCAM-1 
and MBP expression (Roumazeilles et al., 2018; Chernousov et al., 2008; Spivey et 
al., 2012). In addition, from day 7 onwards in culture, the percent total area of MBP 
labelling was greater in sections of DRGs cultured in decellularised nerve than in 
lyophilised decellularised nerve. This may be due to stimuli provided by intact 
endoneurial tubes, either influencing MBP expression directly, or indirectly due to 
the increased neurofilament expression observed in DRGs cultured in 
decellularised nerve (Allodi et al., 2012; Spivey et al., 2012; Chernousov et al., 
2008). However, MBP expression appeared greater in sections of freshly isolated 
DRG than in sections of DRGs cultured in decellularised nerve, lyophilised 
decellularised nerve and collagen hydrogels at any time point in culture, which may 
be due to reduced MBP expression in response to injury during the DRG isolation 
process, or due a lack of stimuli for MBP expression in the in vitro culture 
conditions. 
Other studies of DRGs cultured with scaffolds have identified Schwann cells, but 
have not investigated other cell types in the DRG in detail (Bozkurt et al., 2007; 
Neto et al., 2017; Gnavi et al., 2018). As discussed previously, DRGs also contain 
satellite glial cells (SGCs), which are capable of migrating out of the DRG explant 
and are thought to participate in peripheral nerve injury and repair (George et al., 
2018; Dubový et al., 2019).  
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Quantification of immunofluorescent labelling of GS showed that the percent total 
area of GS labelling decreased in DRGs cultured in collagen hydrogels, 
decellularised nerve, and lyophilised decellularised nerve over 28 days in culture, 
consistent with the finding of other studies, which have reported a loss of GS 
expression when SGCs are cultured in vitro (Belzer et al., 2010). The reduction in 
GS expression may be caused by a loss of axonal contact or reduced axonal 
signalling (Bak et al., 2006; Huang et al., 2013). However, from day 7 onwards, the 
percent total area of GS labelling in DRGs cultured in collagen hydrogels was 
greater than the percent total area of GS labelling in DRGs cultured in 
decellularised nerve or lyophilised decellularised nerve. This may be because 
SGCs retained a closer association with neurons in DRGs cultured in collagen 
hydrogels, or SGCs were responding to a loss of stimuli when DRGs were cultured 
in decellularised nerve or lyophilised decellularised nerve (Geuna et al., 2016; Neto 
et al., 2017).  
SGCs are also thought to be multipotent cells, capable of differentiating into 
multiple cell types, including Schwann cell-like cells and oligodendrocytes 
(Svenningsen et al., 2004; Hanani, 2005; Weider et al., 2015). SGC nuclei have 
also been reported to express Sox2, a stem cell marker, although not all SGCs 
have been found to express Sox2 (Weider et al., 2015; Koike et al., 2015). Sox2 
expression was observed sporadically in sections of DRGs cultured in collagen 
hydrogels, lyophilised nerve or decellularised nerve, although Sox2 expression did 
not appear to co-localise with GS expression, supporting the finding that not all 
SGCs express Sox2 (Koike et al., 2015). However, quantification of 
immunofluorescent labelling of Sox2 showed that the percent total area of Sox2 
labelling was highly variable and did not change with prolonged culture time, 
indicating a lack of differentiation which could be due to the absence of stimuli 
required (George et al., 2018). Previous studies have shown SGCs only 
differentiate in vitro once cultured in isolation, and other studies have required 
elevated levels of Sox10 transcription factor to induce differentiation (Weider et al., 
2015; George et al., 2018). 
As discussed previously, one of the main limitations of the in vitro DRG culture 
experiments discussed in this chapter was the small number of repeats that could 
be included. Therefore, further investigations are required, including a repeat of the 
experiments discussed here, with a larger number of replicates in order to confirm 
the findings of this study. 
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5.6 Conclusions 
The results presented in this chapter suggest that decellularised human femoral 
nerve is a suitable substrate to support cellular infiltration and axon regeneration. 
Decellularised human femoral nerve was shown to support long-term cell viability 
and migration, and the formation of aligned neurites when cultured with primary rat 
DRG explants for up to 28 days in vitro. These results also support the hypothesis 
that inadequate preservation of endoneurial tubes impairs cellular infiltration and 
axon regeneration, as lyophilisation of decellularised nerve adversely affected long-
term cell viability, migration, and neurofilament expression of DRGs. Furthermore, 
decellularised nerve appeared to maintain the expression of MBP better than 
lyophilised decellularised nerve and collagen hydrogels, suggesting that intact 

















6 Chapter 6: General Discussion 
6.1 Introduction 
Current interventions for peripheral nerve repair are limited, variable in efficacy, and 
are associated with a number of limitations which were discussed in Chapter 1. The 
motivation for this study was to develop a decellularised peripheral nerve allograft 
as an alternative surgical intervention for peripheral nerve repair. Decellularised 
nerve grafts offer considerable clinical potential, and there is existing clinical 
evidence to support the use of decellularised nerve grafts for peripheral nerve 
repair (Chapter 1). However, studies of the Avance® graft have not yet 
demonstrated consistently superior clinical outcomes to autografts, even for the 
repair of small defects (up to approximately 30 mm) (Karabekmez et al., 2009; 
Whitlock et al., 2009; Johnson et al., 2011). It has been proposed that the currently 
available decellularised nerve graft has limited regenerative capacity in comparison 
to autografts, particularly for the repair of longer defects (greater than 30 mm), as a 
consequence of ECM disruption caused by the decellularisation process. 
The overarching hypothesis of this study was that a biocompatible, decellularised 
peripheral nerve graft could be developed for future use in peripheral nerve repair, 
with the retention of overall ECM histioarchitecture and basement membrane. As 
discussed in Chapter 1, numerous decellularisation methods have been developed, 
and the effects of different decellularisation processes on the ECM are highly 
variable. The proprietary University of Leeds decellularisation process utilises low 
concentration SDS (0.1 %; w/v) plus proteinase inhibitors in combination with 
hypotonic and hypertonic buffers and nuclease treatment, and has been shown to 
remove cellular and nuclear material sufficiently from several tissues, with minimal 
alterations to the ECM (Booth et al., 2002; Wilshaw et al., 2012; Azhim et al., 2014). 
Zilic et al. (2016) adapted the University of Leeds decellularisation process to 
develop a process for the decellularisation of porcine peripheral nerves, and the 
process was shown to achieve a sufficient reduction in DNA content. Histological 
results demonstrated the retention of basement membrane components, however 
structural changes were observed to the perineurium and endoneurial tubes, and 
changes were observed in the distribution of collagen fibrils, laminin and fibronectin 
(Zilic et al., 2016). 
In this study, the decellularisation process for porcine peripheral nerves described 
by Zilic et al. (2016) was further developed with the aim of minimising structural 
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changes whilst maintaining the efficacy of decellularisation (Chapter 3). Once an 
improved decellularisation process had been identified, the process was translated 
for the decellularisation of human femoral nerves (Chapter 4). Decellularised 
human femoral nerve segments were then cultured with primary adult rat DRG 
explants in order to investigate the ability of human decellularised nerve to support 
neurite outgrowth, cell viability and cell migration in vitro (Chapter 5).  
6.2 Porcine vs human decellularised nerve grafts 
Although the use of porcine tissue as a source material offers considerable clinical 
potential, the use of xenogeneic tissue for decellularised nerve grafts is associated 
with several limitations (Chapter 1). Preclinical and clinical evidence of axon 
regeneration only exists for the use of decellularised allografts, such as the 
Avance® graft, and there is little research comparing the use of decellularised 
allogeneic and xenogeneic nerve grafts in vivo (Wang et al., 2016). A study by 
Wood et al. (2014) compared human (xenograft) and rat (allograft) decellularised 
peripheral nerves in a rat sciatic nerve defect model in comparison to an autograft. 
Both the human and rat decellularised peripheral nerve grafts were prepared by 
AxoGen, using the same methods and quality testing as used for the commercial 
Avance® graft (Wood et al., 2014). The decellularised nerve grafts were evaluated 
12 weeks post implantation, and it was shown that the myelinated axon count in the 
xenograft was significantly lower than in the allograft or autograft, and the authors 
concluded that the xenograft impaired regeneration. Wang et al. (2016), compared 
an autograft to decellularised rat and rabbit peripheral nerves in a rat sciatic defect 
model, and reported no significant differences between autograft, xenograft or 
allograft at 12 weeks post-implantation (Wang et al., 2016). Therefore, the 
importance of species specificity for the clinical use of decellularised nerve grafts 
for peripheral nerve repair and the potential effects of xenografts on axon 
regeneration remain unclear. In this study, a decellularised human femoral nerve 
graft was to developed to overcome the limitations associated with porcine tissue, 
and to provide a human decellularised nerve graft which could then be further 
developed and translated as a Class III medical device by NHSBT TES.  
6.3 Development of improved decellularisation methods 
An improved decellularisation process for porcine peripheral nerves was developed 
(Chapter 3). The major changes to the original process were to minimise chemical 
exposure and reduce the agitation speed during incubations, in order to minimise 
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damage to the ECM architecture and composition. Porcine peripheral nerves 
decellularised using the improved protocol were shown to have sufficient DNA 
content reduction and retain overall histioarchitecture. The improved 
decellularisation process for porcine peripheral nerves was then applied to 
segments of human femoral nerves (Chapter 4). The size of the nerve segments 
was increased from 30 mm (porcine) to 60 mm (human), which was considered 
more appropriate for clinical application. Initial results showed that the porcine 
peripheral nerve decellularisation protocol did not achieve sufficient DNA content 
reduction in human femoral nerves, which was likely due to the increase in the size 
of the nerve segments. Further development of the decellularisation process 
showed that the inclusion of an additional hypertonic buffer incubation achieved 
sufficient DNA content reduction in decellularised human femoral nerve. The 
inclusion of this additional hypertonic buffer incubation did not appear to adversely 
affect the ECM histioarchitecture, as human femoral nerves decellularised using the 
finalised protocol were shown to retain overall histioarchitecture. 
The decellularisation process must result in a scaffold which is biocompatible. Prior 
to clinical application, decellularised nerve grafts must be shown to be 
biocompatible as a regulatory requirement, and International Organisation for 
Standardisation (ISO) standards must be adhered to. Part five of ISO standard 
10993 (Biological evaluation of medical devices) includes guidelines for in vitro 
cytotoxicity testing, including contact and extract cytotoxicity testing. The results 
presented in this study demonstrated that decellularised porcine peripheral nerves 
(Chapter 3) and decellularised human femoral nerves (Chapter 4) were 
biocompatible. Contact cytotoxicity assays using BHK and L929 cells showed no 
changes in cell morphology and growth when cultured with the decellularised nerve. 
However, extract cytotoxicity testing should also be performed prior to clinical 
application. 
It has been proposed that in addition to the criteria for successful decellularisation 
proposed by Crapo et al. (2011), discussed in Chapter 1, criteria should also 
include the removal of cell membrane debris (Kawecki et al., 2018; Crapo et al., 
2011). In addition, a review of methods of quality control for decellularised nerve 
grafts by Philips et al. (2018) suggested that in addition to the previous criteria for 
decellularisation, quality control criteria for decellularised nerve grafts should 
include the removal of myelin, assessed by histological or immunohistochemical 
analyses (Philips et al., 2018). The removal of myelin from a decellularised nerve 
graft is clinically important, as the presence of residual myelin debris has been 
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shown to inhibit axonal growth by prolonging the process of Wallerian degeneration 
(Chapter 1). As discussed in Chapter 3, several studies using other methods of 
decellularisation have shown incomplete removal of myelin from decellularised 
peripheral nerves (Gulati, 1988; Evans et al., 1998; Wang et al., 2016). Histological 
results presented in this study demonstrated the absence of myelin in decellularised 
porcine peripheral nerve (Chapter 3) and decellularised human femoral nerve 
(Chapter 4), indicating the decellularisation processes successfully removed myelin 
from the tissues.  
6.4 Evaluation of biological components 
Biochemical assays, including the quantification of collagen and GAG content using 
colourimetric assays, have been widely used to determine the effects of 
decellularisation processes on the biochemical composition of the ECM of various 
tissues, and to complement histological analysis (Kawecki et al., 2018; Philips et al., 
2018). Interestingly, few studies of the development of decellularised xenogeneic or 
allogeneic peripheral nerve grafts have assessed the effects of decellularisation on 
biochemical composition (Philips et al., 2018). Sridharan et al. (2015) decellularised 
rat sciatic nerves using a modified version of the decellularisation protocol 
described by Sondell et al. (1998), utilising a combination of 3 % (w/v) Triton X-100 
and 2 % (w/v) sodium deoxycholate, and quantified the GAG and collagen content 
of native and decellularised rat sciatic nerves. Following decellularisation, the 
hydroxyproline content (a measure of collagen content) had decreased by more 
than 50 % and the GAG content had decreased by more than 90 %. The authors 
concluded this was likely due to ECM disruption caused by the detergents used 
(Sridharan et al., 2015). In this study, biochemical analyses showed that there were 
no significant differences in the collagen and denatured collagen content of native 
and decellularised porcine peripheral nerves (Chapter 3) and between the collagen 
and denatured collagen content of native and decellularised human femoral nerve 
(Chapter 4). However, similar to the results reported by Sridharan et al. (2015), 
quantification of GAG content showed that there was a significant decrease in the 
GAG content of human femoral nerve following decellularisation (Chapter 4), 
although no significant difference was found between the GAG content of native 
and decellularised porcine peripheral nerve (Chapter 3). Glycosaminoglycans 
(GAGs) have various functions in peripheral nerve ECM, they are implicated in the 
maintenance of other ECM molecules, structural integrity and the regulation of 
cellular growth, and are located in the basement membrane (Krekoski et al., 2001; 
Zuo et al., 2002; Neubauer et al., 2007). As discussed in Chapter 4, chondroitin 
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sulphate proteoglycans (CPSGs) are involved in the inhibition of axonal growth and 
have been shown to be inhibitory to axon regeneration (Krekoski et al., 2001; Zuo 
et al., 2002; Neubauer et al., 2007). Therefore, the loss of GAGs in decellularised 
human femoral nerve may be clinically beneficial to promoting axonal regeneration. 
One of the key advantages of decellularised nerve grafts in comparison to NGCs is 
the provision of specific basement membrane components (Burnett and Zager, 
2004; de Ruiter et al., 2009; Gaudet et al., 2011). The basement membrane, 
located in the endoneurium and perineurium, facilitates cell-matrix interactions, 
enabling Schwann cell adhesion and promoting axon elongation and maturation in 
the endoneurium (Kerns, 2008). Many of the methods used to decellularise 
peripheral nerve been shown to significantly damage the basement membrane 
(Chapter 3) (Sondell et al., 1998; Evans et al., 1998; Krekoski et al., 2001). In this 
study, decellularised porcine peripheral nerve, and decellularised human femoral 
nerve, were shown to retain laminin in comparison to native tissue. Furthermore, 
decellularised porcine peripheral nerve, and decellularised human femoral nerve,  
also retained basement membrane components collagen type IV and fibronectin, 
which have not been assessed by studies of the Avance® graft and may also be of 
clinical benefit (Yang et al., 2011; Wood et al., 2014).  
6.5 Evaluation of the capacity of decellularised human 
femoral nerve to support primary cell populations in 
vitro 
In order to promote axon regeneration, decellularised nerve grafts must be able to 
support the elongation of regenerating axons and viable populations of Schwann 
cells (Chapter 1). It was therefore important to determine whether decellularised 
human femoral nerve segments could support neurite outgrowth and viable 
populations of primary neural cells, including Schwann cells, in vitro. In this study, a 
novel method was developed for the culture of decellularised human femoral nerve 
segments with primary adult rat DRG explants in order to investigate the ability of 
human decellularised nerve to support neurite outgrowth, cell viability and cell 
migration in vitro. As discussed in Chapter 5, currently there is no in vitro model of 
peripheral nerve, and peripheral nerve regeneration cannot be replicated in vitro 
(Geuna et al., 2016; Mobini et al., 2017). DRG explant organotypic cultures are 
commonly used for in vitro studies of peripheral nerve regeneration, as they can be 
easily isolated and inserted into scaffolds, and enable quantification of neurite 
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outgrowth and cell migration from the body of the DRG explant (Geuna et al., 2016; 
Neto et al., 2017). However, there have been no previous studies of decellularised 
nerve grafts cultured with DRG explants in vitro. Therefore, the results presented in 
Chapter 5 represent a novel in vitro culture system for DRG explants with 
decellularised human nerve, which could be used for future in vitro culture studies 
of decellularised nerve. 
The linear microarchitecture of endoneurial tubes is believed to be one of the key 
advantages of decellularised nerve grafts in comparison to NGCs (Khaing and 
Schmidt, 2012; Faroni et al., 2015). In order to investigate the importance of 
endoneurial architecture in a decellularised nerve graft, DRG explants were also 
cultured in segments of lyophilised decellularised human nerve, in which 
endoneurial architecture was disrupted whilst basement membrane components 
laminin and collagen type IV were preserved (Chapter 5). The results presented in 
Chapter 5 represent a novel method for the disruption of endoneurial architecture 
whilst maintaining overall histioarchitecture and basement membrane components. 
Therefore, lyophilisation is a method which could be used for further studies of the 
effects of disruption to the endoneurial architecture on decellularised nerve both in 
vitro and in vivo. DRG explants were also cultured with rat tail type I collagen 
hydrogels, as a non-aligned control scaffold, to investigate the importance of a 
native ECM microenvironment and linear architecture (Whitlock et al., 2009; Khaing 
and Schmidt, 2012; Faroni et al., 2015) 
Collagen hydrogels, decellularised nerve and lyophilised decellularised nerve 
cultured with DRGs were shown to support viable cells up to day 28 in culture. 
There were no differences in the ability of collagen hydrogels and decellularised 
nerve to support viable cells (Chapter 5), indicating that decellularised human 
femoral nerve is also a suitable substrate for supporting long-term cell viability. The 
results presented in Chapter 5 also suggest that disruption of endoneurial 
architecture in a decellularised nerve graft adversely affects long-term cell viability, 
and may be of clinical significance for the development of decellularised nerve 
grafts since sustained axon regeneration is dependent on the presence of viable 
populations of Schwann cells (Wagstaff, 2018; Jessen et al., 2015). These results, 
however, may not necessarily be reflected upon implantation in vivo, and although 
lyophilisation was chosen as method to disrupt endoneurial architecture, this may 
not reflect damage to endoneurial architecture sustained during decellularisation. 
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The results presented in Chapter 5 also suggest that in comparison to DRGs 
cultured in collagen hydrogels, cell migration and the establishment of neurite 
outgrowth in DRGs cultured in decellularised nerve is delayed, although long-term 
neurite outgrowth may not be adversely affected as no differences were observed 
by day 28. It has been hypothesised that the homogenous, permeable structure of 
collagen hydrogels enables rapid and sustained neurite outgrowth and cell 
migration in all directions, whereas only the endoneurial tubes of decellularised 
nerve ECM are permissive to neurite outgrowth, and thus alignment with linear 
endoneurial tubes is required (Bozkurt et al., 2007; Dalamagkas et al., 2016). 
However, delayed neurite outgrowth could potentially impair the regenerative 
process, as axon regeneration progressively fails over distance and time if axon 
contact is not re-established, as discussed previously (Ronchi and Raimondo, 
2017; Wagstaff, 2018; López-Leal and Diaz, 2018). The results presented in 
Chapter 5 also suggest that disruption to endoneurial architecture adversely affects 
long-term neurite outgrowth and cell migration in a decellularised nerve graft. 
However, columnar oriented cell migration was observed in DRGs cultured in 
decellularised nerve and lyophilised nerve, whereas cells migrating from the body of 
DRGs cultured in collagen hydrogels showed no discernible alignment. Therefore, 
these results suggest that the presence of a native ECM architecture promotes 
oriented cell migration, which may be beneficial for promoting oriented axon 
regeneration and increasing axon regeneration distance, as discussed in Chapter 5. 
Directional axon regeneration is required to re-establish axonal contact and prevent 
axon deviation, and NGCs, including collagen type I matrices, are often 
manufactured as complex linear structures with highly aligned channels and parallel 
oriented pores to replicate the native ECM architecture and promote oriented axon 
regeneration (Bozkurt et al., 2007; Khaing and Schmidt, 2012; Allodi et al., 2012)  
Currently, it is thought that the efficacy of decellularised nerve grafts and NGCs is 
limited to shorter distances (up to 30 mm) due to insufficient host Schwann cell 
migration to sustain axon regeneration (Szynkaruk et al., 2012; Gerth et al., 2015; 
Busuttil et al., 2017). Therefore, it is essential that decellularised peripheral nerve 
grafts are able to support Schwann cell infiltration and migration upon implantation 
(Szynkaruk et al., 2012). However, the interaction of Schwann cells with 
decellularised nerve grafts has not been well characterised in vitro. Although 
several studies of DRGs cultured with various scaffolds in vitro investigated neurite 
outgrowth and cell migration, only a small number of the migrating cells were found 
to be Schwann cells, and changes in the expression of Schwann cell markers were 
not assessed (Bozkurt et al., 2007; Gnavi et al., 2018). In this study, the expression 
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of mature Schwann cell markers MBP and NCAM-1, and SGC markers GS and 
Sox2 in DRGs cultured in collagen hydrogels, decellularised and lyophilised 
decellularised nerve were assessed by immunofluorescent labelling (Chapter 5).  
NCAM-1 and MBP expression were found to decrease more in DRGs cultured in 
collagen hydrogels than in decellularised or lyophilised decellularised nerve with 
prolonged culture time (Chapter 5). Therefore, these results suggest that stimuli 
from the native ECM of decellularised nerve, including topographical, ECM protein 
or basement membrane cues, may be influencing Schwann cell phenotype and 
function. Another potential explanation could be that close interaction of columnar-
oriented migrating Schwann cells with developing neurites in endoneurial tubes 
maintained the stimuli for NCAM-1 and MBP expression (Roumazeilles et al., 2018; 
Chernousov et al., 2008; Spivey et al., 2012). MBP expression was also found to 
decrease further in DRGs cultured in lyophilised decellularised nerve than in 
decellularised nerve (Chapter 5). This may be due to stimuli provided by intact 
endoneurial tubes, either influencing MBP expression directly, or indirectly due to 
the increased neurofilament expression observed in DRGs cultured in 
decellularised nerve (Allodi et al., 2012; Spivey et al., 2012; Chernousov et al., 
2008). These findings may be of clinical relevance for the future development of 
decellularised nerve grafts, and future studies investigating the supplementation of 
decellularised nerve grafts with Schwann cells. The results presented (Chapter 5) 
suggest that a native ECM microenvironment may have a role in influencing the 
phenotype and function of Schwann cells (Jessen and Mirsky, 2016; Chernousov et 
al., 2008). Furthermore, in addition to the hypothesis that inadequate preservation 
of endoneurial architecture impairs axon regeneration and cellular infiltration in a 
decellularised nerve graft, it may also be that the preservation of endoneurial 
architecture is important for maintaining Schwann cell function and myelination 







6.6 Future work 
6.6.1 Future studies required for clinical translation 
6.6.1.1 Scale up of production of decellularised human femoral 
nerves 
Further studies are required to investigate how the decellularisation protocol could 
be adapted to produce large numbers of decellularised human femoral nerves for 
clinical use. The UK Human Tissue Act (2004) prevents tissues from individual 
donors coming into contact with tissues from other donors, therefore tissue from 
different donors must be decellularised separately. Increased sample numbers 
could be processed individually in parallel using closed loop systems, which have 
previously been used by NHSBT TES for the decellularisation of tissues. The use of 
a closed loop system for the introduction and removal of decellularisation solutions 
would also enable processing in a lower-grade aseptic cleanroom, as the closed 
system remains sterile and reduces the risk of contamination. It is also possible that 
the decellularisation process could be shortened for use in a commercial setting. 
Furthermore, future automation of solution changes would reduce personnel burden 
and decrease solution change-over times.  
Good Manufacturing Practice (GMP) production must also adhered to meet 
regulatory requirements for the production of decellularised human tissue for clinical 
use and maintain consistency between batches. In this study, Cambridge antibiotic 
solution was used as part of the decellularisation process for human femoral nerves 
(Chapter 4), since this is used by NHSBT TES for human tissue decellularisation for 
clinical use. In order to meet GMP requirements, all other solutions used in the 
decellularisation process would need to be quality assured and obtained from 
approved suppliers.  
6.6.1.2 Sterilisation of decellularised human femoral nerves 
Prior to clinical application, a sterilisation method for decellularised human femoral 
nerves must be identified. Medical devices, including decellularised nerve grafts 
derived from allogeneic and xenogeneic sources, must be sterilised prior to 
implantation. The accepted sterility assurance level (SAL) for medical devices, 
defined in ISO standard 14937, is 10-6 whereby less than 1 in 1,000,000 devices 
sterilised by a given method within a defined set of parameters will contain a 
surviving viable microorganism (ISO, 2009).   
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There are several potential sterilisation methods which could be applied to 
decellularised human femoral nerves, including ethylene oxide, electron beam (E-
beam), γ-irradiation, peracetic acid (PAA), supercritical CO2 and hydrogen peroxide 
(in isolation or in combination with copper (II) chloride) (Delgado et al., 2014; Leow-
Dyke et al., 2016). Terminal sterilisation methods, including γ-irradiation, ethylene 
oxide and E-beam, would enable the decellularised tissue to be sterilised after 
packaging, and are therefore preferable for commercial production as aseptic 
packaging is not required and the risk of contamination post sterilisation is 
eliminated.  
Each sterilisation method presents several advantages and limitations, and 
sterilisation processes can significantly alter the histoarchitecture and 
biomechanical properties of ECM-based scaffolds (Badylak et al., 2009; Hodde et 
al., 2007a). Radiation-based sterilisation methods, such as γ-irradiation and E-
beam, have been shown to damage the collagen chains within the ECM, and 
chemical sterilants (e.g. oxidising agents, including peracetic acid, and alkylating 
agents, including ethylene oxide) may also disrupt ECM proteins (Grant et al., 1973; 
Hodde et al., 2007b). For example, the standard accepted dosage for medical 
device sterilisation using γ-irradiation is 25 kilograys (kGy), as determined by ISO 
11137. However, this dose of γ-irradiation has previously been shown to damage 
the collagen within ECM of decellularised tissues through the generation of free 
radicals, and alter the biomechanical properties of decellularised tissues (Smith and 
Kearney, 1996; Edwards et al., 2017). In this study, lyophilisation of decellularised 
human femoral nerve was shown to damage the internal histioarchitecture (Chapter 
5). Therefore, sterilisation strategies requiring lyophilisation, e.g. γ-irradiation, may 
not be suitable for decellularised human femoral nerve, and would require further 
investigation.  
6.6.1.3 Biomechanical evaluation 
Peripheral nerves are exposed to an array of mechanical forces associated with 
body movement, including tensile, compressive and shear forces (Chapter 1). 
Peripheral nerves are able to withstand mechanical forces because of the 
viscoelastic properties of the ECM, which enables the nerve to elongate in 
response to longitudinal stress during body movements (Topp and Boyd, 2012). 
Therefore, for clinical application, it is essential that decellularised peripheral nerve 
grafts retain the biomechanical properties of native nerve, as any alterations to 
biomechanical properties may adversely affect axon regeneration in vivo.  
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The use of chemical detergent decellularisation methods is known to disrupt the 
structure and composition of ECM molecules, and can alter the biomechanical 
properties of the ECM (Chapter 1). As discussed previously, Zilic et al. (2016) 
developed a decellularisation process for porcine peripheral nerve. The study 
investigated the biomechanical properties of native and decellularised nerves using 
uniaxial tensile testing, and assessed the Young’s modulus, ultimate tensile 
strength (UTS) and strain at UTS (Zilic et al., 2016). The study showed no 
significant difference in the Young’s modulus of native and decellularised porcine 
peripheral nerve, however there was a significant increase in the UTS and strain at 
UTS of decellularised nerve in comparison to native nerve. The authors 
hypothesised that these changes in decellularised nerve were due to uncrimping or 
relaxation of collagen fibres caused by cell removal during the decellularisation 
process, which has previously been associated with increased stiffness in soft 
tissues (Williams et al., 2009; Zilic et al., 2016). The results were comparable to 
other studies of decellularised tissues, including porcine meniscus, which have 
reported similar alterations to biomechanical properties (Stapleton et al., 2008; 
Abdelgaied et al., 2015). However, the clinical implications of alterations to the 
biomechanical properties of decellularised nerve grafts remain unclear.  
In this study, the decellularisation process described by Zilic et al. (2016) was 
modified, and was also applied to human femoral nerves. Therefore, the 
biomechanical properties of the decellularised porcine peripheral nerves and 
decellularised human femoral nerves developed in this study should be evaluated 
by uniaxial tensile testing methods. In addition, biomechanical evaluation could also 
include suture retention tensile testing, as for clinical use decellularised peripheral 
nerve grafts must be able to retain sutures upon implantation, and compression 
testing.  
6.6.1.4 Biological evaluation 
Further biological evaluation of decellularised human femoral nerves is required 
prior to clinical application. Once a sterilisation method has been identified, the 
effects of sterilisation on ECM architecture, biochemical composition and the 
retention of basement membrane components would also need to be determined, 
using the analysis methods described in Chapters 3 and 4.  
Further analyses could include immunohistochemical assessment of different types 
of collagen, including collagen type I, II and III, which have been discussed in 
Chapter 1. Scanning electron microscopy (SEM) or transmission electron 
204 
microscopy (TEM) could also be used to further investigate the preservation of 
ECM ultrastructure, and the preservation of key basement membrane components. 
Further biological evaluation could also include the assessment of residual cellular 
debris and membrane components following decellularisation. As discussed in 
Chapter 1, MHC class I molecules remaining in decellularised tissues could illicit a 
specific host immune response upon implantation. Immunohistochemical analyses 
could be therefore be used to assess the removal of MHC Class I and Class II 
molecules from the decellularised nerve. 
6.6.1.5 In vivo biocompatibility 
Preclinical in vivo studies are necessary prior to clinical translation of decellularised 
nerve grafts or NGCs, in order to ensure biocompatibility and assess the 
occurrence of adverse events, and evaluate the efficacy of axon regeneration 
(Szynkaruk et al., 2012). Therefore, future work should include evaluating the 
decellularised human femoral nerve graft developed in this study in vivo. 
The most commonly used in vivo model for peripheral nerve regeneration is a rat 
sciatic nerve defect model, however various different defect lengths have been 
used, typically ranging from 10 – 30 mm (Mobini et al., 2017). Decellularised 
peripheral nerve grafts and an array of NGCs have been evaluated in vivo using rat 
sciatic nerve defect models, as discussed in Chapter 1 (Pedrini et al., 2018; Lovati 
et al., 2018). Autografts, the gold standard intervention for peripheral nerve repair 
are often used as a control, and outcome measures used to assess regeneration 
include behavioural, electrophysiological and histological analyses. A recent review 
of the use of decellularised nerve grafts for peripheral nerve repair assessed the 
various outcome measures that can be used for peripheral nerve regeneration, and 
reported on the most widely used behavioural, electrophysiological and histological 
analyses (Pedrini et al., 2018). The study reported that common histological 
analyses included assessment of infiltration by cells of the immune system and 
Schwann cells, and assessment of axon count, diameter, myelination and axon 
regeneration distance. Common behavioural analyses were walking-track analysis 
and toe-spreading reflex, and response to surface stimulation, measured using 
electromyography, was the most common electrophysiological analysis. However 
as outcome measures were found to differ between studies, comparing the efficacy 
of different NGCs or decellularised nerve grafts is problematic (Pedrini et al., 2018).  
The decellularised human femoral nerve graft developed in this study should be 
evaluated in vivo, using a rat sciatic nerve defect model. Autografts should be used 
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as a control, and widely used behavioural, electrophysiological and histological 
analyses (as above) should be used to ensure comparison with the findings of other 
studies of decellularised nerve grafts. A number of studies have reported a limited 
efficacy of decellularised nerve grafts over longer distances, typically exceeding 20 
- 30 mm, as discussed in Chapter 1 (Szynkaruk et al., 2012; Karabekmez et al., 
2009). Therefore, a number of different defect lengths could also be used, ranging 
from 10 - 40 mm, in order to assess the efficacy of the decellularised human 
femoral nerve graft over increasing distances and compare with the findings of 
other studies. Lyophilised decellularised human nerve could also be evaluated in 
vivo in a rat sciatic nerve defect model, in order to investigate the importance of 
endoneurial architecture.  
6.6.2 Future studies to support the clinical use of decellularised 
nerve 
6.6.2.1 Repopulation with primary Schwann cells  
It has been hypothesised that the efficacy of decellularised nerve grafts is limited to 
shorter distances due to insufficient host Schwann cell migration to sustain axon 
regeneration (Szynkaruk et al., 2012; Gerth et al., 2015; Busuttil et al., 2017). 
Therefore, it is thought that the development of a decellularised nerve graft 
repopulated with Schwann cells may offer considerable clinical potential as an 
Advanced Therapy Medicinal Product (ATMP). Although recent experimental 
strategies for enhancing peripheral nerve regeneration have included the 
repopulation of decellularised nerve grafts with exogenous autologous Schwann 
cells (Chapter 1), there is currently no clinically viable source of minimally 
manipulated exogenous autologous Schwann cells (Faroni et al., 2015; Mobini et 
al., 2017; Lackington et al., 2017). ASCs and BMSCs have, however, demonstrated 
promising experimental results for peripheral nerve repair, and are currently the 
only potential source of exogenous autologous Schwann cells. 
A number of studies have focused on the repopulation of decellularised human 
nerve grafts with primary rat Schwann cells, and have assessed axon regeneration 
in vivo in rat sciatic nerve defect models (Pedrini et al., 2018). However, few studies 
have investigated the long-term interaction of primary Schwann cells with 
decellularised nerve grafts in vitro, and there is currently no established method for 
the introduction of primary Schwann cells into a decellularised nerve graft 
(Szynkaruk et al., 2012; Pedrini et al., 2018).  
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Future work could therefore include establishing a method for the introduction of 
primary Schwann cells into a decellularised nerve graft, using primary rat Schwann 
cells as an accessible source of a large number of Schwann cells for method 
development. A purified population of primary Schwann cells could be isolated from 
rat sciatic nerves, using a previously established method (Kaewkhaw et al., 2012). 
Direct injection of cell suspension is the most commonly used method to introduce 
Schwann cells into decellularised nerve grafts (Fan et al., 2014; Mobini et al., 
2017). A method for the introduction of Schwann cells into decellularised human 
femoral nerve could be established using primary rat Schwann cells, including 
identifying the number of cells to be injected, volume of cell suspension to be 
injected and the method of injection i.e. location and number of injection points 
within the decellularised nerve. In addition, several studies of repopulating NGCs 
with primary Schwann cells have investigated the use of perfusion bioreactors for 
introducing cells to the conduit. A study by Sun et al. (2008) established a simple 
closed loop perfusion bioreactor to introduce primary Schwann cells on a scaffold 
manufactured from longitudinally aligned microfibers of viscose rayon and 
polystyrene. The study reported that a perfusion rate of 0.8 mL.h-1 increased the 
total cell number within the scaffold 2.5 fold in comparison to static culture, and that 
cells were distributed more uniformly (Sun et al., 2008). Therefore, the use of a 
simple closed loop perfusion bioreactor for the introduction of primary Schwann 
cells to decellularised human femoral nerve could be investigated and assessed 
using DNA quantification, to determine the number of cells introduced to the 
conduit, and histological analysis to assess cell distribution.  
Following the establishment of a method to introduce Schwann cells, future work 
could also include long-term in vitro culture of primary Schwann cells with 
decellularised human nerve, in order to investigate the ability of decellularised 
human femoral nerve to support viable primary Schwann cell populations in 
isolation. A long-term in vitro culture system of up 28 days would be established, 
and cell viability and migration could be assessed in vitro using the analyses 
described in Chapter 5 at various time points in culture. Changes in the expression 
of various Schwann cell markers, including those used in Chapter 5, would also be 
evaluated. The results presented in this study (Chapter 5) suggested that disruption 
to endoneurial architecture adversely affects long term cell viability and migration. 
Therefore, primary human rat Schwann cells could also be cultured with lyophilised 
decellularised human femoral nerve and assessed using the same analyses, in 
order to investigate the importance of endoneurial architecture on cell viability, 
migration and distribution, and the effects on Schwann cell phenotype.  
207 
Future in vivo studies could also include evaluating a decellularised human nerve 
graft repopulated with primary Schwann cells using a rat sciatic nerve defect model, 
as described above. The results of this study could be compared to the use of a 
decellularised nerve graft in isolation to repair a rat sciatic nerve defect, in order to 
investigate the effects of incorporating Schwann cells on axon regeneration. Future 
studies could also include repopulating a lyophilised decellularised nerve graft with 
Schwann cells, in order to assess the effects of disruption to endoneurial 
architecture on implanted Schwann cells and axon regeneration in vivo. 
6.6.3 Development of a decellularised human nerve ECM 
hydrogel 
Hydrogels, including collagen type I hydrogels, are common materials used for 
NGC fabrication (Chapter 1). Recent developments in NGC fabrication have 
focused on replicating the native ECM microenvironment, with the incorporation of 
basement membrane components, adhesion motifs, and altering the biochemical 
composition (Gu et al., 2014). Decellularised ECM hydrogels offer considerable 
clinical potential for tissue repair, as the biochemical composition and basement 
membrane components of the native ECM are preserved, and the hydrogels can be 
developed with highly tuneable properties including stiffness and porosity, and can 
be moulded or injectable for less invasive repair (Saldin et al., 2017). Decellularised 
ECM hydrogels have been developed from a variety of porcine source tissues 
including spinal cord, urinary bladder, small intestinal submucosa and cardiac 
tissues such as myocardium, and have demonstrated promising results both in vitro 
and in vivo in comparison to other hydrogels, including collagen type I hydrogels 
and Matrigel™ (Saldin et al., 2017). Decellularised ECM hydrogels also offer 
potential for the future development of cellular therapies and pharmacotherapies for 
peripheral nerve repair (Faroni et al., 2015; Fathi and Zaminy, 2017). Autologous 
Schwann cells, ASCs or BMSCs could easily be suspended in the hydrogel, and 
growth factors or other small molecules could also be incorporated into the hydrogel 
prior to implantation (Faroni et al., 2015; Houschyar et al., 2016; Jiang et al., 2017). 
Decellularised ECM hydrogels have previously been developed from porcine 
peripheral nerves, and have been evaluated both in vitro and in vivo (Zou et al., 
2018; Lin et al., 2018). Zou et al. (2018) developed an ECM hydrogel derived from 
decellularised porcine peripheral nerves, and evaluated the hydrogel in comparison 
to Matrigel™ and a collagen type I hydrogel, using an in vitro co-culture system with 
primary rat DRGs and Schwann cells. The study reported increased neurite 
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outgrowth, and increased re-myelination of DRGs cultured in the decellularised 
ECM hydrogel in comparison to DRGs cultured in Matrigel™ or the collagen 
hydrogel (Zou et al., 2018). Lin et al. (2018) also developed a decellularised porcine 
peripheral nerve ECM hydrogel, and found that the hydrogel supported primary rat 
Schwann cell proliferation and preserved Schwann cell phenotype when cultured in 
vitro. In addition, the ECM hydrogel was combined with electrospun PLA fibres and 
used to repair a 15 mm rat sciatic nerve defect in vivo, and compared to both an 
empty PLA conduit and a decellularised porcine peripheral nerve graft. The study 
reported morphological, electrophysiological and functional outcomes, and found 
that the ECM hydrogel achieved superior axon regeneration in comparison to the 
empty conduit, and similar outcomes to the autograft control (Lin et al., 2018). 
Future work could include the development of a decellularised human nerve ECM 
hydrogel, which could be translated for clinical application as a Class III medical 
device. Human femoral nerves would be decellularised using the decellularisation 
process described in Chapter 4. A method for the preparation of a decellularised 
nerve ECM hydrogel would be developed using previously established methods for 
producing decellularised ECM hydrogels, including enzymatic digestion and acid 
hydrolysis (Saldin et al., 2017). The ECM hydrogel would be characterised using 
histological and biochemical analyses (including collagen, fat and 
glycosaminoglycan (GAG) quantification) to ensure retention of ECM components, 
spectrophotometry to study gelation kinetics, and SEM to determine fibril diameter 
and orientation. Gel stiffness and compressive strength would also be determined 
using rheology and biomechanical analyses. The developed ECM hydrogel could 
then be cultured in vitro with primary rat DRG explants. Cell viability, migration and 
neurite outgrowth could be assessed as described in Chapter 5, using viability 
assays and immunofluorescent labelling.  
In addition, a decellularised human nerve ECM hydrogel incorporating Schwann 
cells could be developed by resuspending cells within the hydrogel (Faroni et al., 
2015; Houschyar et al., 2016). A repopulated ECM hydrogel could then be 
evaluated in vitro, using the analyses described above, and in vivo using a rat 






Current surgical interventions for peripheral nerve repair are associated with a 
number of limitations (Burnett and Zager, 2004). Autografts require the sacrifice of a 
functional nerve and often provide insufficient material for major reconstruction, and 
cadaveric fresh-frozen allografts present significant risks associated with potential 
immunogenicity and patient immunosuppression (Lee and Wolfe, 2000; Schmidt 
and Leach, 2003). A small number of NGCs are clinically available, however clinical 
trials have reported that the efficacy of NGCs is restricted to the repair of small 
defects, up to 20 mm in length (Gu et al., 2011; De Luca et al., 2014). 
Decellularised peripheral nerve grafts offer considerable clinical potential, and there 
is existing clinical evidence to support their use for peripheral nerve repair (Moore 
et al., 2011; Gerth et al., 2015). However, clinical trials have not yet demonstrated 
consistently superior outcomes to autografts, and it is hypothesised that the 
decellularised nerve graft has diminished regenerative capacity as a consequence 
of ECM disruption caused by the decellularisation process (Whitlock et al., 2009; 
Karabekmez et al., 2009). In this study, a novel decellularised human femoral nerve 
graft of clinical utility was developed. Decellularised human femoral nerves were 
shown to retain a native ECM histioarchitecture and biochemical composition, and 
were shown to be biocompatible and support the viability, migration and phenotype 
of primary DRG cells for up to 28 days in vitro. However, further investigations are 
required to evaluate clinical potential for use in peripheral nerve repair. A 
sterilisation process must be developed and evaluated for the decellularised nerve 
graft. Decellularised and sterilised human femoral nerves must be biomechanically 
evaluated to ensure the retention of native biomechanical properties. In addition, 
although results of the in vitro experiments presented in this study are promising, 
the efficacy of a sterilised decellularised human femoral nerve graft for peripheral 
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8 Appendix A: Materials 
Table I Equipment used throughout the study 
Equipment Reference code Supplier 
Automatic pipettes Various Gilson / Finnpipette 
Balance GR200 A&D Instruments Ltd 
Bench top Eppendorf Centrifuge 5415R Hyland Scientific 
Class I laminar flow cabinet - Howarth Airtech Ltd 
Class II safety cabinet HERASafeKS Heraeus 
Centrifuge Harrier 15/80 Sanyo Biomedical 
Confocal microscope LSM800 Carl Zeiss Ltd 
Cryotome CM1850 Leica 
Dissection equipment Various Fine Scientific Tools Ltd 
Freeze Drier ModulyoD-230 Thermo Savant 
Freezer (-20 °C) Electrolux 3000 Jencons Plc 
Freezer (-80 °C) Various Sanyo Biomedical 
Fridge ER8817C Jencons Plc 
Fluorescent microscope AXIO Imager M2 Carl Zeiss Ltd 
Haemocytometer (22 x 47 mm) Neubauer VWR International 
Histology moulds E10.8/4161 Raymond A Lamb 
Histology water bath MH8515 Barnstead Electrothermal 
Hotplate stirrer CB162 Stuart Scientific 
Hotplate E18/1 Raymond A Lamb 
Hot wax oven E18/31 Raymond A Lamb 
Incubator (inCu safe 37 °C) - Sanyo Biomedical 
Inverted microscope CK40 Olympus 
Liquid Nitrogen Dewar BIO65 Jencons Plc 
Magnetic stirrer Stuart SB161 Scientific Laboratory Supplies Ltd 
Microtome RM2255 Leica 
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Microplate spectrophotometer Multiscan 
Spectrum 1500 
Thermo Scientific Ltd 
NanoDrop spectrophotometer ND-1000 Labtech 
Oven (hot air) - Genlab Ltd 
pH meter Jenway 3510 VWR International 
Pipette boy Various Integra Biosciences 
Plate shaker Vari-shaker Dynatech Ltd 
Slide holders E102 Raymond A Lamb 
Staining troughs E105 Raymond A Lamb 
Stainless steel spatulas Various Fisher Scientific 
Stainless steel pins (11 x 3 mm) Various Fisher Scientific 
Table shaker KS130 IKA 
Table shaker PSU 10i Grant 
Tissue processor TP1020 Leica 
Topcount luminescence plate 
reader 
- Packard Bioscience 
Wax dispenser E66 Raymond A Lamb 













Table II Consumables used throughout the study 
Consumable Reference code Supplier 
Automatic pipettes Various Gilson / Finnpipette 
Autoclave plain closure bags - Westfield Medical Ltd 
Bijoux tubes (5 mL) SLS7522 Scientific Laboratory Supplies Ltd 
Black-walled 96 well plate G655076 Scientific Laboratory Supplies Ltd 
Coverslips (22 x 64 mm) MIC3228 Scientific Laboratory Supplies Ltd 
Cryovials, 1mL Various Nunc International 
Histology cassettes EMB-130-020R Fisher Scientific 
Filter pipette tips Various Starlab 
Flat bottomed clear 96-well plate 269620 Scientific Laboratory Supplies Ltd 
Microtube, 1.5 mL loop cap 212-9573 VWR International 
Microtome blades SD3050835 Fisher Scientific 
Optiplate (96 well plate) 165305 Fisher Scientific 
Parafilm - Bemis 
Pasteur pipettes (3 mL) pmk-500-070w Fisher Scientific 
Petri dishes 82.1473.001 Sarstedt 
Scalpel blades Various Fisher Scientific 
Serological pipettes (5, 10, 25 
mL) 
Various Sigma Aldrich 
Specimen pots (150 mL, 250 
mL) 
Various Scientific Laboratory Supplies Ltd 
Superfrost Plus slides J1800-AMNZ Thermo Scientific Ltd 
Syringes (1 mL, 10 mL) Various Terumo 
Syringe (hypodermic) needle 23 
G 
NN2332R Terumo 
Syringe filter (0.22 µm pore size) 10268401 Millex Merck Millipore 
Tissue Culture flasks (T75, 
T175) 
Various Thermo Scientific Ltd 
Tissue Culture plates (6-well) 140675-6 Thermo Scientific Ltd 
Universal tubes (25 mL) CON9000 Scientific Laboratory Supplies Ltd 
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Table III Chemicals and reagents used throughout the study 
Chemical / reagent Reference code Supplier 
1,9 dimethylene blue 34-1088 Sigma-Aldrich 
Acetic acid, glacial 10001CU VWR International 
Acetone 20065.362 Fisher Scientific 
Agarose A9539 Sigma Aldrich 
Aprotinin (50 mL; 10,000 KIU.mL-1) AP020 Nordic Pharma 
ATPLiteM® assay kit 6016947 Perkin Elmer Ltd 
Bovine Serum Albumin A7030 Sigma Aldrich 
Benzonase nuclease hc, purity > 99 
% (250 U.µL-1) 
70664 Merck 
Calcium chloride C7902 Sigma Aldrich 
Calf thymus DNA D4522 Sigma 
Cambridge antibiotic solution 04-301 Resource Bioscience 
Carbon dioxide (CO2) in air (5% 
(v/v)) 
- British Oxygen Company Ltd 
Chloramine T C9887 Sigma Aldrich 
Chondroitin sulphate B C3788 Sigma Aldrich 
Citric acid 20276.292 VWR International 
Collagen (rat tail) type 1 2 mg·mL1, 
in 0.6% (v/v) acetic acid (60-30-
810) 
60-30-810 First Link Ltd 




D9564 Sigma Aldrich 
DeadEnd™ Fluorometric TUNEL 
system 
G3250 Promega 
Dimethyl sulfoxide (DMSO) D9564 Sigma 
disodium hydrogen orthophosphate 
(anhydrous) 
1.06586.0500 Merck Millipore 
DNeasy blood and tissue kit 69504 Qiagen 
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Dulbecco's minimal essential 
medium 
D6546 Sigma 
DPBS (without Ca/Mg) D8537 Sigma 
DPBS (with Ca/Mg) D8662 Sigma 
DPX mountant RRSP29 Atom Scientific 
EDTA (disodium 
ethylenediaminetetraacetic acid) 
E/P140/53 Thermo Fisher Scientific Ltd 
Eosin Y 1.09844.1000 Merck Millipore 
Ethanol (100 % v/v) E/0650DF Fisher Scientific 
Fluorescence mounting medium S3023 Dako 
Foetal bovine serum EU-000 Sera Lab 
Formic acid F-4166 Sigma Aldrich 
Goat serum 5425S New England Biolabs 
Giemsa stain 352603R VWR International 
Gentamycin sulphate 345814 Sigma Aldrich 
Glasgow's minimal essential 
medium 
G5154 Sigma 
Hams F12 nutrient mixture (+ L-
glutamine) 
N4888 Sigma 
Haematoxylin (Mayer's) RRSP60 Atom Scientific 
Haematoxylin (Weigert's) A/B RRSP72-
D/RRSP73-D 
Atom Scientific 
Hanks Balanced Salt Solution 
(HBSS) 
H9269 Sigma 
Hydroxylamine hydrochloride 159417 Sigma Aldrich 
Hydrochloric acid (6 M) H/1200/PB17 Fisher Scientific 
Iron (III) chloride (hexahydrate) F2877 Sigma Aldrich 
Lard - Tesco 
L-cystine hydrochloride C1276 Sigma Aldrich 
L-glutamine (200 mM) G7513 Sigma 
Luxol Fast Blue 212171000 Acros Organics 
Lithium carbonate 203629 Sigma 
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Magnesium chloride hexahydrate 25108.26 Thermo Fisher Scientific Ltd 
Methanol-free formaldehyde (16 %; 
w/v) 
28906 Thermo Fisher Scientific Ltd 
Miller's stain LAMB/080-D Raymond A Lamb 
Nerve Growth factor N8133 Sigma 
Neutracon - Deacon Laboratories Ltd 
Neutral Buffered Formalin (10 % 
v/v) 
RRFFD4000-G Fisher Scientific 
Nuclease free water 436912C VWR International 
OCT compound 361606E VWR International 
Oxalic acid 1017440 Thermo Fisher Scientific Ltd 
Papain A3814.0100 Applichem 
Parrafin wax W2 Raymond A Lamb 
PBS tablets BR0014G Oxoid 
p-dimethylaminobenzaldehyde S647861 Sigma Aldrich 
Penicillin (5000 U.mL-
1)/Streptomycin (5 mg.mL-1) 
P4458 Sigma 
Perchloric acid (60 % vv/v) 294583P Sigma Aldrich 
pH standards (4, 7, 10) - Scientific Laboratory Supplies 
Ltd 
PicoGreen™ detection kit P7589 Invitrogen Life Technologies 
Picric acid 36011 Sigma Aldrich 
Polymyxin B sulphate 5291 Merck Chemicals 
Potassium permanganate P/6520/53 Thermo Fisher Scientific Ltd 
Propan-1-ol 20861.363 VWR International 
Proteinase K solution S3020 Dako 
Scott's tap water RRSP/190 Atom Scientific 
Sirius Red F3B Raymond A Lamb 
Sodium acetate (trihydrate) S/2040/53 Thermo Fisher Scientific Ltd 
Sodium azide solution (1 % w/v) 786-229 G Biosciences 




102454R VWR International 
sodium hydroxide S8045 Thermo Fisher Scientific Ltd 
SteriSrips R1540C Medisave 
Sucrose S9378-500G Sigma 
Trans-4-hydroxy-L-proline H7279 Sigma Aldrich 
Trichloroacetic acid (99% w/v) 152130010 Acros Organics 
Trigene CLE1230 Scientific Laboratory Supplies 
Ltd 
Tris (trizma base) T1503 Sigma Aldrich 
Triton X-100 X100-500ML Sigma 
Trypan blue solution (0.4 % v/v) T8154 Sigma 
Trypsin-EDTA solution (0.5 %; w/v) T3924 Sigma 
Tryptone phosphate broth (TPB) T8782 Sigma 
Tween-20 P1379 Sigma Aldrich 
UltraPure™ 10 % (w/v) sodium 
dodecyl sulphate solution 
24730-020 Invitrogen Life Technologies 
Vancomycin hydrochloride 861987-1G Merck Chemicals 
Virkon® CLE1554 DuPont 
Xylene GPS1001-G Atom Scientific 




14 Appendix B: Conference presentations and awards 
 
 Georgina Webster, Richard M Hall, Paul Rooney and Stacy-Paul Wilshaw 
(July 2015), Development of acellular allogeneic nerve grafts, EPSRC 
Centre of Doctoral Training Joint Conference, University of Leeds, UK. 
(Poster presentation) 
 
 Georgina Webster, Richard M Hall, Paul Rooney and Stacy-Paul Wilshaw 
(July 2016), Development and characterisation of an acellular allogeneic 
nerve graft, Annual Tissue and Cell Engineering Society meeting (TCES), 
London, UK. (Poster presentation) 
 
 Georgina Webster, Richard M Hall, Paul Rooney and Stacy-Paul Wilshaw 
(December 2016), Development and characterisation of a decellularised 
allogeneic nerve graft for peripheral nerve repair, Annual White Rose Work 
in Progress Meeting; Biomaterials and Tissue Engineering Group (BiTEG), 
York, UK. (Poster presentation) 
  
 Georgina Webster, Richard M Hall, Paul Rooney and Stacy-Paul Wilshaw 
(June 2017), Development and characterisation of a decellularised 
allogeneic nerve graft for peripheral nerve repair, Tissue Engineering and 
Regenerative Medicine International Society (TERMIS) EU Meeting, Davos, 
Switzerland. (Poster presentation) 
 
 Georgina Webster, Richard M Hall, Paul Rooney and Stacy-Paul Wilshaw 
(July 2017), Development and characterisation of a decellularised allogeneic 
nerve graft, Annual Tissue and Cell Engineering Society meeting (TCES), 
Manchester, UK. (Poster presentation) 
 
 Georgina Webster, Richard M Hall, Paul Rooney and Stacy-Paul Wilshaw 
(July 2017), Development and characterisation of a decellularised allogeneic 
nerve graft for peripheral nerve repair, EPSRC Centre of Doctoral Training 
Symposium, University of Leeds, UK. (Oral presentation). Second prize: 
Best oral presentation  
 
 Georgina Webster, Richard M Hall, Paul Rooney and Stacy-Paul Wilshaw 
(October 2017), Development and characterisation of a decellularised 
allogeneic nerve graft for peripheral nerve repair, EPSRC Centre of Doctoral 
Training Joint Conference, Leeds, UK. (Oral presentation) 
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 Georgina Webster, Richard M Hall, Paul Rooney and Stacy-Paul Wilshaw 
(December 2017), Development and characterisation of a decellularised 
human femoral nerve graft, Annual White Rose Work in Progress Meeting; 
Biomaterials and Tissue Engineering Group (BiTEG), Leeds, UK. (Poster 
presentation) 
 
 Georgina Webster, Richard M Hall, Paul Rooney and Stacy-Paul Wilshaw 
(September 2018), Development and characterisation of a decellularised 
allogeneic nerve graft for peripheral nerve reconstruction, Tissue 
Engineering and Regenerative Medicine International Society (TERMIS) 
Wold Congress, Kyoto, Japan. (Poster presentation)  
 
 
 
